1 Appendix D: Evidence Tables – Treatment of active TB (RQs N & Q)

1 Арр	oendix l	D: Evidence Tables – Treatment of active TB (RQs N & Q)	1
1.1	regim cortic decre	& Q: In people with active TB receiving the standard recommended en (isoniazid, rifampicin, pyrazinamide and ethambutol), do osteroids as an adjunct to the antituberculosis drug treatment regimen ease morbidity and mortality compared to the standard recommended	0
	•	en alone? TUBERCULOSIS	
PULINO	1.1.1		
	1.1.2	Bilaçeroglu et al, 1999 Mayanja-Kizza et al, 2005	
	1.1.2		
	1.1.3		
		ERCULOSIS	
FLLON	1.1.5	Elliott et al, 2004	
	1.1.6	Galarza et al, 1995	
	-	Lee et al, 1988	
	1.1.8	Wyser et al, 1996	
	1.1.9	Singh & Yesikar, 1965	
TUBER	-	IS WITH SEVERE BRONCHIAL OBSTRUCTION	
		D Toppet et al, 1990	
CENTR		RVOUS SYSTEM TUBERCULOSIS	
		1 Chotmongkol et al, 1996	
		2 Girgis et al, 1983	
		3 Girgis et al, 1991	
	1.1.14	4 Malhotra et al, 2009	94
	1.1.15	5 O'Toole et al, 1969	109
	1.1.16	6 Kumarvelu et al, 1994	114
	1.1.17	7 Schoeman et al, 1997	126
	1.1.18	8 Thwaites et al, 2004/7 / Török et al, 2011	133
BONE 8		, INCLUDING SPINAL, TUBERCULOSIS	151
	1.1.19	9 Cathro, 1958	151
PERICA	RDIAL	TUBERCULOSIS	155
	1.1.20	0 Hakim et al, 2000	155
	1.1.2	1 Reuter et al, 2006	166
	1.1.22	2 Strang et al, 1987/2004	173
	1.1.23	3 Strang et al, 1988/2004	182
IMMUNI	E RECC	DNSTITUTION INFLAMMATORY SYNDROME	190
	1.1.24	4 Meinties et al. 2010	190

1.1 RQ N & Q: In people with active TB receiving the standard recommended regimen (isoniazid, rifampicin, pyrazinamide and ethambutol), do corticosteroids as an adjunct to the antituberculosis drug treatment regimen decrease morbidity and mortality compared to the standard recommended regimen alone?

RQ Q has been integrated into this question.

PULMONARY TUBERCULOSIS

1.1.1 Bilaçeroglu et al, 1999

Bibliographic reference	Bilaçeroglu S, Perim K, Büyüksirin M et al (1999) Prednisolone: a beneficial and safe adjunct to antituberculosis treatment? A randomised controlled trial. International Journal of Tuberculosis and Lung Disease 3(1): 47-54
Study type	RCT
Study type	RCT Appropriate method of randomisation used? unclear Allocation concealment used? unclear Blinding used? only laboratory staff and those reading chest scans were blinded Groups comparable at baseline? yes Groups received the same care apart from the intervention(s) studied? yes Groups followed up for an equal and appropriate length of time? follow-up period was appropriate (1 to 3 years), although it is unclear if it was the same in each group Groups comparable for treatment completion and availability of outcome data? yes
	Study used precise definitions and reliable measures of outcome? yes

	Population studied is the same as the population of interest?
	yes
	Intervention used is the same as the intervention of interest?
	antituberculosis regimens do not use all of or just the 4 standard recommended drugs
	Have substitute outcomes been used instead of the patient-important outcomes of interest?
	yes – change in bacillary count is a surrogate for cure/treatment success/treatment failure
	Analysis followed the intent-to-treat principle?
	yes
	Randomised = 178
	prednisolone group = 91
Number of patients	antituberculosis chemotherapy alone group = 87
Number of patients	Outcome data available for = 178
	prednisolone group = 91
	antituberculosis chemotherapy alone group = 87
	Inclusion
	Advanced pulmonary tuberculosis causing persistent high-grade fever (≥38°C), weight loss (≥2 kg/week) and/or low serum albumin levels (<3 g/dL)
Patient	HIV-negative
characteristics	Diagnostic criteria
	Confirmed by acid-fast bacilli positivity on smear or culture, and/or granulomatous inflammation with caseous necrosis in the pulmonary biopsy specimen
	Other febrile causes were excluded by serial blood culture, sputum and urine culture, total body gallium-67

	ntigraphy for occult abscesses, screening for occult mannation temperature response, and a trial of intravenous		
Ex	clusion		
	companying uncontrollable hypertension, recalcitrant c eding, resistant hypokalemia or florid sepsis	liabetes, active or recen	t peptic ulcer or gastrointestinal
Ba	seline		
		Prednisolone group	Antituberculosis chemotherapy alone group
		(n = 91)	(n = 87)
	Age (mean±SD), years	36±2.8	34±3.1
	Sex, male:female	70:21	64:23
	Weight (mean±SD), kg	50.3±1.9	51.1±1.4
	Serum albumin level (mean±SD), g/dl	2.57±0.29	2.62±0.17
	Fever (mean±SD), °C	38.7±0.4	38.4±0.2
	Patients with cavities:patients with miliary lesions	74:17	67:20
	Radiographic extent of the disease		
	fraction of both lung fields (mean±SD)	7/8±1/8	13/16±1/16
	number of patients with bilateral involvement	91	87
	Bacillary count on smear (mean±SD)	2±1	2±1
Intervention An	tituberculosis chemotherapy plus prednisolone		

	Prednisolone (40 days)
	initially administered 20 mg b.i.d IV/IM for 10 days, after which it was given orally and reduced by 10 mg every 10 days
	Antituberculosis chemotherapy:
	drug susceptible cases: 3HRZS/3HRE/6HR or 3HRZE/3HRE/6HR
	drug resistant cases (n = 18): additional drugs (ciprofloxacin, ethionamide and/or amikacin) were given
	doses not stated
	Antituberculosis chemotherapy alone
	Antituberculosis chemotherapy:
Comparison	drug susceptible cases: 3HRZS/3HRE/6HR or 3HRZE/3HRE/6HR
	drug resistant cases (n = 18): additional drugs (ciprofloxacin, ethionamide and/or amikacin) were given
	doses not stated
Length of follow up	1 to 3 years
Location	Izmir, Turkey
	Mortality
	Number of deaths
	prednisolone group = 0 of 91
Outcomes	antituberculosis chemotherapy alone group = 0 of 87
measures and effect size	OR ¹ (95% CI) = 0.96 (0.02 to 48.73)
	i.e. not statistically significant
	Response to treatment – bacillary count
	Number of to experience a drop in bacillary count 50 days after prednisolone was initiated ³

prednisolone group = 91 of 91antituberculosis chemotherapy alone group = 81 of 87 OR^1 (95% Cl) = 14.60 (0.81 to 263.12)i.e. not statistically significantNumber of to experience a marked drop in bacillary count 50 days after prednisolone was initiated ³ prednisolone group = 78 of 91antituberculosis chemotherapy alone group = 54 of 87 OR^1 (95% Cl) = 3.67 (1.77 to 7.61)i.e. statistically significantTime (mean, days) to drop in bacillary count $p = 0.04$ i.e. statistically significantChanges in signs and symptoms – feverChange (mean, °C) in temperature within 72 hoursprednisolone group (n = 91) = -1.2antituberculosis chemotherapy alone group (n = 87) = 0.2 $MD^2 = 1.4$ Changes in signs and symptoms – weight changeWeight change (mean, kg) during treatmentprednisolone group (n = 91) = 7.2antituberculosis chemotherapy alone group (n = 87) = 4.2	
OR1 (95% CI) = 14.60 (0.81 to 263.12)i.e. not statistically significantNumber of to experience a marked drop in bacillary count 50 days after prednisolone was initiated3prednisolone group = 78 of 91antituberculosis chemotherapy alone group = 54 of 87OR1 (95% CI) = 3.67 (1.77 to 7.61)i.e. statistically significantTime (mean, days) to drop in bacillary countp = 0.04i.e. statistically significantChanges in signs and symptoms – feverChange (mean, °C) in temperature within 72 hoursprednisolone group (n = 91) = -1.2antituberculosis chemotherapy alone group (n = 87) = 0.2MD2 = 1.4Changes in signs and symptoms – weight changeWeight change (mean, kg) during treatmentprednisolone group (n = 91) = 7.2	prednisolone group = 91 of 91
i.e. not statistically significantNumber of to experience a marked drop in bacillary count 50 days after prednisolone was initiated3prednisolone group = 78 of 91antituberculosis chemotherapy alone group = 54 of 87 OR^1 (95% CI) = 3.67 (1.77 to 7.61)i.e. statistically significantTime (mean, days) to drop in bacillary count $p = 0.04$ i.e. statistically significantChanges in signs and symptoms – feverChange (mean, °C) in temperature within 72 hoursprednisolone group (n = 91) = -1.2antituberculosis chemotherapy alone group (n = 87) = 0.2 $MD^2 = 1.4$ Changes in signs and symptoms – weight changeWeight change (mean, kg) during treatmentprednisolone group (n = 91) = 7.2	antituberculosis chemotherapy alone group = 81 of 87
Number of to experience a marked drop in bacillary count 50 days after prednisolone was initiated3prednisolone group = 78 of 91antituberculosis chemotherapy alone group = 54 of 87 OR^1 (95% Cl) = 3.67 (1.77 to 7.61)i.e. statistically significantTime (mean, days) to drop in bacillary count $p = 0.04$ i.e. statistically significantChanges in signs and symptoms – feverChange (mean, °C) in temperature within 72 hoursprednisolone group (n = 91) = -1.2antituberculosis chemotherapy alone group (n = 87) = 0.2MD ² = 1.4Changes in signs and symptoms – weight changeWeight change (mean, kg) during treatmentprednisolone group (n = 91) = 7.2	OR ¹ (95% CI) = 14.60 (0.81 to 263.12)
prednisolone group = 78 of 91antituberculosis chemotherapy alone group = 54 of 87 OR^1 (95% CI) = 3.67 (1.77 to 7.61)i.e. statistically significantTime (mean, days) to drop in bacillary count $p = 0.04$ i.e. statistically significantChanges in signs and symptoms – feverChange (mean, °C) in temperature within 72 hoursprednisolone group (n = 91) = -1.2antituberculosis chemotherapy alone group (n = 87) = 0.2MD ² = 1.4Changes in signs and symptoms – weight changeWeight change (mean, kg) during treatmentprednisolone group (n = 91) = 7.2	i.e. not statistically significant
antituberculosis chemotherapy alone group = 54 of 87 OR^1 (95% Cl) = 3.67 (1.77 to 7.61)i.e. statistically significantTime (mean, days) to drop in bacillary count $p = 0.04$ i.e. statistically significantChanges in signs and symptoms – feverChange (mean, °C) in temperature within 72 hoursprednisolone group (n = 91) = -1.2antituberculosis chemotherapy alone group (n = 87) = 0.2 $MD^2 = 1.4$ Changes in signs and symptoms – weight changeWeight change (mean, kg) during treatmentprednisolone group (n = 91) = 7.2	Number of to experience a marked drop in bacillary count 50 days after prednisolone was initiated ³
OR^1 (95% Cl) = 3.67 (1.77 to 7.61)i.e. statistically significantTime (mean, days) to drop in bacillary count $p = 0.04$ i.e. statistically significantChanges in signs and symptoms – feverChange (mean, °C) in temperature within 72 hoursprednisolone group (n = 91) = -1.2antituberculosis chemotherapy alone group (n = 87) = 0.2 $MD^2 = 1.4$ Changes in signs and symptoms – weight changeWeight change (mean, kg) during treatmentprednisolone group (n = 91) = 7.2	prednisolone group = 78 of 91
i.e. statistically significantTime (mean, days) to drop in bacillary count $p = 0.04$ i.e. statistically significantChanges in signs and symptoms – feverChange (mean, °C) in temperature within 72 hoursprednisolone group (n = 91) = -1.2antituberculosis chemotherapy alone group (n = 87) = 0.2MD ² = 1.4Changes in signs and symptoms – weight changeWeight change (mean, kg) during treatmentprednisolone group (n = 91) = 7.2	antituberculosis chemotherapy alone group = 54 of 87
Time (mean, days) to drop in bacillary count $p = 0.04$ i.e. statistically significantChanges in signs and symptoms – feverChange (mean, °C) in temperature within 72 hoursprednisolone group (n = 91) = -1.2antituberculosis chemotherapy alone group (n = 87) = 0.2 $MD^2 = 1.4$ Changes in signs and symptoms – weight changeWeight change (mean, kg) during treatmentprednisolone group (n = 91) = 7.2	OR ¹ (95% CI) = 3.67 (1.77 to 7.61)
$p = 0.04$ i.e. statistically significantChanges in signs and symptoms – feverChange (mean, °C) in temperature within 72 hoursprednisolone group (n = 91) = -1.2antituberculosis chemotherapy alone group (n = 87) = 0.2 $MD^2 = 1.4$ Changes in signs and symptoms – weight changeWeight change (mean, kg) during treatmentprednisolone group (n = 91) = 7.2	i.e. statistically significant
i.e. statistically significant Changes in signs and symptoms – fever Change (mean, °C) in temperature within 72 hoursprednisolone group (n = 91) = -1.2antituberculosis chemotherapy alone group (n = 87) = 0.2 $MD^2 = 1.4$ Changes in signs and symptoms – weight change Weight change (mean, kg) during treatmentprednisolone group (n = 91) = 7.2	Time (mean, days) to drop in bacillary count
Changes in signs and symptoms – fever Change (mean, °C) in temperature within 72 hours prednisolone group (n = 91) = -1.2 antituberculosis chemotherapy alone group (n = 87) = 0.2 MD ² = 1.4 Changes in signs and symptoms – weight change Weight change (mean, kg) during treatment prednisolone group (n = 91) = 7.2	p = 0.04
Change (mean, °C) in temperature within 72 hours prednisolone group (n = 91) = -1.2 antituberculosis chemotherapy alone group (n = 87) = 0.2 MD ² = 1.4 Changes in signs and symptoms – weight change Weight change (mean, kg) during treatment prednisolone group (n = 91) = 7.2	i.e. statistically significant
prednisolone group (n = 91) = -1.2 antituberculosis chemotherapy alone group (n = 87) = 0.2 $MD^2 = 1.4$ Changes in signs and symptoms – weight change Weight change (mean, kg) during treatment prednisolone group (n = 91) = 7.2	Changes in signs and symptoms – fever
antituberculosis chemotherapy alone group (n = 87) = 0.2 $MD^2 = 1.4$ Changes in signs and symptoms – weight change Weight change (mean, kg) during treatment prednisolone group (n = 91) = 7.2	Change (mean, °C) in temperature within 72 hours
MD ² = 1.4 Changes in signs and symptoms – weight change Weight change (mean, kg) during treatment prednisolone group (n = 91) = 7.2	prednisolone group (n = 91) = -1.2
Changes in signs and symptoms – weight change Weight change (mean, kg) during treatment prednisolone group (n = 91) = 7.2	antituberculosis chemotherapy alone group (n = 87) = 0.2
Weight change (mean, kg) during treatment prednisolone group (n = 91) = 7.2	MD ² = 1.4
prednisolone group (n = 91) = 7.2	Changes in signs and symptoms – weight change
	Weight change (mean, kg) during treatment
antituberculosis chemotherapy alone group (n = 87) = 4.2	prednisolone group (n = 91) = 7.2
	antituberculosis chemotherapy alone group (n = 87) = 4.2

$MD^2 = 3.0$
p = 0.002
i.e. statistically significant
Changes in signs and symptoms – radiographic improvement
Radiographic improvement was defined as the combined average percentage of the reductions in the sizes of the initial lesions (infiltrates, cavities and/or pleural effusion):
marked (>90%)
moderate (50–89%)
slight (10–49%)
no improvement (<10%)
Number of to experience radiographic improvement (marked, moderate or slight) 50 days after prednisolone initiation ³
prednisolone group = 91 of 91
antituberculosis chemotherapy alone group = 83 of 87
OR ¹ (95% CI) = 9.86 (0.52 to 185.96)
i.e. not statistically significant
Number of to experience marked radiographic improvement 50 days after prednisolone initiation ³
prednisolone group = 15 of 91
antituberculosis chemotherapy alone group = 8 of 87
OR ¹ (95% CI) = 1.95 (0.78 to 4.86)
i.e. not statistically significant
Relapse

antituberculosis chemotherapy alone group = 0 of 87 OR ¹ (95% CI) = 0.96 (0.02 to 48.73) i.e. not statistically significant	
i.e. not statistically significant	
Source of funding No details provided	
Comments	

² Mean difference and 95% confidence interval calculated by reviewer

³ Read off graph by reviewer

Abbreviations: CI, confidence intervals; E, ethambutol; H, isoniazid; OR, odds ratio; R, rifampicin; RCT, randomised controlled trial; S, streptomycin; SD, standard deviation; Z, pyrazinamide

1.1.2 Mayanja-Kizza et al, 2005

Bibliographic reference	Mayanja-Kizza H, Jones-Lopez E, Okwera A et al (2005) Immunoadjuvant prednisolone therapy for HIV-associated tuberculosis: a phase 2 clinical trial in Uganda. Journal of Infectious Diseases 191(6): 856-65
Study type	RCT
	Appropriate method of randomisation used?
Study quality	eligible patients were randomly assigned in blocks of 6 to receive either prednisolone or placebo; the randomisation schedule was developed before the trial by use of computer-generated random numbers with corresponding treatment assignments
	Allocation concealment used?
	assignments were placed in sealed envelopes and drawn sequentially by a study nurse who was not involved with patient care

Blinding used?
double-blind
Groups comparable at baseline?
fever and night sweats were present in significantly more patients who went on to receive prednisolone than amongst those that went on to receive placebo
Groups received the same care apart from the intervention(s) studied?
yes
Groups followed up for an equal and appropriate length of time?
yes
Groups comparable for treatment completion and availability of outcome data?
yes
Study used precise definitions and reliable measures of outcome?
yes
Population studied is the same as the population of interest?
yes
Intervention used is the same as the intervention of interest?
yes
Have substitute outcomes been used instead of the patient-important outcomes of interest?
yes – event-free survival is a substitute for mortality and adverse events; sputum conversion is a substitute for treatment success; recurrence is a substitute for relapse
Analysis followed the intent-to-treat principle?
yes

	Randomised = 187
Number of patients	prednisolone group = 93
	placebo group = 94
	Treatment completion = 181
	prednisolone group = 90
	placebo group = 91
	Outcome data available after 2 years of follow-up = 136
	prednisolone group = 69
	placebo group = 67
Patient characteristics	Inclusion
	Initial episodes of acid fast smear-positive pulmonary tuberculosis
	HIV-infected patients
	>18 years of age
	Exclusion
	Previous treatment for tuberculosis
	Advanced HIV infection (World Health Organization stage IV)
	Karnofsky performance score <80
	Peripheral blood CD4+ T cell count <200 cells/µL
	Kaposi sarcoma
	Active herpes zoster
	Glucose level >160 mg/dL or diabetes mellitus by history

Serum aminotransferase level >65 IU/L

Potassium level >5.5 mmol/L

Positive β -urinary human chorionic gonadotrophin test

Previous use of immunomodulators

Presence or history of hypertension

Psychiatric disease

Peptic ulcer disease

Pancreatitis

Baseline

	Prednisolone group	Placebo group
	(n = 93)	(n = 94)
Sex		
males, n (%)	55 (59)	58 (62)
BCG scar present, n (%)	40 (44)	42 (46)
PPD induration		
≥5 mm, n (%)	83 (89)	79 (84)
mean±SD, mm	16±5.4	16±5.4
Karnofsky performance status		
90, n (%)	28 (30)	21 (22)
80, n (%)	60 (65)	68 (72)

70, n (%)	5 (5)	5 (5)
Age (mean±SD), years	31±7.1	31±7.2
Body mass index (mean±SD), kg/m ²	19±2.8	19±2.6
Haemoglobin level (mean±SD), g/dl	11±1.8	11±1.8
White blood cell count (mean±SD), cells/mm ³	8±2.8	7.8±2.8
Lymphocyte count (mean±SD), cells/mm ³	1.9±0.8	2.0±0.9
Aspartate aminotransferase level (mean±SD), IU/I	26±12	24±12
Glucose level (mean±SD), mg/dl	85±24	88±24
Potassium level (mean±SD), mmol/dl	4.7±0.4	4.8±0.5
Symptoms		
cough, n (%)	93 (100)	94 (100)
chest pain, n (%)	53 (57)	55 (59)
hemoptysis, n (%)	5 (5)	11 (12)
dyspnea, n (%)	36 (40)	31 (33)
fever, n (%)	62 (67)	46 (49)
weight loss, n (%)	78 (84)	76 (81)
purulent sputum, n (%)	76 (82)	81 (86)
night sweats, n (%)	60 (65)	50 (53)
Physical examination		
respiratory		

		consolidation, n (%)	90 (97)	93 (99)	
		wheezing or rhonchi, n (%)	2 (2)	1 (1)	
		pleural effusion, n (%)	0 (0)	1 (1)	
		lymph node enlargement, n (%)	6 (6)	4 (4)	
		sputum smear			
		scanty, n (%)	7 (8)	7 (7)	
		grade 1, n (%)	22 (24)	17 (18)	
		grade 2, n (%)	13 (14)	26 (28)	
		grade 3, n (%)	49 (54)	44 (47)	
		cavitatory	80 (86)	74 (79)	
		chest radiograph finding			
		normal, n (%)	2 (1)	0 (0)	
		minimal, n (%)	3 (3)	4 (4)	
		moderately advanced, n (%)	23 (25)	25 (27)	
		far advanced, n (%)	66 (71)	65 (69)	
	Antitubercul	osis chemotherapy plus prednisolone			
	Prednisolone (8 weeks)				
Intervention	given at a de week course	ose of 2.75 mg/kg daily for 4 weeks and tap	pered over the course o	of the next 4 weeks to complete a	n 8-
	Antitubercul	osis chemotherapy: HRZE – duration and o	losing unclear		

	Medications were self-administered
Comparison	Antituberculosis chemotherapy plus placebo
	Placebo (8 weeks)
	given at a dose of 2.75 mg/kg daily for 4 weeks and tapered over the course of the next 4 weeks to complete an 8- week course
	Antituberculosis chemotherapy: HRZE – duration and dosing unclear
	Medications were self-administered
Length of follow up	36 months
Location	Uganda
	Mortality
	Number of deaths
	prednisolone group = 17 of 93
	placebo group = 14 of 94
	OR ¹ (95% CI) = 1.28 (0.59 to 2.77)
Outcomes	i.e. not statistically significant
measures and effect size	Event-free survival
	Number of patients to survive to 36 months without significant adverse event
	prednisolone group = 36 of 93
	placebo group = 40 of 94
	OR ¹ (95% CI) = 0.85 (0.48 to 1.53)
	i.e. not statistically significant

Treatment failure
Defined as the failure to clear acid-fast bacilli from the sputum after 5 consecutive months of antituberculous therapy to which the organism was susceptible
Number of patients to experience treatment failure
prednisolone group = 1 of 93
placebo group = 1 of 94
OR ¹ (95% CI) = 1.01 (0.06 to 16.41)
i.e. not statistically significant
Response to treatment – sputum conversion
Number of patients to have a sputum culture negative for <i>M. tuberculosis</i> after 1 month of treatment
prednisolone group = 58 of 93
placebo group = 35 of 94
OR ¹ (95% CI) = 2.79 (1.54 to 5.05)
i.e. statistically significant
Number of patients to have a sputum culture negative for <i>M. tuberculosis</i> after 2 months of treatment
prednisolone group = 80 of 93
placebo group = 80 of 94
OR ¹ (95% CI) = 1.08 (0.48 to 2.44)
i.e. not statistically significant
Recurrence
Defined as the recurrence of active TB after the establishment of cure

	Number of patients to experience recurrence within 2 years of initiating treatment	
	prednisolone group = 8 of 93	
	placebo group = 11 of 94	
	OR ¹ (95% CI) = 0.71 (0.27 to 1.85)	
	i.e. not statistically significant	
	Adverse events	
	Number of patients to experience any adverse event	
	prednisolone group = 87 of 93	
	placebo group = 82 of 94	
	OR ¹ (95% CI) = 2.55 (0.86 to 7.54)	
	i.e. not statistically significant	
	Number of patients to experience a severe or life-threatening adverse event	
	prednisolone group = 22 of 93	
	placebo group = 18 of 94	
	OR ¹ (95% CI) = 1.31 (0.65 to 2.64)	
	i.e. not statistically significant	
Source of funding	No details provided	
Comments		
¹ Odds ratio and 95% confidence interval calculated by reviewer		

Abbreviations: BCG, Bacille Calmette-Guerin; CI, confidence intervals; H, isoniazid; OR, odds ratio; PPD, purified protein derivative; R, rifampicin; RCT, randomised controlled trial; S, streptomycin; TB, tuberculosis

1.1.3 Park et al, 1997

·	
Bibliographic reference	Park IW, Choi BW & Hue SH (1997) Prospective study of corticosteroid as an adjunct in the treatment of endobronchial tuberculosis in adults. Respirology 2: 275-81
Study type	RCT
	Appropriate method of randomisation used?
	unclear
	Allocation concealment used?
	unclear
	Blinding used?
	unclear
	Groups comparable at baseline?
	yes
Study quality	Groups received the same care apart from the intervention(s) studied?
Study quality	yes, although details provided are limited
	Groups followed up for an equal and appropriate length of time?
	not for the full treatment period: only 2 months
	Groups comparable for treatment completion and availability of outcome data?
	yes
	Study used precise definitions and reliable measures of outcome?
	yes
	Population studied is the same as the population of interest?
	yes

	Intervention used is the same as the intervention of interest?		
	yes, although some patients received streptomycin instead of ethambutol		
	Have substitute outcomes been used instead of the patient-important outcomes of interest?		
	no		
	Analysis followed the intent-to-treat principle?		
	unclear		
	Randomised = 34		
Number of patients	prednisolone group= 17		
	antituberculosis chemotherapy alone group = 17		
	Inclusion		
	Endobronchial tuberculosis		
	Diagnostic criteria		
	Endobronchial lesions suggestive of endobronchial tuberculosis – such as cheese-like material, stenosis, granular, ulceration, or inflammatory changes – observed bronchoscopy with either caseating necrosis on tissue biopsy or positive stains/culture of acid-fast bacilli on the sputum, bronchial washing or brushing		
Patient	Exclusion		
characteristics	Systemic disease or infection		
	History of previous tuberculosis		
	Patients who have stopped antituberculosis medications or corticosteroids due to severe side effects		
	Pregnancy		
	Baseline		
	Prednisolone group Antituberculosis		

	(n = 17)	chemotherapy alone group
		(n = 17)
Sex, male:female	3:14	4:13
Age		
15–19, n (%)	3 (33.5)	2 (11.8)
20–29, n (%)	8 (47.2)	7 (41.0)
30–39, n (%)	1 (5.8)	2 (11.8)
40–49, n (%)	4 (23.7)	2 (11.8)
50–59, n (%)	1 (5.8)	2 (11.8)
>60, n (%)	0 (0)	2 (11.8)
Age (mean), years	31.0	34.8
Sputum-positive, %	70.6	58.8
Pulmonary function		
FEV1 (mean±SD), % predicted	77.3±16.7	87.0±13.9
FVC (mean±SD), % predicted	77.1±21.3	84.6±17.7
Posteroanterior chest-x-ray		
total atelectasis, n	2	0
segmental atelectasis, n	3	5
Bronchoscopic findings		
actively caseating, n	12	7
stenosis without fibrosis, n	9	9

			1	
	stenosis with fibrosis, n	5	2	
	non-specific bronchitic, n	5	6	
	glandular, n	2	4	
	granular, n	2	2	
	ulcerative, n	0	0	
	Antituberculosis chemotherapy plus prednisolone			
	Prednisolone (4 to 8 weeks)			
Intervention	administered at a dosage of 0.5 mg, approximately 1.0 mg/kg of body weight/day, for 4 to 8 weeks, and then tapered gradually			
	Antituberculosis chemotherapy: HRZS, HRZE or HRZSE			
	dosing and duration not specified			
	Antituberculosis chemotherapy alone			
Comparison	Antituberculosis chemotherapy: HRZS, HRZE or HRZSE			
	dosing and duration not specified			
Length of follow up	2 months after treatment initiation			
Location	Seoul, Korea			
	Change in signs and symptoms – endobronchial lesions	5		
Outcomes measures and effect size	Including actively caseating lesions, stenosis with and without fibrosis, glandular-type lesions and granular-type lesions			
	Number of endobronchial lesions identified using bronchoscopy before treatment to have improved after 2 months of treatment			
	prednisolone group= 24 of 35			

	antituberculosis chemotherapy alone group = 22 of 30	
	OR ¹ (95% CI) = 0.79 (0.27 to 2.33)	
	i.e. not statistically significant	
	Change in signs and symptoms – pulmonary lesions	
	Including atelectasis, patchy infiltration, fibrostreaky density, hilar mass shadow, nodular lesions and cavitatory lesions	
	Number of lesions identified using chest-x-ray before treatment to have improved after 2 months of treatment	
	prednisolone group= 22 of 29	
	antituberculosis chemotherapy alone group = 23 of 28	
	OR ¹ (95% CI) = 0.68 (0.19 to 2.48)	
	i.e. not statistically significant	
Source of funding	No details provided	
Comments		
¹ Odds ratio and 95%	confidence interval calculated by reviewer	
Abbreviations: CI, confidence intervals; E, ethambutol; H, isoniazid; OR, odds ratio; R, rifampicin; RCT, randomised controlled trial; S,		

streptomycin; SD, standard deviation; Z, pyrazinamide

1.1.4 Tuberculosis Research Centre (Madras), 1983

Bibliographic reference	Tuberculosis Research Centre (Madras) (1983) Study of chemotherapy regimens of 5 and 7 months' duration and the role of corticosteroids in the treatment of sputum-positive patients with pulmonary tuberculosis in South India. Tuberculosis Research Centre. Tubercle 64: 73-91
Study type	RCT
Study quality	Appropriate method of randomisation used? unclear

Allocation concealment used?
unclear
Blinding used?
unclear
Groups comparable at baseline?
yes
Groups received the same care apart from the intervention(s) studied?
yes
Groups followed up for an equal and appropriate length of time?
yes
Groups comparable for treatment completion and availability of outcome data?
unclear
Study used precise definitions and reliable measures of outcome?
yes
Population studied is the same as the population of interest?
yes
Intervention used is the same as the intervention of interest?
yes, although patients received streptomycin instead of ethambutol, and some patients did not receive rifampicin
Have substitute outcomes been used instead of the patient-important outcomes of interest?
yes – sputum conversion is a substitute for cure/treatment failure
Analysis followed the intent-to-treat principle?

	unclear
	Randomised = 530
	prednisolone group = 261
	antituberculosis chemotherapy alone group = 269
Number of patients	Outcome data available at 24 months = 530
	prednisolone group = 261
	antituberculosis chemotherapy alone group = 269
	Inclusion
	Newly diagnosed pulmonary tuberculosis
	Aged ≥12 years
Patient characteristics	Diagnostic criteria
	At least 2 positive sputum cultures
	Baseline
	Unclear
	Antituberculosis chemotherapy plus prednisolone
	Prednisolone (8 weeks)
Intervention	20 mg 3 times/day (except Sundays) for the first week, 3 doses of 10 mg, 5 mg, and 5 mg daily for the next 5 weeks, 5 mg twice-daily in the 7 th week and 5 mg daily in the eighth week
	Antituberculosis chemotherapy: 2SHRZ ₇ /3SHZ ₂ , 2SHRZ ₇ /5SHZ ₂ or 2SHZ ₇ /5SHZ
	isoniazid at 400 mg/day during initial phase, followed by 15 mg/kg of body weight/day thereafter, rifampicin at 12 mg/kg of body weight/day, weight/day, pyrazinamide at 40 mg/kg of body weight/day, and streptomycin at 750 mg/kg of body weight/day

	Treated as outpatients, though were given their drugs under close supervision by a clinic nurse
Comparison	Antituberculosis chemotherapy alone Antituberculosis chemotherapy: 2SHRZ ₇ /3SHZ ₂ , 2SHRZ ₇ /5SHZ ₂ or 2SHZ ₇ /5SHZ isoniazid at 400 mg/day during initial phase, followed by 15 mg/kg of body weight/day thereafter, rifampicin at 12 mg/kg of body weight/day, pyrazinamide at 40 mg/kg of body weight/day, and streptomycin at 750 mg/kg of body weight/day
	Treated as outpatients, though were given their drugs under close supervision by a clinic nurse
Location	Madras, India
Length of follow up	24 months
Outcomes measures and effect size	Response to treatment – sputum conversion Number of patients with all cultures negative after 1 month of treatment prednisolone group = 81 of 261 antituberculosis chemotherapy alone = 80 of 269 OR ¹ (95% CI) = 1.06 (0.73 to 1.54) i.e. not statistically significant Number of patients with all cultures negative after 2 months of treatment prednisolone group = 167 of 261 antituberculosis chemotherapy alone = 167 of 269 OR ¹ (95% CI) = 1.09 (0.76 to 1.54) i.e. not statistically significant Number of patients with all cultures negative after 3 months of treatment prednisolone group = 187 of 261

antituberculosis chemotherapy alone = 183 of 269
OR ¹ (95% CI) = 1.19 (0.82 to 1.72)
i.e. not statistically significant
Changes in signs and symptoms – radiographic improvement
Number of patients to achieve moderate or greater radiographic improvement after 2 months of treatment
prednisolone group = 130 of 261
antituberculosis chemotherapy alone = 107 of 269
OR ¹ (95% CI) = 1.50 (1.06 to 2.12)
i.e. statistically significant
Number of patients in whom cavitation was present on admission but disappeared by the end of treatment
prednisolone group = 103 of 245
antituberculosis chemotherapy alone = 88 of 250
OR ¹ (95% CI) = 1.34 (0.93 to 1.92)
i.e. not statistically significant
Number of patients in whom the cavitation that was present on admission had lessened by the end of treatment
prednisolone group = 97 of 245
antituberculosis chemotherapy alone = 111 of 250
OR ¹ (95% CI) = 0.82 (0.57 to 1.17)
i.e. not statistically significant
Relapse
Defined as 2 or more cultures positive for <i>M. tuberculosis</i> out of 6 examined in any 3 consecutive monthly

examinations up to 24 months after treatment initiation, or in any 4 consecutive monthly examinations beyond 2 months			
	Number to experience bacteriological relapse requiring treatment		
	prednisolone group = 5 of 261		
	antituberculosis chemotherapy alone = 6 of 269		
	OR ¹ (95% CI) = 0.86 (0.26 to 2.84)		
	i.e. not statistically significant		
Source of funding	No details provided		
Comments			
¹ Odds ratio and 95% confidence interval calculated by reviewer			
Abbreviations: CI, confidence intervals; H, isoniazid; OR, odds ratio; R, rifampicin; RCT, randomised controlled trial; S, streptomycin; TB, tuberculosis			

PLEURAL TUBERCULOSIS

1.1.5 Elliott et al, 2004

Bibliographic reference	Elliott AM, Luzze H, Quigley MA et al (2004) A randomised, double-blind, placebo-controlled trial of the use of prednisolone as an adjunct to treatment in HIV-1-associated pleural tuberculosis. Journal of Infectious Diseases 190: 869-78			
Study type	RCT			
	Appropriate method of randomisation used?			
	yes – computer-generated randomisation sequence			
	Allocation concealment used?			
	yes – sequence was generated by a statistician who was not involved in the care of the patients; prednisolone and matching placebo tablets were packaged in identical plastic bags labelled with randomisation code numbers by 2 people who were not involved in the study			
	Blinding used?			
Study quality	yes – sequence was generated by a statistician who was not involved in the care of the patients; prednisolone and matching placebo tablets were packaged in identical plastic bags labelled with randomisation code numbers by 2 people who were not involved in the study; medical staff gave participants the next number in the sequence in the order in which they were enrolled; all participants and medical, laboratory, and statistical staff remained blinded to the treatment allocation until all data collection had been completed			
	Groups comparable at baseline?			
	yes			
	Groups received the same care apart from the intervention(s) studied?			
	yes			
	Groups followed up for an equal and appropriate length of time?			


	yes
	Groups comparable for treatment completion and availability of outcome data?
	yes
	Study used precise definitions and reliable measures of outcome?
	yes
	Population studied is the same as the population of interest?
	yes
	Intervention used is the same as the intervention of interest?
	yes
	Have substitute outcomes been used instead of the patient-important outcomes of interest?
	yes – recurrence is a substitute for relapse
	Analysis followed the intent-to-treat principle?
	yes
	Randomised = 297
	prednisolone group = 99
	antituberculosis chemotherapy alone group = 98
Number of patients	Outcome data available at 24 weeks for anorexia, weight and cough = 151
Number of patients	prednisolone group = 80
	antituberculosis chemotherapy alone group = 71
	Outcome data available at 24 weeks for residual effusion = 148
	prednisolone group = 76


	antituberculosis chemotherapy alone group = 72					
	Inclusion					
	Presented with clinical features suggesting pleural tuberculosis, with a pleural effusion occupying at least one-third of 1 hemithorax (as determined by a radiograph)					
	≥18 years old					
	HIV-1-associated					
	Residents o	f Kampala				
	Diagnostic criteria					
	Pleural tuberculosis was considered to be confirmed if a patient had a positive culture for Mycobacterium tuberculosisfrom pleural biopsy tissue, pleural fluid, or sputum or if histopathologic analysis of pleural tissue was consistent with tuberculous pleurisy					
	Exclusion					
Patient characteristics	Previous treatment or prophylaxis for tuberculosis					
	Recent treatment with glucocorticoids					
	Pregnant or breast-feeding					
	Baseline					
			Prednisolone group	Placebo group		
			(n = 98)	(n = 99)		
		Sex				
		males, n	54	60		
		females, n	45	38		
		Age (mean±SD), years	34±9	34±8		


	1	
Weight (mean±SD), kg	54±9	53±8
Blood pressure		
systolic (mean±SD), mm Hg	102±13	101±10
diastolic (mean±SD), mm Hg	73±11	72±11
Symptoms		
fever, n	66	60
cough, n	91	84
dyspnea, n	83	86
chest pain, n	84	82
anorexia, n	72	77
weight loss, n	86	83
Signs		
fever ≥37.5°C, n	55	53
Karnofsky score ≥80%, n	59	49
oral thrus, n	9	5
herpes zoster scars, n	13	12
lymphadenopathy, n	12	11
Laboratory findings		
CD4+ count (median (interquartile range)), cells/ μ l	118 (57–211)	93 (58–219)
confirmed tuberculosis, n	89	91


	isoniazid resistance, n	5	5			
	pyrazinamide resistance, n	1	0			
	Radiography findings					
	1 zone affected, n	14	18			
	2 zones affected, n	49	46			
	≥3 zones affected, n	33	33			
	Antituberculosis chemotherapy plus prednisolone					
Intervention	Prednisolone (8 weeks)					
	supplied as 5-mg tablets and was given concomitantly with tuberculous therapy at a dosage of 50 mg daily for 2 weeks, followed by 40 mg daily for 2 weeks, followed by 25 mg daily for 2 weeks, followed by 15 mg daily for 2 weeks; prednisolone treatment was then stopped					
	Antituberculosis chemotherapy: 2HRZE/4HR					
	doses were adjusted according to each patient's weight, using the American Thoracic Society's standard criteria					
	Participants either were admitted to the tuberculosis ward or (in exceptional circumstances) attended the ward daily, for directly observed treatment for 1 week					
	Antituberculosis chemotherapy plus placebo					
Comparison	Placebo (8 weeks)					
	supplied as 5-mg tablets and was given concomitantly with tuberculous therapy at a dosage of 50 mg daily for 2 weeks, followed by 40 mg daily for 2 weeks, followed by 25 mg daily for 2 weeks, followed by 15 mg daily for 2 weeks; placebo treatment was then stopped					
	Antituberculosis chemotherapy: 2HRZE/4HR					
	doses were adjusted according to each patient's wei	ght, using the Americar	n Thoracic Society's stan	dard criteria		

	Participants either were admitted to the tuberculosis ward or (in exceptional circumstances) attended the ward daily, for directly observed treatment for 1 week			
Length of follow up	42 months			
Location	Kampala, Uganda			
	Mortality			
	Mortality rate (deaths/100 person years)			
Outcomes	prednisolone group (n = 99) = 21			
measures and effect	antituberculosis chemotherapy alone group (n = 98) = 25			
size	RR (95% CI) = 0.84 (0.53 to 1.32)			
	i.e. not statistically significant			
	Kaplan-Meier survival curve			









i.e. statistically significant
Adverse events – incidence of HIV-related disease
Number of patients to experience Kaposi sarcoma
prednisolone group = 6 of 99
antituberculosis chemotherapy alone group = 0 of 98
OR ¹ (95% CI) = 13.70 (0.76 to 246.52)
i.e. not statistically significant
Number of patients to experience cryptococcal meningitis
prednisolone group = 3 of 99
antituberculosis chemotherapy alone group = 5 of 98
OR ¹ (95% CI) = 0.58 (0.14 to 2.50)
i.e. not statistically significant
Number of patients to experience oesophageal candidiasis
prednisolone group = 35 of 99
antituberculosis chemotherapy alone group = 23 of 98
OR ¹ (95% CI) = 1.78 (0.96 to 3.32)
i.e. not statistically significant
Number of patients to experience herpes zoster
prednisolone group = 22 of 99
antituberculosis chemotherapy alone group = 19 of 98
OR ¹ (95% CI) = 1.19 (0.60 to 2.37)

	i.e. not statistically significant
	Number of patients to experience oral or genital herpes simplex
	prednisolone group = 22 of 99
	antituberculosis chemotherapy alone group = 20 of 98
	OR ¹ (95% CI) = 1.11 (0.56 to 2.21)
	i.e. not statistically significant
	Number of patients to experience oral thrush
	prednisolone group = 31 of 99
	antituberculosis chemotherapy alone group = 31 of 98
	OR ¹ (95% CI) = 1.43 (0.79 to 2.56)
	i.e. not statistically significant
	Number of patients to experience gastroenteritis
	prednisolone group = 34 of 99
	antituberculosis chemotherapy alone group = 28 of 98
	OR ¹ (95% CI) = 1.31 (0.72 to 2.39)
	i.e. not statistically significant
Source of funding	Details not provided
Comments	
¹ Odds ratio and 95% o	confidence interval calculated by reviewer
² Read off graph by rev	viewer

³ Mean difference calculated by reviewer

Abbreviations: CI, confidence intervals; E, ethambutol; H, isoniazid; OR, odds ratio; R, rifampicin; RCT, randomised controlled trial; RR, rate ratio; Z, pyrazinamide


1.1.6 Galarza et al, 1995


Bibliographic reference	Galarza I, Cañete C, Granados A et al (1995) Randomised trial of corticosteroids in the treatment of tuberculous pleurisy. Thorax 50: 1305-7
Study type	RCT
	Appropriate method of randomisation used?
	unclear
	Allocation concealment used?
	unclear
	Blinding used?
	double-blind
	Groups comparable at baseline?
Study quality	yes
	Groups received the same care apart from the intervention(s) studied?
	yes, although the details provided were limited
	Groups followed up for an equal and appropriate length of time?
	yes
	Groups comparable for treatment completion and availability of outcome data?
	yes
	Study used precise definitions and reliable measures of outcome?

		(n = 57)	(n = 60)
		Prednisolone group	Placebo group
characteristics	Definite microbiological or pathological diagnosis was obtain	and in 63% of patients	
Patient	Baseline		
	HIV infection		
	Pleural effusion of tuberculous aetiology <i>Exclusion</i>		
	Inclusion		
	placebo group = 60		
Number of patients	prednisolone group = 57		
	Randomised = 117		
	yes		
	Analysis followed the intent-to-treat principle?		
	no		
	Have substitute outcomes been used instead of the patient-	important outcomes of inter	rest?
	yes, although patients received only 2 drugs, lacking etham		
	Intervention used is the same as the intervention of interest	?	
	yes		
	Population studied is the same as the population of interest	?	
	yes		

	Sex, male:female	33:27	30:31
	Side		
	right, n (%)	34	36
	left, n (%)	23	24
	Fever (mean (range)), days	3.32 (0–50)	4.15 (0–60)
	Thickening (mean (range)), mm	1.77 (0–40)	2.23 (0–15)
	FVC (mean (range)), % predicted	95 (65–130)	95 (63–140)
	Follow-up (mean (range)), months	46 (12–94)	46 (12–96)
	Antituberculosis chemotherapy plus prednisolone		
	Prednisolone (30 days)		
Intervention	vention administered in a single oral dose of 1 mg/kg of body weight/day during the first 15 days, and then graduated off as follows: to 0 5 mg/kg of body weight/day from day 16-20 of treatment, then to 0-25 mg/ kg of body weight/day for the remaining days of the month		to 0-25 mg/ kg of body weight/day
	Antituberculosis chemotherapy: 6HR		
	isoniazid, 5 mg/kg/day or a total daily dose of 300 dose of 600 mg/day, once a day for six months as		f body weight/day or a total daily
	Antituberculosis chemotherapy plus placebo		
	Placebo (30 days)		
Comparison	administered in a single oral dose of 1 mg/kg of bo off as follows: to 0 5 mg/kg of body weight/day fro from day 21-26, and finally to 0 10 mg/kg of body	m day 16-20 of treatment, then	to 0-25 mg/ kg of body weight/day
	Antituberculosis chemotherapy: 6HR		

	isoniazid, 5 mg/kg/day or a total daily dose of 300 mg, and rifampicin, 10 mg/kg of body weight/day or a total daily dose of 600 mg/day, once a day for six months as a combination tablet
Length of follow up	46 months
Location	Barcelona, Spain
	Changes in signs and symptoms – pleural thickening
	Number of patients to show pleural thickening at 12 months, as assessed using a chest x-ray
	prednisolone group = 1 of 57
	placebo group = 5 of 60
Outcomes measures and effect	OR ² (95% CI) = 0.20 (0.02 to 1.74)
size	i.e. not statistically significant
	Pleural thickening (mean (range), days) at 46 months, as assessed using a chest x-ray
	prednisolone group (n = 57) = 1.77 (0–40)
	placebo group (n = 60) = 2.23 (0–15)
	MD ³ = -0.46





² Odds ratio and 95% confidence intervals, where possible, calculated by reviewer

³ Mean difference and 95% confidence intervals, where possible, calculated by reviewer

Abbreviations: CI, confidence intervals; H, isoniazid; MD, mean difference; OR, odds ratio; R, rifampicin; RCT, randomised controlled trial; S, streptomycin; SE, standard error

1.1.7 Lee et al, 1988

Bibliographic reference	Lee C-H, Wang W-J, Lan R-S et al (1988) Corticosteroids in the treatment of tuberculosis pleurisy. A double-blind, placebo-controlled, randomised study. Chest 94(6): 1256-9
Study type	RCT
	Appropriate method of randomisation used?
	unclear
	Allocation concealment used?
	unclear
	Blinding used?
	unclear
Study quality	Groups comparable at baseline?
	yes
	Groups received the same care apart from the intervention(s) studied?
	yes, although details provided are limited
	Groups followed up for an equal and appropriate length of time?
	yes
	Groups comparable for treatment completion and availability of outcome data?

	yes
	Study used precise definitions and reliable measures of outcome?
	yes
	Population studied is the same as the population of interest?
	yes
	Intervention used is the same as the intervention of interest?
	yes, although patients did not receive pyrazinamide
	Have substitute outcomes been used instead of the patient-important outcomes of interest?
	no
	Analysis followed the intent-to-treat principle?
	no
	Randomised = 45
	Outcome data available for = 40
Number of patients	prednisolone group = 21
	placebo group = 19
	Inclusion
Patient	Onset of pleural effusion without previous treatment; other aetiologies of pleural effusion, such as congestive heart failure, pneumonia and malignancy, were excluded through diagnostic testing
characteristics	Aged <45 years
	Diagnostic criteria
	Diagnosis of tuberculous pleurisy was confirmed on the basis of pleural biopsy

	Exclusion		
	Other diseases or pulmonary diseases		
	Conditions that contraindicated the use of corticosteroids, such as	diabetes, peptic ulcer o	r hypertension
	Baseline		
		Prednisolone group	Placebo group
		(n = 21)	(n = 19)
	Sex		
	male, n	12	12
	female, n	9	7
	Age (mean (range)), years	28.4 (18–44)	28.9 (18–45)
	Time from onset of symptoms to diagnosis (mean), days	20.6	15.4
	Initial amount of pleural effusions ¹		
	small, n	9	5
	moderate, n	9	9
	large, n	3	5
	Antituberculosis chemotherapy plus prednisolone		
	Prednisolone		
Intervention	administered in an oral dose of 0.75 mg/kg of body weight/day init	ially	
	the dosage was tapered once the chest radiograph showed impro	vement	
	the dosage was diminished by two-thirds if any of the following co	nditions existed: 1) the e	ffusion was right-sided and

	the fluid level was only one intercostal space higher than that of the left hemidiaphragm, 2) the effusion was left-sided and the fluid level was at the same height as the right hemidiaphragm, or 3) complete disappearance of pleural effusion; the dosage of prednisolone was then diminished by 5 mg/week until discontinued
	Antituberculosis chemotherapy: 3HRE/6-9HR
	isoniazid at 300 mg/day, rifampicin at 450 mg/day, ethambutol at 20 mg/kg of body weight/day for the initial 3 months, followed by isoniazid and rifampicin at the same doses for the subsequent 6 to 9 months
	Antituberculosis chemotherapy plus placebo
	Placebo
	administered in an oral dose of 0.75 mg/kg of body weight/day initially
	the dosage was tapered once the chest radiograph showed improvement
Comparison	the dosage was diminished by two-thirds if any of the following conditions existed: 1) the effusion was right-sided and the fluid level was only one intercostal space higher than that of the left hemidiaphragm, 2) the effusion was left-sided and the fluid level was at the same height as the right hemidiaphragm, or 3) complete disappearance of pleural effusion; the dosage of prednisolone was then diminished by 5 mg/week until discontinued
	Antituberculosis chemotherapy: 3HRE/6-9HR
	isoniazid at 300 mg/day, rifampicin at 450 mg/day, ethambutol at 20 mg/kg of body weight/day for the initial 3 months, followed by isoniazid and rifampicin at the same doses for the subsequent 6 to 9 months
Length of follow up	Exact period unclear, though at least 1 year
Location	Taipei, Taiwan
	Change in signs and symptoms – disappearance of clinical signs and symptoms
Outcomes	Time (mean±SD ² (range), days) to disappearance of clinical signs and symptoms (including fever, chest pain and dyspnea)
measures and effect size	prednisolone group (n = 21) = 2.4 ± 1.6 (1–7)
	placebo group (n = 19) = 9.2±16.5 (1–75)
	p<0.05

	MD ³ (95% CI) = -6.8 (-14.3 to 0.7)
	i.e. not statistically significant
	Change in signs and symptoms – pleural effusion
	Time (mean ⁴ (range), days) to clearance of pleural effusion (as defined by roentgenologic evidence of clearing of the lung field, with visualisation of the diaphragm and costophrenic angle)
	prednisolone group (n = 21) = 54.5 (6 -365)
	placebo group (n = 19) = 123.2 (7–395)
	p<0.01
	MD ³ = -68.7
	Change in signs and symptoms – pleural adhesions
	Number of patients to experience pleural adhesions
	prednisolone group = 1 of 21
	placebo group = 3 of 19
	p = 0.27
	OR ⁵ (95% CI) = 0.27 (0.03 to 2.82)
	i.e. not statistically significant
Source of funding	No details provided
Comments	
¹ Small = less than one thirds of one hemithora	e-third of one hemithorax; moderate = between one-third and two-thirds of one hemithorax; large = morTime (e than two- ax

² Standard deviation calculated from the individual patient data read off the graph by reviewer

³ Mean difference and 95% confidence intervals, where possible, calculated by reviewer

⁴ Standard deviation could not be calculated by reviewer as individual patient data could not be read off the graph

⁵ Odds ratio and 95% confidence intervals calculated by reviewer

Abbreviations: CI, confidence intervals; E, ethambutol; H, isoniazid; MD, mean difference; OR, odds ratio; R, rifampicin; RCT, randomised controlled trial; SD, standard deviation

1.1.8 <u>Wyser et al, 1996</u>

reference place	acebo-controlled, randomised study. Chest 110(2): 333-8
Study type RCT	СТ
Study quality Appl Appl uncle Alloc uncle Blind doub Grou grou	ppropriate method of randomisation used? clear location concealment used? clear inding used? uble-blind roups comparable at baseline? hough not statistically significant (p = 0.06), more patients receiving placebo (44.4%) had pleuritis and pulmonary perculosis than amongst those receiving prednisolone (21.2) roups received the same care apart from the intervention(s) studied? s, although details provided are limited roups followed up for an equal and appropriate length of time? low-up not for the full treatment period roups comparable for treatment completion and availability of outcome data?

	yes
	Study used precise definitions and reliable measures of outcome?
	yes
	Population studied is the same as the population of interest?
	yes
	Intervention used is the same as the intervention of interest?
	yes, although patients did not receive ethambutol
	Have substitute outcomes been used instead of the patient-important outcomes of interest?
	yes – 'morbidity' is a patient-reported, surrogate outcome made of a composite of well-being, appetite, night sweats, pleuritic chest pain, tiredness, dyspnea and cough
	Analysis followed the intent-to-treat principle?
	no
	Randomised = 74
	Outcome data available for = 70
Number of patients	prednisolone group = 34
	placebo group = 36
	Inclusion
	Exudative pleural effusions
Patient characteristics	Biopsy specimen-proven tuberculous pleurisy
	Diagnostic criteria
	Diagnosis confirmed by the presence of caseating granulomas with or without acid-fast bacilli on histologic study and/or a positive <i>M. tuberculosis</i> culture

Exclusion		
Other causes of pleural exudates, such as pneumonia or malign	ancy	
Contraindications to corticosteroid use, such as diabetes mellitu empyema	s, uncontrolled hypertension	on, peptic ulcer dis
HIV-seropositive		
Neoplastic disease		
Baseline		
	Prednisolone group	Placebo group
	(n = 34)	(n = 36)
Sex		
male, %	61.8	61.2
Age (mean±SD), years	32.9±13.0	32.8±12.5
Duration of illness prior to hospital admission (mean±SD), weeks	2.9±2.7	3.7±2.2
Pleuritis only, %	78.8	55.6
Pleuritis and pulmonary tuberculosis	21.2	44.4
Initial amount of pleural effusions on chest x-ray		
small, %	2.9	0
moderate, %	14.7	13.9
large, %	82.4	86.1
Positive M. tuberculosis culture		
pleural fluid, %	8.8	13.9

	pleural biopsy specimen, %	78.8	77.8	
	bronchial lavage, %	14.7	8.6	
	Histology			
	caseating granuloma, %	93.7	91.7	
	non-caseating granuloma, %	6.1	8.3	
	Ziehl-Neelsen positive, %	51.5	47.2	
	Appearance on thoracoscopy ¹			
	type 1	9.0	5.7	
	type 2	66.6	62.8	
	type 3	30.4	31.5	
	Antituberculosis chemotherapy plus prednisolone			
	Prednisolone			
	administered in an oral dose of 0.75 mg/kg of body weight/day initially			
Intervention	after 2 to 4 weeks, depending on the therapeutic response as assessed by a progressive reduction of symptoms and radiologic improvement, the dosage was tapered over a 2-week period by 5 mg/dl in all patients			
	Antituberculosis chemotherapy: 6HRZ			
	isoniazid at 8 mg/kg of body weight/day, rifampicin at 10 mg/kg of body weight/day and pyrazinamide at 25 mg/kg of body weight/day for 6 months			
	All patients received 25 mg/kg of body weight/day of pyridoxine			
Composio	Antituberculosis chemotherapy plus placebo			
Comparison	Placebo			

	administered in an oral dose of 0.75 mg/kg of body weight/day initially
	after 2 to 4 weeks, depending on the therapeutic response as assessed by a progressive reduction of symptoms and radiologic improvement, the dosage was tapered over a 2-week period by 5 mg/dl in all patients
	Antituberculosis chemotherapy: 6HRZ
	isoniazid at 8 mg/kg of body weight/day, rifampicin at 10 mg/kg of body weight/day and pyrazinamide at 25 mg/kg of body weight/day for 6 months
	All patients received 25 mg/kg of body weight/day of pyridoxine
Length of follow up	24 weeks
Location	Cape Town, South Africa
	Changes in signs and symptoms – 'morbidity'
	A combined index score for morbidity, measured using a visual analogue scale, incorporating well-being, appetite, night sweats, pleuritic chest pain, tiredness, dyspnea and cough
	Morbidity score (median (range)) at 24 weeks
	prednisolone group (n = 34) = 0 (0–0)
	placebo group (n = 36) = 0 (0–0)
Outcomes measures and effect	Median difference ² = 0
size	i.e. not statistically significant
	Changes in signs and symptoms – pleural thickening
	Number of people to with residual pleural thickening, as assessed using a chest x-ray
	prednisolone group = 17 of 34
	placebo group = 18 of 36
	OR ³ (95% CI) = 1.00 (0.39 to 2.55)

i.e. not statistically significant
Number of people to with residual pleural thickening, as assessed using a CT scan
prednisolone group = 17 of 34
placebo group = 21 of 36
OR ³ (95% CI) = 0.71 (0.28 to 1.84)
i.e. not statistically significant
Pleural thickening (mean±SD, mm) at 24 weeks, as assessed using a chest x-ray
prednisolone group (n = 34) = 2.1 ± 2.7
placebo group (n = 36) = 2.5 ± 3.7
MD ⁴ (95% CI) = -0.4 (-1.9 to 1.1)
i.e. not statistically significant
Change in pleural thickening (MD (95% CI), mm) from baseline to 24 weeks, as assessed using a chest x-ray ⁵
prednisolone group (n = 34) = -7.3 (-9.0 to -5.6)
placebo group (n = 36) = -7.9 (-10.1 to -5.7)
Difference in change in means ⁶ = -0.6
Pleural thickening (mean±SD, mm) at 24 weeks, as assessed using a CT scan
prednisolone group (n = 34) = 3.0 ± 3.7
placebo group (n = 36) = 4.3 ± 5.1
MD ⁴ (95% CI) = -1.3 (-3.4 to 0.8)
Adverse events
Number of people to experience an adverse event

	prednisolone group = 4 of 34	
	placebo group = 3 of 36	
	$OR^3 (95\% \text{ CI}) = 1.47 (0.30 \text{ to } 7.10)$	
	i.e. not statistically significant	
Source of funding	No details provided	
Comments		
¹ Type 1 = non-specific inflammation of the parietal pleura with no or only a few fibrinous adhesions; type 2 = 'classic' tuberculous pleurisy with an inflamed reddish pleura and multiple greyish-white nodules; type 3 = fibrous inflammation with a thickened parietal pleura and multiple fibrous adhesions and/or loculations		
² Median difference calculated by reviewer		
³ Odds ratio and 95% confidence interval calculated by reviewer		
⁴ Mean difference and 95% confidence interval calculated by reviewer		
⁵ Changes in mean and 95% confidence interval calculated by reviewer		
⁵ Difference in the changes in mean calculated by reviewer		
Abbreviations: CI, confidence intervals; CT, computerised tomography; H, isoniazid; MD, mean difference; OR, odds ratio; R, rifampicin; RCT, randomised controlled trial; SD, standard deviation; Z, pyrazinamide		

1.1.9 Singh & Yesikar, 1965

Bibliographic reference	Singh D & Yesikar SS (1965) Role of intrapleural corticosteroids in tuberculous pleural effusion. A clinicotherapeutic trial of 50 cases. Journal of the Indian Medical Association 45(6): 306-9
Study type	Non-randomised controlled trial
Study quality	Appropriate method of randomisation used?

Allocation concealment used?
no
Blinding used?
no
Groups comparable at baseline?
unclear
Groups received the same care apart from the intervention(s) studied?
yes, although details provided are limited
Groups followed up for an equal and appropriate length of time?
unclear
Groups comparable for treatment completion and availability of outcome data?
yes
Study used precise definitions and reliable measures of outcome?
yes
Population studied is the same as the population of interest?
yes
Intervention used is the same as the intervention of interest?
yes, although patients did not receive rifampicin, pyrazinamide and ethambutol but received streptomycin
Have substitute outcomes been used instead of the patient-important outcomes of interest?
recurrence is a substitute for relapse
Analysis followed the intent-to-treat principle?

	yes
	Randomised = 50
Number of patients	dexamethasone group = 30
	antituberculosis chemotherapy alone group = 20
	Inclusion
Patient	Pleural effusion with tuberculous aetiology
characteristics	Typical onset and course of disease
	Positive Mantoux test
	Antituberculosis chemotherapy plus dexamethasone
	Dexamethasone
	4 mg of dexamethasone injected intrapleurally and the pleural fluid aspirated every 15 days until the puncture was dry
Intervention	Antituberculosis chemotherapy: SH
	isoniazid at 300 mg/day and streptomycin at 1 g/day
	All patients received vitamins and haematinics
	All patients were hospitalised and were at rest
	Antituberculosis chemotherapy alone
	Antituberculosis chemotherapy: SH
Comparison	isoniazid at 300 mg/day and streptomycin at 1 g/day
	Half of the patients also underwent aspirations every 15 days until the puncture was dry
	All patients received vitamins and haematinics
	All patients were hospitalised and were at rest

Length of follow up	Unclear
Location	Bhopal, India
	Changes in signs and symptoms – effusion
	Time (mean, days) taken for complete absorption of pleural effusion
	dexamethasone group (n = 30) = 23.5
	antituberculosis chemotherapy alone group (n = 20) = 71.2
	MD ¹ = -47.7
	Time (mean, days) taken for complete absorption of pleural effusion among those with a large effusion
	dexamethasone group (n = 9) = 30.0
	antituberculosis chemotherapy alone group (n = 4) = 93.8
Outcomes	MD ¹ = -63.8
measures and effect	Time (mean, days) taken for complete absorption of pleural effusion among those with a medium effusion
size	dexamethasone group (n = 16) = 22.5
	antituberculosis chemotherapy alone group (n = 12) = 72.5
	MD ¹ = -50.0
	Time (mean, days) taken for complete absorption of pleural effusion among those with a small effusion
	dexamethasone group (n = 5) = 15.0
	antituberculosis chemotherapy alone group $(n = 4) = 45.0$
	MD ¹ = -30.0
	Changes in signs and symptoms – cough
	Time (mean, days) to relief of cough

dexamethasone group (n = 30) = 20.1
antituberculosis chemotherapy alone group (n = 20) = 32.2
MD ¹ = -12.1
Changes in signs and symptoms – shortness of breath
Time (mean, days) to relief of shortness of breath
dexamethasone group (n = 30) = 3.1
antituberculosis chemotherapy alone group (n = 20) = 15.7
MD ¹ = -12.6
Changes in signs and symptoms – chest pain
Time (mean, days) to relief of chest pain
dexamethasone group (n = 30) = 6.9
antituberculosis chemotherapy alone group (n = 20) = 20.7
MD ¹ = -13.8
Changes in signs and symptoms – temperature
Time (mean, days) to normalisation of temperature
dexamethasone group (n = 30) = 9.0
antituberculosis chemotherapy alone group (n = 20) = 28.8
MD ¹ = -19.8
Changes in signs and symptoms – weight
Final weight (mean, kg)
dexamethasone group (n = 30) = 43.4

	antituberculosis chemotherapy alone group (n = 20) = 41.8
	$MD^1 = 1.6$
	Change in mean weight (kg) from baseline to the end of follow-up
	dexamethasone group (n = 30) = 2.0
	antituberculosis chemotherapy alone group (n = 20) = 1.5
	MD ¹ = 0.5
	Recurrence
	Number of patients to experience recurrence
	dexamethasone group = 0 of 30
	antituberculosis chemotherapy alone group = 4 of 20
	OR ² (95% CI) = 0.06 (0.00 to 1.19)
	i.e. not statistically significant
Source of funding	No details provided
Comments	
¹ Mean difference and 95% confidence interval calculated by reviewer	
² Odds ratio and 95% confidence interval calculated by reviewer	

Abbreviations: CI, confidence intervals; H, isoniazid; MD, mean difference; OR, odds ratio; S, streptomycin

TUBERCULOSIS WITH SEVERE BRONCHIAL OBSTRUCTION

1.1.10 Toppet et al, 1

Bibliographic reference	Toppet M, Malfroot A, Derde MP et al (1990) Corticosteroids in primary tuberculosis with bronchial obstruction. Archives of Disease in Childhood 65: 1222-6
Study type	RCT
	Appropriate method of randomisation used?
	numbered envelopes
	Allocation concealment used?
	unclear
	Blinding used?
	'open' trial, although examination of bronchoscopy and radiographs blinded
	Groups comparable at baseline?
Study quality	yes
	Groups received the same care apart from the intervention(s) studied?
	unclear – those receiving steroids were recommended a sodium-restricted diet, potassium glucoconate supplements and gastric protection by aluminium phosphate, but it is unclear if those on antituberculosis chemotherapy alone received these
	Groups followed up for an equal and appropriate length of time?
	yes
	Groups comparable for treatment completion and availability of outcome data?
	yes

	Study used precise definitions and reliable measures of outcome?
	yes
	Population studied is the same as the population of interest?
	yes
	Intervention used is the same as the intervention of interest?
	antituberculosis regimens do not use all of or just the 4 standard recommended drugs: lack pyrazinamide
	Have substitute outcomes been used instead of the patient-important outcomes of interest?
	yes – need for multiple bronchoscopies is a surrogate for changes in signs and symptoms
	Analysis followed the intent-to-treat principle?
	yes
	Randomised = 29
	prednisolone group = 15
	antituberculosis chemotherapy alone group = 14
	Outcome data available for outcomes based on bronchoscopy = 29
Number of patients	prednisolone group = 15
	antituberculosis chemotherapy alone group = 14
	Outcome data available for outcomes based on radiography = 23
	prednisolone group = 13
	antituberculosis chemotherapy alone group = 10
Patient	Inclusion
characteristics	Children

		(n = 15)	chemotherapy alone group	
		Prednisolone	Antituberculosis	
Baseli	ine ¹			
Patien	ts without clinical and radiological abnorma	lities and negative bacteriology	for <i>M. tuberculosis</i>	
Miliary	/ tuberculosis			
Menin	gitis			
	ts who already had bronchial fistulisation w ation could be prevented	ere not included in this study as	the aim was to verify whether	
Exclus	sion			
bronch	noscopy			
chest	radiographs			
family	history of tuberculosis			
clinica	I signs such as an unexpected course of pu	Imonary consolidation, long sta	nding unexplained fever or cough	
recent	tuberculin conversion with an induration of	at least 10 mm after 48 or 72 he	ours	
A com	bination of the following:			
Diagn	ostic criteria			
import	ance of the obstruction: total or >75% = 4; §	50-75% = 2; <50% = 1; no obstr	ruction = 0	
localis	ation: trachea = 4; main bronchus = 3; loba	r bronchus = 2; segmental bron	chus = 1	
A bror	nchoscopy score equal or higher than 2, acc	cording to the following scoring s	system:	
A com	pression of at least 50% of a bronchus			
	tomatic tuberculosis with severe bronchial o noscopy	bstruction suspected by radiolog	gy and demonstrated by	
				_

			(n = 10)		
	Age (mean±SD (range)), years	4.3±4.2 (0.3–12)	5.5±4.2 (0.5–15)		
	Sex				
	males, n	11	8		
	females, n	4	6		
	M. tuberculosis culture				
	positive, n	9	9		
	negative, n	6	5		
	Score on radiology ² (mean±SD (range))	4.8±2.2 (3–10)	3.9±1.4 (2–6)		
	Score on bronchoscopy ³ (mean±SD (range))	15.4±6.9 (2–26)	11.8±5.7 (3–21)		
	Antituberculosis chemotherapy plus prednisolo	ne			
	Prednisolone (3 to 3.5 months)				
	started at a daily dose of 2 mg/kg of body weight for 15 days and was progressively decreased to be stopped between 2.5 and 3 months				
Intervention	Antituberculosis chemotherapy: 2HRZE/10HR				
	10 mg/kg of body weight/day of isoniazid (up to a maximum of 300 mg/day), 15 mg/kg of body weight/day of rifampicin (up to a maximum of 600 mg/day) and 20 mg/kg of body weight/day of ethambutol for 2 months				
	isoniazid and rifampicin at the same doses for the following 10 months				
	Antituberculosis chemotherapy alone				
Comparison	Antituberculosis chemotherapy: 2HRZE/10HR				

	10 mg/kg of body weight/day of isoniazid (up to a maximum of 300 mg/day), 15 mg/kg of body weight/day of rifampicin (up to a maximum of 600 mg/day) and 20 mg/kg of body weight/day of ethambutol for 2 months
	isoniazid and rifampicin at the same doses for the following 10 months
Length of follow up	Full treatment period (12 months)
Location	Brussels, Belgium
	Changes in signs and symptoms – radiological status
	Number of patients whose radiological score normalised during treatment
	prednisolone group = 13 of 15
	antituberculosis chemotherapy alone group = 9 of 14
	OR ⁴ (95% CI) = 3.61 (0.57 to 22.90)
	i.e. not statistically significant
	Number of patients whose radiological score improved in ≤1 month
Outcomes	prednisolone group = 7 of 15
measures and effect size	antituberculosis chemotherapy alone group = 0 of 14
	OR ^₄ (95% CI) = 25.59 (1.29 to 506.48)
	i.e. statistically significant
	Number of patients whose radiological score deteriorated during treatment
	prednisolone group = 2 of 15
	antituberculosis chemotherapy alone group = 5 of 14
	OR ⁴ (95% CI) = 0.28 (0.04 to 1.76)
	i.e. not statistically significant

Changes in signs and symptoms – bronchial status Change (mean±SD) in bronchoscopy score ³ from baseline to 1 month post-treatment prednisolone group (n = 15) = 12.1±6.9 antituberculosis chemotherapy alone group (n = 14) = 5.9±5.0 MD ⁶ (95% Cl) = 6.2 (1.83 to 10.57) i.e. statistically significant Response to treatment – need for multiple bronchoscopies Number of patients to require >2 bronchoscopies Number of patients to require >2 bronchoscopies nettuberculosis chemotherapy alone group = 6 of 14 OR ⁴ (95% Cl) = 0.10 (0.01 to 0.94) i.e. statistically significant Source of funding No details provided Comments ¹ Authors provided individual patient data; reviewer summarised for comparison of the 2 groups ² Radiological score: size of the adenopathy scored 1 to 3; segmental consolidation or hyperinflation scored 1; lobar consolidation or hyperinflation scored 6 ³ Bronchoscopy score: localisation: trachea = 4; main bronchus = 3; lobar bronchus = 2; segmental bronchus = 1		
Prednisolone group (n = 15) = 12.1±6.9 antituberculosis chemotherapy alone group (n = 14) = 5.9±5.0 MD ⁵ (95% CI) = 6.2 (1.83 to 10.57) i.e. statistically significant Response to treatment – need for multiple bronchoscopies Number of patients to require >2 bronchoscopies prednisolone group = 1 of 15 antituberculosis chemotherapy alone group = 6 of 14 OR ⁴ (95% CI) = 0.10 (0.01 to 0.94) i.e. statistically significant Source of funding No details provided Comments ¹ Authors provided individual patient data; reviewer summarised for comparison of the 2 groups ² Radiological score: size of the adenopathy scored 1 to 3; segmental consolidation or hyperinflation scored 1; lobar consolidation or hyperinflation scored 3; pulmonary consolidation or hyperinflation scored 6 ³ Bronchoscopy score:		Changes in signs and symptoms – bronchial status
antituberculosis chemotherapy alone group (n = 14) = 5.9±5.0 MD ⁵ (95% Cl) = 6.2 (1.83 to 10.57) i.e. statistically significant Response to treatment – need for multiple bronchoscopies Number of patients to require >2 bronchoscopies prednisolone group = 1 of 15 antituberculosis chemotherapy alone group = 6 of 14 OR ⁴ (95% Cl) = 0.10 (0.01 to 0.94) i.e. statistically significant Source of funding No details provided Comments ¹ Authors provided individual patient data; reviewer summarised for comparison of the 2 groups ² Radiological score: size of the adenopathy scored 1 to 3; segmental consolidation or hyperinflation scored 1; lobar consolidation or hyperinflation scored 3; pulmonary consolidation or hyperinflation scored 6 ³ Bronchoscopy score:		Change (mean±SD) in bronchoscopy score ³ from baseline to 1 month post-treatment
MD ⁵ (95% Cl) = 6.2 (1.83 to 10.57) i.e. statistically significant Response to treatment – need for multiple bronchoscopies Number of patients to require >2 bronchoscopies prednisolone group = 1 of 15 antituberculosis chemotherapy alone group = 6 of 14 OR ⁴ (95% Cl) = 0.10 (0.01 to 0.94) i.e. statistically significant Source of funding No details provided Comments ¹ Authors provided individual patient data; reviewer summarised for comparison of the 2 groups ² Radiological score: size of the adenopathy scored 1 to 3; segmental consolidation or hyperinflation scored 1; lobar consolidation or hyperinflation scored 3; pulmonary consolidation or hyperinflation scored 6 ³ Bronchoscopy score:		prednisolone group (n = 15) = 12.1 ± 6.9
i.e. statistically significant Response to treatment – need for multiple bronchoscopies Number of patients to require >2 bronchoscopies prednisolone group = 1 of 15 antituberculosis chemotherapy alone group = 6 of 14 OR ⁴ (95% Cl) = 0.10 (0.01 to 0.94) i.e. statistically significant Source of funding No details provided Comments ¹ Authors provided individual patient data; reviewer summarised for comparison of the 2 groups ² Radiological score: size of the adenopathy scored 1 to 3; segmental consolidation or hyperinflation scored 1; lobar consolidation or hyperinflation scored 3; pulmonary consolidation or hyperinflation scored 6 ³ Bronchoscopy score:		antituberculosis chemotherapy alone group (n = 14) = 5.9 ± 5.0
Response to treatment – need for multiple bronchoscopies Number of patients to require >2 bronchoscopies prednisolone group = 1 of 15 antituberculosis chemotherapy alone group = 6 of 14 OR ⁴ (95% Cl) = 0.10 (0.01 to 0.94) i.e. statistically significant Source of funding No details provided Comments ¹ Authors provided individual patient data; reviewer summarised for comparison of the 2 groups ² Radiological score: size of the adenopathy scored 1 to 3; segmental consolidation or hyperinflation scored 1; lobar consolidation or hyperinflation scored 3; pulmonary consolidation or hyperinflation scored 6 ³ Bronchoscopy score:		MD ⁵ (95% CI) = 6.2 (1.83 to 10.57)
Number of patients to require >2 bronchoscopies prednisolone group = 1 of 15 antituberculosis chemotherapy alone group = 6 of 14 OR ⁴ (95% CI) = 0.10 (0.01 to 0.94) i.e. statistically significant Source of funding No details provided Comments ¹ Authors provided individual patient data; reviewer summarised for comparison of the 2 groups ² Radiological score: size of the adenopathy scored 1 to 3; segmental consolidation or hyperinflation scored 1; lobar consolidation or hyperinflation scored 3; pulmonary consolidation or hyperinflation scored 6		i.e. statistically significant
prednisolone group = 1 of 15 antituberculosis chemotherapy alone group = 6 of 14 OR ⁴ (95% Cl) = 0.10 (0.01 to 0.94) i.e. statistically significant Source of funding No details provided Comments ¹ Authors provided individual patient data; reviewer summarised for comparison of the 2 groups ² Radiological score: size of the adenopathy scored 1 to 3; segmental consolidation or hyperinflation scored 1; lobar consolidation or hyperinflation scored 6 ³ Bronchoscopy score:		Response to treatment – need for multiple bronchoscopies
antituberculosis chemotherapy alone group = 6 of 14 OR ⁴ (95% Cl) = 0.10 (0.01 to 0.94) i.e. statistically significant Source of funding No details provided Comments ¹ Authors provided individual patient data; reviewer summarised for comparison of the 2 groups ² Radiological score: size of the adenopathy scored 1 to 3; segmental consolidation or hyperinflation scored 1; lobar consolidation or hyperinflation scored 3; pulmonary consolidation or hyperinflation scored 6 ³ Bronchoscopy score:		Number of patients to require >2 bronchoscopies
OR ⁴ (95% Cl) = 0.10 (0.01 to 0.94) i.e. statistically significant Source of funding No details provided Comments ¹ Authors provided individual patient data; reviewer summarised for comparison of the 2 groups ² Radiological score: size of the adenopathy scored 1 to 3; segmental consolidation or hyperinflation scored 1; lobar consolidation or hyperinflation scored 3; pulmonary consolidation or hyperinflation scored 6 ³ Bronchoscopy score:		prednisolone group = 1 of 15
i.e. statistically significant Source of funding No details provided Comments Image: Comment and the state and		antituberculosis chemotherapy alone group = 6 of 14
Source of funding No details provided Comments Image: No details provided ¹ Authors provided individual patient data; reviewer summarised for comparison of the 2 groups Image: No details provided ² Radiological score: size of the adenopathy scored 1 to 3; segmental consolidation or hyperinflation scored 1; lobar consolidation or hyperinflation scored 3; pulmonary consolidation or hyperinflation scored 6 ³ Bronchoscopy score: Image: No details provided		OR ⁴ (95% CI) = 0.10 (0.01 to 0.94)
Comments ¹ Authors provided individual patient data; reviewer summarised for comparison of the 2 groups ² Radiological score: size of the adenopathy scored 1 to 3; segmental consolidation or hyperinflation scored 1; lobar consolidation or hyperinflation scored 3; pulmonary consolidation or hyperinflation scored 6 ³ Bronchoscopy score:		i.e. statistically significant
 ¹ Authors provided individual patient data; reviewer summarised for comparison of the 2 groups ² Radiological score: size of the adenopathy scored 1 to 3; segmental consolidation or hyperinflation scored 1; lobar consolidation or hyperinflation scored 3; pulmonary consolidation or hyperinflation scored 6 ³ Bronchoscopy score: 	Source of funding	No details provided
 ² Radiological score: size of the adenopathy scored 1 to 3; segmental consolidation or hyperinflation scored 1; lobar consolidation or hyperinflation scored 6 ³ Bronchoscopy score: 	Comments	
hyperinflation scored 3; pulmonary consolidation or hyperinflation scored 6 ³ Bronchoscopy score:	¹ Authors provided indi	vidual patient data; reviewer summarised for comparison of the 2 groups
localisation: trachea = 4; main bronchus = 3; lobar bronchus = 2; segmental bronchus = 1	³ Bronchoscopy score:	
	localisation: trachea =	4; main bronchus = 3; lobar bronchus = 2; segmental bronchus = 1
importance of the obstruction: total or >75% = 4; 50-75% = 2; <50% = 1; no obstruction = 0	importance of the obst	ruction: total or >75% = 4; 50-75% = 2; <50% = 1; no obstruction = 0
⁴ Odds ratio and 95% confidence interval calculated by reviewer	⁴ Odds ratio and 95% o	confidence interval calculated by reviewer

⁵ Mean difference and 95% confidence interval calculated by reviewer

Abbreviations: CI, confidence intervals; E, ethambutol; H, isoniazid; OR, odds ratio; R, rifampicin; RCT, randomised controlled trial; SD, standard deviation

CENTRAL NERVOUS SYSTEM TUBERCULOSIS

1.1.11 Chotmongkol et al, 1996

Bibliographic reference	Chotmongkol V, Jitpimolmard S & Thavornpitak Y (1996) Corticosteroid in tuberculous meningitis. Journal of the Medical Association of Thailand 79(2): 83-90
Study type	RCT
	Appropriate method of randomisation used?
	unclear – patients were randomised by a block size of 4 using coded treatment (A = placebo; B = prednisolone)
	Allocation concealment used?
	unclear
	Blinding used?
	double-blind – participants receiving care and individuals administering care were blind to treatment allocation; unclear if investigators were blind to treatment allocation, or to important confounding or prognostic factors
	Groups comparable at baseline?
Study quality	clinical presentations and staging were similar in the intervention and comparator groups at randomisation; however, although not statistically significant, more patients in the prednisolone group (17%) had motor weakness than in the placebo group (3%), and more patients in the prednisolone group (17%) had motor weakness than in the placebo group (10%)
	additionally, there were more patients with severe (stage 3) disease and fewer patients with less severe (stage 1) disease in the prednisolone group than in the placebo group, although again this was not statistically significant
	Groups received the same care apart from the intervention(s) studied?
	yes, although details provided are limited
	Groups followed up for an equal and appropriate length of time?
	yes – 12 months after treatment completion

	Groups comparable for treatment completion and availability of outcome data?
	yes – 100% in both groups
	Study used precise definitions and reliable measures of outcome?
	yes, although details provided are limited
	Population studied is the same as the population of interest?
	yes
	Intervention used is the same as the intervention of interest?
	antituberculosis regimens do not use all of or just the 4 standard recommended drugs: lack ethambutol and contain streptomycin
	Have substitute outcomes been used instead of the patient-important outcomes of interest?
	yes - need for additional intervention (response to treatment) is a substitute for treatment success/failure
	Analysis followed the intent-to-treat principle?
	yes
	Randomised = 59
Number of patients	prednisolone group = 29
	placebo group = 30
	Inclusion
	Tuberculous meningitis
Patient characteristics	Aged more than 15 years
	Negative serologic test for syphilis and HIV
	Diagnostic criteria

Acc				
	ording to characteristic clinical features a	and CSF findings:		
lym	phocytic meningitis			
low	glucose level			
ele	vation of protein content			
ste	ile routine bacterial and fungal culture			
neç	ative latex agglutination test for bacteria	l and cryptococcal antigen		
neç	ative cytologic study for malignancy			
Sev	verity of disease			
Cla	ssified according to the system of Gordo	n and Parsons (1972):		
	ge 1: patients were conscious and rationa rocephalus	al with meningism but no focal	l neurological signs or si	igns of
sta	ge 2: patients were confused or had foca	l nourological signa quab as a		
		in neurological signs such as s	quint, hemiparesis or sig	gns of hydrocep
	ge 3: the patients' mental state could not aplegia			
par	ge 3: the patients' mental state could not			
par	ge 3: the patients' mental state could not aplegia		or or delirium, complete Placebo group	
par	ge 3: the patients' mental state could not aplegia	be assessed because of stup Prednisolone	or or delirium, complete	hemiplegia or
par	ge 3: the patients' mental state could not aplegia	be assessed because of stup Prednisolone group	or or delirium, complete Placebo group	hemiplegia or
par	ge 3: the patients' mental state could not aplegia seline	be assessed because of stup Prednisolone group (n = 29)	or or delirium, complete Placebo group (n = 30)	hemiplegia or
par	ge 3: the patients' mental state could not aplegia seline Age (mean±SD), years	be assessed because of stup Prednisolone group (n = 29) 42±18.6	or or delirium, complete Placebo group (n = 30) 39±18.3	hemiplegia or p value 0.51

2, %	69.0	66.7	
3, %	20.7	13.3	
Headache, %	93.1	96.7	0.61
Fever (temperature > 38.0°C), %	93.1	76.7	0.15
Stiff neck, %	96.6	96.7	1.00
Mental impairment (confusion, stuporous), %	69.0	63.3	0.85
Papilloedema, %	24.1	16.7	0.70
Cranial nerve palsies, %	24.1	20.0	0.94
Decreased vision, %	10.3	10.0	
Motor weakness (parapesis, hemiparesis), %	17.2	10.0	0.10
Other foci of tuberculous infection, %	58.6	43.3	0.36
lung, %	51.7	26.7	
lymph node, %	0.0	10.0	
spine, %	0.0	3.3	
larynx, %	3.4	0.0	
peritoneum, %	3.4	0.0	
intestine, %	0.0	3.3	
Abnormal chest x-ray, %	51.7	26.7	0.08
Abnormal CT scan of brain (hydrocephalus, lacunar infarction, tuberculoma, brain oedema), %	83.3	84.6	1.0
Hyponatraemia (<125 mEq/L), %	20.7	10.0	0.29

	CSF abnormalities				
	high opening pressure (>300 mmH2O), %	51.7	56.7	0.90	
	white blood cell count (/mm3)				
	mean	403	388	0.80	
	range	25–1202	10–2000		
	protein content (mg/dl)				
	mean	247.8	287	0.67	
	range	57–9570	76–8500		
	positive AFB stain, %	3.4	0.0		
	positive culture for <i>M. tuberculosis</i> , %	13.8	3.3		
	Antituberculosis chemotherapy plus prednisolone				
	Prednisolone (5 weeks)				
	60 mg/day taken orally with alum milk in 3 divided doses after meals during the first week				
Intervention	the dose was reduced to 45, 30, 20 and 10 mg/day for the second, third, forth and fifth weeks respectively, then discontinued				
	Antituberculosis chemotherapy: 2HRZS/4HR				
	300 mg isoniazid, 600 mg rifampicin (450 mg for those weighing less than 50 kg), 1500 mg pyrazinamide and 750 mg streptomycin for the first 2 months				
	isoniazid and rifampicin at the same doses for the following 4 months				
	Antituberculosis chemotherapy plus placebo				
Comparison	Placebo (5 weeks)				

	tablets of identical appearance to the prednisolone
	60 mg/day taken orally with alum milk in 3 divided doses after meals during the first week
	the dose was reduced to 45, 30, 20 and 10 mg/day for the second, third, forth and fifth weeks respectively, then discontinued
	Antituberculosis chemotherapy: 2HRZS/4HR
	300 mg isoniazid, 600 mg rifampicin (450 mg for those weighing less than 50 kg), 1500 mg pyrazinamide and 750 mg streptomycin for the first 2 months
	isoniazid and rifampicin at the same doses for the following 4 months
Length of follow up	12 months after treatment completion
Location	Khon Kaen, Thailand
	Mortality
	Number of deaths
	prednisolone group = 5 of 29
	placebo group = 2 of 30
	p = 0.25
Outcomes	OR ¹ (95% CI) = 2.92 (0.52 to 16.42)
measures and effect size	i.e. not statistically significant
	Stage 1
	prednisolone group = 0 of 3
	placebo group = 0 of 6
	OR ¹ (95% CI) = 1.86 (0.03 to 115.45)
	i.e. not statistically significant

Stage 2
prednisolone group = 1 of 20
placebo group = 0 of 20
OR ¹ (95% CI) = 3.15 (0.12 to 82.17)
i.e. not statistically significant
Stage 3
prednisolone group = 4 of 6
placebo group = 2 of 4
OR ¹ (95% CI) = 2.00 (0.15 to 26.74)
i.e. not statistically significant
Response to treatment – need for additional intervention (ventricular shunting)
Number of patients to require ventricular shunting (as indicated by persistent high CSF pressure after 4 weeks of repeated lumbar puncture)
prednisolone group = 5 of 29
placebo group = 4 of 30
p = 0.73
OR ¹ (95% CI) = 1.35 (0.33 to 5.64)
i.e. not statistically significant
Changes in signs and symptoms – neurological abnormalities during treatment
Number of patients to experience neurological abnormalities newly developed during treatment
prednisolone group = 2 of 29

placebo group = 4 of 30
p = 0.67
OR ¹ (95% CI) = 0.48 (0.08 to 2.86)
i.e. not statistically significant
Number of patients to experience urinary retention newly developed during treatment
prednisolone group = 1 of 29
placebo group = 1 of 30
OR ¹ (95% CI) = 1.04 (0.06 to 17.38)
i.e. not statistically significant
Number of patients to experience arm weakness newly developed during treatment
prednisolone group = 1 of 29
placebo group = 0 of 30
OR ¹ (95% CI) = 3.21 (0.13 to 82.07)
i.e. not statistically significant
Number of patients to experience paraparesis newly developed during treatment
prednisolone group = 0 of 29
placebo group = 2 of 30
OR ¹ (95% CI) = 0.19 (0.01 to 4.20)
i.e. not statistically significant
Number of patients to experience hemiparesis newly developed during treatment
prednisolone group = 0 of 29

placebo group = 1 of 30
OR ¹ (95% CI) = 0.33 (0.01 to 8.52)
i.e. not statistically significant
Changes in signs and symptoms – neurological abnormalities after treatment
Number of patients to experience neurological abnormalities after treatment
prednisolone group = 4 of 29
placebo group = 2 of 30
p = 0.42
OR ¹ (95% CI) = 2.24 (0.38 to 13.30)
i.e. not statistically significant
Number of patients to experience decreased vision after treatment
prednisolone group = 2 of 29
placebo group = 1 of 30
OR ¹ (95% CI) = 2.15 (0.18 to 25.07)
i.e. not statistically significant
Number of patients to experience spastic paraparesis after treatment
prednisolone group = 1 of 29
placebo group = 1 of 30
OR ¹ (95% CI) = 1.04 (0.06 to 17.38)
i.e. not statistically significant
Number of patients to experience hemiparesis after treatment

prednisolone group = 1 of 29
placebo group = 0 of 30
OR ¹ (95% CI) = 3.21 (0.13 to 82.07)
i.e. not statistically significant
Changes in signs and symptoms - headache
Time (mean, days) until disappearance of headache
prednisolone group (n = 29) = 15.9
placebo group (n = 30) = 13.3
p = 0.61
MD ² = 2.6
Changes in signs and symptoms - fever
Time (mean (range), days) until normal body temperature
prednisolone group (n = 29) = $5.6(1 - 27)$
placebo group (n = 30) = 9.3 (2 – 21)
p = 0.06
MD ² = -3.7
Recurrence
Number of patients to experience recurrence of meningitis during follow-up
prednisolone group = 0 of 29
placebo group = 0 of 30
OR ¹ (95% CI) = 1.03 (0.02 to 53.83)

	i.e. not statistically significant
	Adverse events - gastrointestinal bleeding
	Number of patients to experience gastrointestinal bleeding
	prednisolone group = 0 of 29
	placebo group = 0 of 30
	OR ¹ (95% CI) = 1.03 (0.02 to 53.83)
	i.e. not statistically significant
	Adverse events - hyperglycaemia
	Number of patients to experience hyperglycaemia
	prednisolone group = 0 of 29
	placebo group = 0 of 30
	OR ¹ (95% CI) = 1.03 (0.02 to 53.83)
	i.e. not statistically significant
Source of funding	Tablets of prednisolone and placebo were provided by Siam Pharmaceutical Co. Ltd.
Comments	

¹ Odds ratio and 95% confidence interval calculated by reviewer

² Mean difference calculated by reviewer

Abbreviations: AFB, acid-fast bacilli; CI, confidence intervals; CSF, cerebrospinal fluid; CT, computerised tomography; H, isoniazid; HIV, human immunodeficiency virus; MD, mean difference; OR, odds ratio; R, rifampicin; RCT, randomised controlled trial; S, streptomycin; SD, standard deviation; TB, tuberculosis; Z, pyrazinamide

1.1.12 Girgis et al, 1983

Bibliographic reference	Girgis NI, Farid Z, Hanna LS (1983) The use of dexamethasone in preventing ocular complications in tuberculous meningitis. Transactions of the Royal Society of Tropical Medicine and Hygiene 77(5): 658-9
Study type	Non-randomised controlled trial
reference	meningitis. Transactions of the Royal Society of Tropical Medicine and Hygiene 77(5): 658-9
	unclear Groups comparable for treatment completion and availability of outcome data?
	unclear
	Study used precise definitions and reliable measures of outcome?

	yes, although details provided are limited			
	Population studied is the same as the population of interest?			
	yes			
	Intervention used is the same as the intervention of interest?			
	antituberculosis regimens do not use all of or just the 4 standard recommended drugs: lack rifampicin and pyrazinamide, but contain streptomycin			
	Have substitute outcomes been used instead of the patien	nt-important outcomes of inter	est?	
	no			
	Included = 136			
Number of patients	dexamethasone group = 66			
	antituberculosis chemotherapy alone group = 70			
	Inclusion			
	Tuberculous meningitis			
	Diagnostic criteria			
	Isolation of tubercle bacilli from the CSF, or a CSF findings consistent with tuberculous meningitis (increased protein, low glucose, and lymphocytotic pleocytosis)			
Patient	Baseline			
characteristics		Dexamethasone group (n = 66)	Antituberculosis chemotherapy alone group	
			(n = 70)	
	Sex			
	males, %	45.5	54.3	

	formalian D/	545	45.7	
	females, %	54.5	45.7	
	Age (mean (range)), years	14.6 (0.5 – 52)	13.6 (0.6 – 42)	
	CSF positive for tubercle bacilli, %	45.5	48.6	
	Duration of symptoms prior to admission (mean (range)), days	27.8 (6 – 120)	25.5 (5 – 105)	
	Clinical condition on admission			
	alert, %	3.0	7.1	
	drowsy, %	34.8	47.1	
	comatose, %	62.1	45.7	
	Antituberculosis chemotherapy plus dexamethasone			
	Dexamethasone (3 weeks)			
	8 to 12 mg/day			
Intervention Antituberculosis chemotherapy: 1.5HSE/22.5HE				
	10 mg/kg of body weight/day isoniazid, 25 mg/kg of body weight/day streptomycin and 25 mg/kg of bod ethambutol for the first 60 days			
	10 mg/kg of body weight/day isoniazid and 25 mg/kg of body weight/ day ethambutol for the remainder of the 2 treatment period			
	Antituberculosis chemotherapy alone			
	Antituberculosis chemotherapy: 1.5HSE/22.5HE			
Comparison	10 mg/kg of body weight/day isoniazid, 25 mg/kg of body weight/day streptomycin and 25 mg/kg of body weight/day ethambutol for the first 60 days			
	10 mg/kg of body weight/day isoniazid and 25 mg/kg of b	oody weight/ day ethambu	tol for the remainder of the 2-year	

	treatment period
Length of follow up	Unclear
Location	Cairo, Egypt
	Mortality
	Number of deaths
	dexamethasone group = 39 of 66
	antituberculosis chemotherapy alone group = 42 of 70
	OR ¹ (95% CI) = 0.96 (0.49 to 1.91)
	i.e. not statistically significant
	Alert on admission
	dexamethasone group = 0 of 2
Outcomes measures and effect	antituberculosis chemotherapy alone group = 2 of 5
size	OR ¹ (95% CI) = 0.28 (0.01 to 8.76)
	i.e. not statistically significant
	Drowsy on admission
	dexamethasone group = 8 of 23
	antituberculosis chemotherapy alone group = 14 of 33
	OR ¹ (95% CI) = 0.72 (0.24 to 2.18)
	i.e. not statistically significant
	Comatose admission
	dexamethasone group = 31 of 41

	antituberculosis chemotherapy alone group = 26 of 32
	OR ¹ (95% CI) = 0.72 (0.23 to 2.23)
	i.e. not statistically significant
	CSF positive for tubercle bacilli
	dexamethasone group = 19 of 30
	antituberculosis chemotherapy alone group = 21 of 34
	OR ¹ (95% CI) = 1.07 (0.39 to 2.95)
	i.e. not statistically significant
	Adverse events – ocular complications
	Number of patients with ocular complications
	dexamethasone group = 2 of 66
	antituberculosis chemotherapy alone group = 7 of 70
	OR ¹ (95% CI) = 0.28 (0.06 to 1.41)
	i.e. not statistically significant
	Number of patients with CSF positive for tubercle bacilli with ocular complications
	dexamethasone group = 2 of 30
	antituberculosis chemotherapy alone group = 4 of 34
	OR ¹ (95% CI) = 2.46 (0.42 to 14.52)
	i.e. not statistically significant
Source of funding	No details provided
Comments	

¹ Odds ratio and 95% confidence interval calculated by reviewer

Abbreviations: CI, confidence intervals; CSF, cerebrospinal fluid; E, ethambutol H, isoniazid; OR, odds ratio; RCT, randomised controlled trial; S, streptomycin; TB, tuberculosis

1.1.13 Girgis et al, 1991

Bibliographic reference	Girgis NI, Farid Z, Kilpatrick ME (1991) Dexamethasone adjunctive treatment for tuberculous meningitis. Pediatric Infectious Disease Journal 10(3): 179-83
Study type	RCT
	Groups comparable for treatment completion and availability of outcome data?
	limited data available for the incidence of neurologic abnormalities due to a high rate of mortality, though the loss to follow-up was similar in the 2 groups (dexamethasone = 72 of 145; antituberculosis chemotherapy alone = 79 of 135)

	Study used precise definitions and reliable measures of outcome?
	yes, although details provided are limited
	Population studied is the same as the population of interest?
	yes
	Intervention used is the same as the intervention of interest?
	antituberculosis regimens do not use all of or just the 4 standard recommended drugs: lack rifampicin and pyrazinamide, but contain streptomycin
	Have substitute outcomes been used instead of the patient-important outcomes of interest?
	no
	Analysis followed the intent-to-treat principle?
	yes
	Included = 280
Number of patients	dexamethasone group = 145
	antituberculosis chemotherapy alone group = 135
	Inclusion
	Tuberculous meningitis
	Diagnostic criteria
Patient characteristics	Clinical history
	Signs and symptoms compatible with tuberculous meningitis:
	low grade fever
	severe progressive headache

vomiting				
generalised weakness				
diplopia				
cranial nerve affections				
deterioration of mental alertness				
duration of illness more than 30 days				
comparison of results from the first and	d second CSF examination	IS		
poor response to antibacterial therapy				g/kg of body
weight/day of ampicillin plus 100 mg/k	g of body weight/day of chl	oramphenicol) f	or 48 hours	
Baseline				
	Dexamethaso	ne group	Antituberculo chemotherapy	
	(n = 145)		(n = 135)	y alone group
	CSF culture-	CSF culture-	CSF culture-	
	positive	negative	positive	CSF culture- negative
	(n = 75)	negative (n = 70)		
Sex	-		positive	negative
Sex male, n	-		positive	negative
	(n = 75)	(n = 70)	positive (n = 85)	negative (n = 50)
male, n	(n = 75) 38	(n = 70) 43	positive (n = 85) 46	negative (n = 50) 31
male, n female, n	(n = 75) 38	(n = 70) 43	positive (n = 85) 46	negative (n = 50) 31

	1–5 years, n	19	27	25	11	
	6–15 years, n	23	11	21	7	
	16–25 years, n	15	7	12	14	
	>25 years, n	14	17	22	13	
	Duration of symptoms prior to hospitalisation					
	<14 days, n	13	20	21	20	
	15–28 days, n	49	24	46	14	
	29–43 days, n	5	18	6	7	
	>43 days, n	8	8	12	9	
	State of consciousness on admission					
	alert, n	4	2	4	1	
	drowsy, n	27	15	35	10	
	comatose, n	44	53	46	39	
	Cranial nerve afflictions, n	41	59	37	46	
	Pupillary abnormalities, n	65	63	70	48	
	Fundus changes, n	2	5	2	4	
	Hemiparesis, n	1	2	2	3	
	Hydrocephalus, n	1	2	0	1	
						_
Intervention	Antituberculosis chemotherapy plus dexamethe	asone				

	Dexamethasone (3 weeks)
	12 mg/day in adults, and 8 mg/day in children weighing less than 25 kg
	Antituberculosis chemotherapy: 1.5HSE/22.5HE
	10 mg/kg of body weight/day isoniazid (to a maximum of 600 mg), 25 mg/kg of body weight/day streptomycin (to a maximum of 1000 mg) and 25 mg/kg of body weight/day ethambutol (to a maximum of 1200 mg) for the first 6 weeks
	10 mg/kg of body weight/day isoniazid (to a maximum of 600 mg) and 15 mg/kg of body weight/day ethambutol for the remainder of the 2-year treatment period
	In patients with permanent CT-confirmed hydrocephalus, ventriculoperitoneal shunts were performed
	Antituberculosis chemotherapy alone
	Antituberculosis chemotherapy: 1.5HSE/22.5HE
Comparison	10 mg/kg of body weight/day isoniazid (to a maximum of 600 mg), 25 mg/kg of body weight/day streptomycin (to a maximum of 1000 mg) and 25 mg/kg of body weight/day ethambutol (to a maximum of 1200 mg) for the first 6 weeks
	10 mg/kg of body weight/day isoniazid (to a maximum of 600 mg) and 15 mg/kg of body weight/day ethambutol for the remainder of the 2-year treatment period
	In patients with permanent CT-confirmed hydrocephalus, ventriculoperitoneal shunts were performed
Length of follow up	Full treatment period
Location	Cairo, Egypt
	Mortality
	Number of deaths
Outcomes	dexamethasone group = 72 of 145
measures and effect size	antituberculosis chemotherapy alone group = 79 of 135
	OR ¹ (95% CI) = 0.70 (0.44 to 1.12)
	i.e. not statistically significant

CSF positive for tubercle bacilli
dexamethasone group = 32 of 75
antituberculosis chemotherapy alone group = 50 of 85
OR ¹ (95% CI) = 0.52 (0.28 to 0.98)
i.e. statistically significant
CSF negative for tubercle bacilli
dexamethasone group = 40 of 70
antituberculosis chemotherapy alone group = 29 of 50
OR ¹ (95% CI) = 0.97 (0.46 to 2.01)
i.e. not statistically significant
Alert on admission
dexamethasone group = 0 of 6
antituberculosis chemotherapy alone group = 2 of 5
OR ¹ (95% CI) = 0.11 (0.00 to 2.93)
i.e. not statistically significant
Drowsy on admission
dexamethasone group = 10 of 42
antituberculosis chemotherapy alone group = 18 of 45
OR ¹ (95% CI) = 0.47 (0.19 to 1.18)
i.e. not statistically significant
Comatose admission

dexamethasone group = 62 of 97
antituberculosis chemotherapy alone group = 59 of 85
OR ¹ (95% CI) = 0.78 (0.42 to 1.45)
i.e. not statistically significant
Changes in signs and symptoms – neurologic abnormalities (developed during treatment)
Number of patients to develop neurologic abnormalities (fundus, hemiparesis or hydrocephalus) during treatment
dexamethasone group = 8 of 145
antituberculosis chemotherapy alone group = 15 of 135
OR ¹ (95% CI) = 0.47 (0.19 to 1.14)
i.e. not statistically significant
CSF positive for tubercle bacilli
dexamethasone group = 4 of 75
antituberculosis chemotherapy alone group = 10 of 85
OR ¹ (95% CI) = 0.42 (0.13 to 1.41)
i.e. not statistically significant
CSF negative for tubercle bacilli
dexamethasone group = 4 of 70
antituberculosis chemotherapy alone group = 5 of 50
OR ¹ (95% CI) = 0.67 (0.17 to 2.60)
i.e. not statistically significant
Changes in signs and symptoms – neurologic abnormalities (permanent residual sequelae)

Number of patients to with permanent residual neurologic abnormalities (fundus, hemiparesis or hydrocephalus)
dexamethasone group = 14 of 145
antituberculosis chemotherapy alone group = 27 of 135
OR ¹ (95% CI) = 0.43 (0.21 to 0.86)
i.e. statistically significant
CSF positive for tubercle bacilli
dexamethasone group = 6 of 75
antituberculosis chemotherapy alone group = 13 of 85
OR ¹ (95% CI) = 0.48 (0.17 to 1.34)
i.e. not statistically significant
CSF negative for tubercle bacilli
dexamethasone group = 8 of 70
antituberculosis chemotherapy alone group = 14 of 50
OR ¹ (95% CI) = 0.33 (0.13 to 0.87)
 i.e. statistically significant
Changes in signs and symptoms – fever
Time (mean±SD, days) to become afebrile (defined as a temperature of <37.5°C) (patients who were CSF positive for tubercle bacilli on admission)
dexamethasone group (n = 75) = 20 ± 13
antituberculosis chemotherapy alone group (n = 85) = 23 ± 12
MD ² (95% CI) = -3 (-6.9 to 0.9)

	i.e. not statistically significant	
	Changes in signs and symptoms – responsiveness	
	Time (mean±SD, days) to become fully alert (defined as adult patients able to respond and answer complicated questions correctly, and infants knowing their mothers, responding to voice or noise and able to feed properly) (patients who were CSF positive for tubercle bacilli on admission)	
	dexamethasone group (n = 75) = 35 ± 33	
	antituberculosis chemotherapy alone group (n = 85) = 31 ± 23	
	MD ² (95% CI) = 4 (-4.9 to 12.9)	
	i.e. not statistically significant	
Source of funding	Supported by the United States Navy Department, the Department of Defence, the United States Government and the Egyptian Ministry of Health	
Comments		
¹ Odds ratio and 95% confidence interval calculated by reviewer		
² Mean difference and 95% confidence interval calculated by reviewer		
Abbreviationer OL confidence intervaler OCE, combreaning fluid: CE, computaring ditercomputer in the mount of the mount of the second tercomputer in tercompute		

Abbreviations: CI, confidence intervals; CSF, cerebrospinal fluid; CT, computerised tomography; E, ethambutol H, isoniazid; MD, mean difference; OR, odds ratio; RCT, randomised controlled trial; S, streptomycin; SD, standard deviation; TB, tuberculosis

1.1.14 <u>Malhotra et al, 2009</u>

Bibliographic reference	Malhotra HS, Garg RK, Singh MK et al (2009) Corticosteroids (dexamethasone <i>versus</i> intravenous methyl prednisolone) in patients with tuberculous meningitis. Annals of Tropical Medicine & Parasitology 103(7): 625-34
Study type	RCT
	Appropriate method of randomisation used?
Study quality	yes – computer-generated randomisation sheet
	Allocation concealment used?

unclear
Blinding used?
no
Groups comparable at baseline?
yes
Groups received the same care apart from the intervention(s) studied?
yes
Groups followed up for an equal and appropriate length of time?
yes
Groups comparable for treatment completion and availability of outcome data?
yes
Study used precise definitions and reliable measures of outcome?
yes
Population studied is the same as the population of interest?
yes
Intervention used is the same as the intervention of interest?
yes, although some patients received streptomycin instead of ethambutol during the initial phase of treatment
Have substitute outcomes been used instead of the patient-important outcomes of interest?
no
Analysis followed the intent-to-treat principle?
yes

	Randomised = 97
	dexamethasone group = 32
	methylprednisolone group = 33
	antituberculosis chemotherapy alone group = 32
Number of patients	
	Outcome data available for = 91
	dexamethasone group = 31
	methylprednisolone group = 30
	antituberculosis chemotherapy alone group = 30
	Inclusion
	Tuberculous meningitis
	Aged >14 years
	Diagnostic criteria
	Based on the results of clinical and radiological examination, the evaluation of cell types and numbers, and protein and glucose concentrations in the CSF
Patient characteristics	The essential clinical indicator was the presence of a meningitic syndrome, as defined by the presence of headache vomiting and fever
	In the CSF samples, a predominantly lymphocytotic pleocytosis and an elevated protein concentration were taken as further evidence tuberculous meningitis
	'Definite' meningitis = acid-fast bacilli detected in the CSF; contrast-enhanced CT often demonstrated the presence of exudates, hydrocephalus, tuberculoma and infarction, singly or in combination
	'Probable' meningitis = suspected active pulmonary TB, as indicated by a chest x-ray; acid-fast bacilli in any specimen other than CSF; and/or clinical evidence of other extrapulmonary tuberculosis
	'Possible' meningitis = at least 4 of the following:

	Dexamethasone	Methylprednisolone	Antituberculosis
Baseline			
Evidence of a brain abscess or tumour – e.c	g. an intracranial space-o	ccupying lesion visible by	CT
Previous use of antituberculosis chemothera	apy and/or corticosteroids	8	
Contraindication of corticosteroids			
HIV infection			
on the Glasgow coma scale	vuisions, focal neurologic	al deficit and involuntary r	movements; scoring ≤10
с с	ulaiana faashaanad		
	ight or no clouding of sen	sorium and minor neurold	ogical deficit or no deficit;
stage 1: no definite neurological symptoms;	scoring 15 on the Glasgo	ow coma scale	
Classified according to the system of the Br	itish Medical Research C	ouncil:	
Severity of disease			
Drug susceptibility was not tested			
focal neurological signs			
yellow CSF			
altered consciousness			
a ratio of CSF glucose concentration:plasma	a glucose concentration o	of <0.5	
illness lasting >5 days			
predominance of lymphocytes in the CSF			
history of tuberculosis			
	predominance of lymphocytes in the CSF illness lasting >5 days a ratio of CSF glucose concentration:plasm altered consciousness yellow CSF focal neurological signs Drug susceptibility was not tested <i>Severity of disease</i> Classified according to the system of the Br stage 1: no definite neurological symptoms; stage 2: signs of meningeal irritation with sli scoring 11–14 on the Glasgow coma scale stage 3: severe clouding of sensorium, com on the Glasgow coma scale <i>Exclusion</i> HIV infection Contraindication of corticosteroids Previous use of antituberculosis chemother Evidence of a brain abscess or tumour – e.g	predominance of lymphocytes in the CSF illness lasting >5 days a ratio of CSF glucose concentration:plasma glucose concentration of altered consciousness yellow CSF focal neurological signs Drug susceptibility was not tested <i>Severity of disease</i> Classified according to the system of the British Medical Research C stage 1: no definite neurological symptoms; scoring 15 on the Glasgo stage 2: signs of meningeal irritation with slight or no clouding of sen scoring 11–14 on the Glasgow coma scale stage 3: severe clouding of sensorium, convulsions, focal neurologic on the Glasgow coma scale <i>Exclusion</i> HIV infection Contraindication of corticosteroids Previous use of antituberculosis chemotherapy and/or corticosteroids Evidence of a brain abscess or tumour – e.g. an intracranial space-o <i>Baseline</i>	predominance of lymphocytes in the CSF illness lasting >5 days a ratio of CSF glucose concentration:plasma glucose concentration of <0.5 altered consciousness yellow CSF focal neurological signs Drug susceptibility was not tested <i>Severity of disease</i> Classified according to the system of the British Medical Research Council: stage 1: no definite neurological symptoms; scoring 15 on the Glasgow coma scale stage 2: signs of meningeal irritation with slight or no clouding of sensorium and minor neurolog scoring 11–14 on the Glasgow coma scale stage 3: severe clouding of sensorium, convulsions, focal neurological deficit and involuntary to on the Glasgow coma scale <i>Exclusion</i> HIV infection Contraindication of corticosteroids Previous use of antituberculosis chemotherapy and/or corticosteroids Evidence of a brain abscess or tumour – e.g. an intracranial space-occupying lesion visible by <i>Baseline</i>

			chemotherapy alon
Sex			
male, n	15	14	14
female, n	16	16	16
Age (mean (range)), years	31.97 (15–66)	30.00 (15–67)	32.87 (15–70)
Duration of illness (mean (range)), days	56.13 (7–240)	35.17 (6–180)	60.77 (7–200)
Glasgow coma scale score (median (range))	15 (8–15)	14.5 (5–15)	15 (8–15)
Severity of disease			
stage 1, n	7	7	7
stage 2, n	18	17	18
stage 3, n	6	6	5
History of tuberculosis, n	4	6	7
Fever, n	27	29	27
Headache, n	27	27	25
Vomiting, n	22	17	17
Seizures, n	7	11	7
Visual symptoms, n	15	14	16
Altered sensorium, n	12	15	12
Cranial nerve palsies, n	12	11	9
Focal deficits, n	5	4	4

	Vieuel impeirment	11	0	8	
	Visual impairment, n		9		
	Miliary shadow on chest x-ray, n	2	5	3	
	Parenchymal shadow on chest x-ray, n	1	0	3	
	Pleural effusion on chest x-ray, n	0	2	1	
	Basal exudates on CT scan of brain, n	13	11	10	
	Hydrocephalus on CT scan of brain, n	10	3	7	
	Infarction on CT scan of brain, n	5	4	3	
	Culture-positive for <i>M. tuberculosis</i> , n	1	1	1	
	PCR-positive for <i>M. tuberculosis</i> , n	5	8	3	
	Antituberculosis chemotherapy plus dexamethasone				
	Dexamethasone (4 weeks)				
	0.4, 0.3, 0.2 and 0.1 mg/kg of bodyweight/day during weeks 1, 2, 3 and 4, respectively				
	Antituberculosis chemotherapy: 2HRZE/7HR or 2HRZS/7HR				
Intervention 1	10 mg/kg of body weight/day isoniazid, 15 mg/kg of body weight/day rifampicin, 30 mg/kg of body weight/day pyrazinamide, and 15 mg/kg of body weight/day streptomycin or 20 mg/kg of body weight/day ethambutol for the first 2 months				
	10 mg/kg of body weight/day isoniazid and 15 mg/kg of body weight/day rifampicin for the following 7 months				
	Appropriate symptomatic treatments – intravenous fluids, mannitol, anti-epileptic drugs and/or analgesics – were supplied, as required				
	Antituberculosis chemotherapy plus methylprednisolone				
Intervention 2	Methylprednisolone (5 days)				

	daily doses of 1 g for patients weighing >50 kg, or 20 mg/kg for lighter patients, for 5 days	
	Antituberculosis chemotherapy: 2HRZE/7HR or 2HRZS/7HR	
	10 mg/kg of body weight/day isoniazid, 15 mg/kg of body weight/day rifampicin, 30 mg/kg of body weight/day pyrazinamide, and 15 mg/kg of body weight/day streptomycin or 20 mg/kg of body weight/day ethambutol for the first 2 months	
	10 mg/kg of body weight/day isoniazid and 15 mg/kg of body weight/day rifampicin for the following 7 months	
	Appropriate symptomatic treatments – intravenous fluids, mannitol, anti-epileptic drugs and/or analgesics – were supplied, as required	
	Antituberculosis chemotherapy alone	
	Antituberculosis chemotherapy: 2HRZE/7HR or 2HRZS/7HR	
Comparison	10 mg/kg of body weight/day isoniazid, 15 mg/kg of body weight/day rifampicin, 30 mg/kg of body weight/day pyrazinamide, and 15 mg/kg of body weight/day streptomycin or 20 mg/kg of body weight/day ethambutol for the first 2 months	
	10 mg/kg of body weight/day isoniazid and 15 mg/kg of body weight/day rifampicin for the following 7 months	
	Appropriate symptomatic treatments – intravenous fluids, mannitol, anti-epileptic drugs and/or analgesics – were supplied, as required	
Length of follow up	10 months after treatment initiation	
Location	Lucknow, India	
	Mortality	
Outcomes	Number of deaths after 6 months of treatment	
measures and effect	dexamethasone group = 8 of 32	
size	methylprednisolone group = 9 of 33	
	antituberculosis chemotherapy alone group = 13 of 32	

Any corticosteroid vs antituberculosis chemotherapy alone ¹
OR (95% CI) = 0.52 (0.21 to 1.27)
i.e. not statistically significant
Dexamethasone vs antituberculosis chemotherapy alone ²
OR (95% CI) = 0.56 (0.15 to 2.02)
i.e. not statistically significant
Methylprednisolone vs antituberculosis chemotherapy alone ²
OR (95% CI) = 0.48 (0.14 to 1.68)
i.e. not statistically significant
Stage 1
dexamethasone group = 0 of 7
methylprednisolone group = 0 of 7
antituberculosis chemotherapy alone group = 1 of 7
Any corticosteroid vs antituberculosis chemotherapy alone ¹
OR (95% CI) = 0.15 (0.01 to 4.18)
i.e. not statistically significant
Stage 2
dexamethasone group = 5 of 18
methylprednisolone group = 6 of 17
antituberculosis chemotherapy alone group = 8 of 18
Any corticosteroid vs antituberculosis chemotherapy alone ¹

OR (95% CI) = 0.57 (0.18 to 1.85)
i.e. not statistically significant
Stage 3
dexamethasone group = 3 of 6
methylprednisolone group = 3 of 6
antituberculosis chemotherapy alone group = 4 of 5
Any corticosteroid vs antituberculosis chemotherapy alone ¹
OR (95% CI) = 0.25 (0.02 to 2.94)
i.e. not statistically significant
Changes in signs and symptoms – disability
Assessed using a modified Rankin scale:
score of 0 = no symptoms at all
score of 1 = no significant disability despite the presence of symptoms, with the subject able to carry out all their usual duties and activities
score of 2 = slight disability, with the subject unable to carry out all their previous activities, but able to look after their own affairs without assistance
score of 3 = moderate disability, with the subject requiring help but able to walk without assistance
score of 4 = moderately severe disability, with the subject unable to walk without assistance and unable to attend to own bodily needs without assistance
score of 5 = severe disability, with the subject bedridden, incontinent and requiring constant nursing care and attention
Final scores:
0 = good outcome

1–2 = intermediate disability
3–5 = severe disability
Number of patients to experience severe disability after 6 months of treatment
dexamethasone group = 5 of 32
methylprednisolone group = 6 of 33
antituberculosis chemotherapy alone group = 5 of 32
Any corticosteroid vs antituberculosis chemotherapy alone ¹
OR (95% CI) = 1.10 (0.35 to 3.49)
i.e. not statistically significant
Dexamethasone vs antituberculosis chemotherapy alone ²
OR (95% CI) = 1.30 (0.22 to 7.55)
i.e. not statistically significant
Methylprednisolone vs antituberculosis chemotherapy alone ²
OR (95% CI) = 0.96 (0.21 to 4.47)
i.e. not statistically significant
Severe disability among patients defined as stage 1 at baseline
dexamethasone group = 1 of 7
methylprednisolone group = 1 of 7
antituberculosis chemotherapy alone group = 1 of 7
Any corticosteroid vs antituberculosis chemotherapy alone ¹
OR (95% CI) = 1.00 (0.07 to 13.37)

i.e. not statistically significant
Severe disability among patients defined as stage 2 at baseline
dexamethasone group = 3 of 18
methylprednisolone group = 3 of 17
antituberculosis chemotherapy alone group = 3 of 18
Any corticosteroid vs antituberculosis chemotherapy alone ¹
OR (95% CI) = 1.03 (0.23 to 4.73)
i.e. not statistically significant
Severe disability among patients defined as stage 3 at baseline
dexamethasone group = 1 of 6
methylprednisolone group = 2 of 6
antituberculosis chemotherapy alone group = 1 of 5
Any corticosteroid vs antituberculosis chemotherapy alone ¹
OR (95% CI) = 1.22 (0.10 to 17.10)
i.e. not statistically significant
Number of patients to experience intermediate disability after 6 months of treatment
dexamethasone group = 3 of 32
methylprednisolone group = 0 of 33
antituberculosis chemotherapy alone group = 4 of 32
Any corticosteroid vs antituberculosis chemotherapy alone ¹
OR (95% CI) = 0.34 (0.07 to 1.62)

i.e. not statistically significant
Dexamethasone vs antituberculosis chemotherapy alone ²
OR (95% CI) = 0.72 (0.11 to 4.84)
i.e. not statistically significant
Methylprednisolone vs antituberculosis chemotherapy alone ²
OR (95% CI) = 0.09 (0.00 to 1.92)
i.e. not statistically significant
Number of patients with a good outcome after 6 months of treatment
dexamethasone group = 15 of 32
methylprednisolone group = 15 of 33
antituberculosis chemotherapy alone group = 8 of 32
Any corticosteroid vs antituberculosis chemotherapy alone ¹
OR (95% CI) = 2.57 (1.01 to 6.56)
i.e. statistically significant
Dexamethasone vs antituberculosis chemotherapy alone ²
OR (95% CI) = 2.65 (0.70 to 9.99)
i.e. not statistically significant
Methylprednisolone vs antituberculosis chemotherapy alone ²
OR (95% CI) = 2.50 (0.67 to 9.39)
i.e. not statistically significant
Adverse events - hepatic

Number of patients to experience clinical or subclinical hepatitis
dexamethasone group = 5 of 32
methylprednisolone group = 7 of 33
antituberculosis chemotherapy alone group = 8 of 32
Any corticosteroid vs antituberculosis chemotherapy alone ¹
OR (95% CI) = 0.68 (0.25 to 1.88)
i.e. not statistically significant
Dexamethasone vs antituberculosis chemotherapy alone ²
OR (95% CI) = 0.56 (0.13 to 2.44)
i.e. not statistically significant
Methylprednisolone vs antituberculosis chemotherapy alone ²
OR (95% CI) = 0.81 (0.20 to 3.30)
i.e. not statistically significant
Number of patients to experience clinical hepatitis
dexamethasone group = 1 of 32
methylprednisolone group = 2 of 33
antituberculosis chemotherapy alone group = 2 of 32
Any corticosteroid vs antituberculosis chemotherapy alone ¹
OR (95% CI) = 0.73 (0.12 to 4.58)
i.e. not statistically significant
Dexamethasone vs antituberculosis chemotherapy alone ²

OR (95% CI) = 0.48 (0.03 to 8.28)
i.e. not statistically significant
Methylprednisolone vs antituberculosis chemotherapy alone ²
OR (95% CI) = 0.97 (0.08 to 11.54)
i.e. not statistically significant
Adverse events – gastrointestinal bleeding
Number of patients to experience gastrointestinal bleeding
dexamethasone group = 4 of 32
methylprednisolone group = 2 of 33
antituberculosis chemotherapy alone group = 1 of 32
Any corticosteroid vs antituberculosis chemotherapy alone ¹
OR (95% CI) = 3.15 (0.36 to 27.37)
i.e. not statistically significant
Dexamethasone vs antituberculosis chemotherapy alone ²
OR (95% CI) = 5.21 (0.26 to 103.00)
i.e. not statistically significant
Methylprednisolone vs antituberculosis chemotherapy alone ²
OR (95% CI) = 0.97 (0.08 to 11.54)
i.e. not statistically significant
Adverse events – paradoxical tuberculoma
Number of patients to experience paradoxical tuberculoma

	dexamethasone group = 2 of 32
	methylprednisolone group = 1 of 33
	antituberculosis chemotherapy alone group = 5 of 32
	Any corticosteroid vs antituberculosis chemotherapy alone ¹
	OR (95% CI) = 0.26 (0.06 to 1.17)
	i.e. not statistically significant
	Dexamethasone vs antituberculosis chemotherapy alone ²
	OR (95% CI) = 0.47 (0.06 to 3.66)
	i.e. not statistically significant
	Methylprednisolone vs antituberculosis chemotherapy alone ²
	OR (95% CI) = 0.14 (0.01 to 1.42)
	i.e. not statistically significant
Source of funding	No details provided
Comments	

¹ Pooled odds ratio, combining the data for the dexamethasone and methylprednisolone arms into a single 'corticosteroid' arm, and 95% confidence interval calculated by reviewer

² Odds ratio and 95% confidence interval calculated by reviewer; data for the control group (received antituberculosis chemotherapy alone) was divided in half to allow 2 pairwise comparisons of dexamethasone plus antituberculosis chemotherapy *versus* antituberculosis chemotherapy alone and methylprednisolone plus antituberculosis chemotherapy *versus* antituberculosis chemotherapy alone

³ Pooled mean difference, combining the data for the dexamethasone and methylprednisolone arms into a single 'corticosteroid' arm, calculated by reviewer

⁴ Mean difference calculated by reviewer; data for the control group (received antituberculosis chemotherapy alone) was divided in half to allow 2 pairwise comparisons of dexamethasone plus antituberculosis chemotherapy *versus* antituberculosis chemotherapy alone and

methylprednisolone plus antituberculosis chemotherapy versus antituberculosis chemotherapy alone

Abbreviations: CI, confidence intervals; CSF, cerebrospinal fluid; CT, computerised tomography; E, ethambutol H, isoniazid; MD, mean difference; OR, odds ratio; PCR, polymerase chain reaction; RCT, randomised controlled trial; S, streptomycin; SD, standard deviation; TB, tuberculosis; Z, pyrazinamide

1.1.15 O'Toole et al, 1969

Bibliographic reference	O'Toole RD, Thornton GF, Mukherjee MK et al (1969) Dexamethasone in tuberculous meningitis. Relationship of cerebrospinal fluid effects to therapeutic efficacy. Annals of Internal Medicine 70(1): 39-48		
Study type	RCT		
Study quality	Appropriate method of randomisation used? yes – block randomisation using coded medication Allocation concealment used? unclear Blinding used? double-blind Groups comparable at baseline? yes, although details provided are limited Groups received the same care apart from the intervention(s) studied? yes, although details provided are limited Groups followed up for an equal and appropriate length of time? unclear Groups comparable for treatment completion and availability of outcome data? unclear		

	Study used precise definitions and reliable measures of outcome?
	yes
	Population studied is the same as the population of interest?
	yes
	Intervention used is the same as the intervention of interest?
	antituberculosis regimens do not use all of or just the 4 standard recommended drugs: lack rifampicin, pyrazinamide and ethambutol, but contain streptomycin
	Have substitute outcomes been used instead of the patient-important outcomes of interest?
	no
	Analysis followed the intent-to-treat principle?
	unclear
	Outcome data available for = 23
Number of patients	dexamethasone group = 11
	placebo group = 12
	Inclusion
Patient characteristics	Tuberculous meningitis (only those patients presenting with short histories or acute signs and symptoms mimicking pyrogenic meningitis were admitted to the hospital since hospital policy is to refer tuberculous meningitis to other institutions)
	Moderately advanced or severe disease
	Severity of disease
	Classified according to the system of the British Medical Research Council:
	stage 1: mild cases; without altered consciousness or focal neurologic signs

	stage 2: moderately advanced cases; altered consciousness; not comatose; moderate neurologic deficits, such as single cranial nerve palsies, parapesis and hemiparesis				
	stage 3: severe cases; comatose patients; multiple cranial nerve palsies; hemiplegia and/or paraplegia				
	Baseline				
			Dexamethasone	Placebo group	
			group	(n = 12	
			(n = 11)		
		Age, years			
		<2, n	2	3	
		2 to 45, n	8	9	
		>45, n	1	0	
		Severity of disease			
		stage 1, n	1	0	
		stage 2, n	6	8	
		stage 3, n	4	4	
		Culture-positive CSF, n	8	6	
	Antitubercu	losis chemotherapy plus dexameth	asone		
	Dexamethasone (4 weeks)				
Intervention	adults received 2.25 mg parenterally every 6 hours during the first week; the dose was reduced to 1.50 mg every 6 hours for he second week, 0.75 mg every 6 hours in the third week, and 0.375 mg every 6 hours in the fourth week				
	paediatric dosage was derived from a standard table based on surface area				

	Antituberculosis chemotherapy: isoniazid (10 mg/kg of body weight/day, or 20 mg/kg of body weight/day in children less than 2 years of age) and streptomycin (20 mg/kg of body weight/day, up to a maximum of 1 g); total duration of antituberculosis chemotherapy unclear		
	All patients received high doses of vitamin B ₆		
	Antituberculosis chemotherapy plus placebo		
	Placebo (4 weeks)		
	adults received 2.25 mg parenterally every 6 hours during the first week; the dose was reduced to 1.50 mg every 6 hours for he second week, 0.75 mg every 6 hours in the third week, and 0.375 mg every 6 hours in the fourth week		
Comparison	paediatric dosage was derived from a standard table based on surface area		
	Antituberculosis chemotherapy: isoniazid (10 mg/kg of body weight/day, or 20 mg/kg of body weight/day in children less than 2 years of age) and streptomycin (20 mg/kg of body weight/day, up to a maximum of 1 g); total duration of antituberculosis chemotherapy unclear		
	All patients received high doses of vitamin B ₆		
Length of follow up	Unclear		
Location	Calcutta, India		
	Mortality		
	Number of deaths		
	dexamethasone group = 6 of 11		
Outcomes	placebo group = 9 of 12		
measures and effect size	OR ¹ (95% CI) = 0.40 (0.07 to 2.34)		
	i.e. not statistically significant		
	Number of deaths amongst those <2 years of age		
	dexamethasone group = 2 of 2		

	placebo group = 3 of 3		
	OR ¹ (95% CI) = 0.71 (0.01 to 49.71)		
	i.e. not statistically significant		
	Number of deaths amongst those classed as stage 2 on admission		
	dexamethasone group = 3 of 6		
	placebo group = 5 of 8		
	OR ¹ (95% CI) = 0.60 (0.07 to 5.14)		
	i.e. not statistically significant		
	Number of deaths amongst those classed as stage 3 on admission		
	dexamethasone group = 3 of 4		
	placebo group = 4 of 4		
	OR ¹ (95% CI) = 0.26 (0.01 to 8.52)		
	i.e. not statistically significant		
	(Mean) survival time (days)		
	dexamethasone group = 14		
	placebo group = 14		
	MD ² = 0		
Source of funding	No details provided		
Comments			
¹ Odds ratio and 95% c	¹ Odds ratio and 95% confidence interval calculated by reviewer		
² Mean difference calculated by reviewer			

Abbreviations: CI, confidence intervals; CSF, cerebrospinal fluid; MD, mean difference; OR, odds ratio; RCT, randomised controlled trial

Bibliographic reference	Kumarvelu S, Prasad K, Khosla A et al (1994) Randomised controlled trial of dexamethasone in tuberculous meningitis. Tubercle and Lung Disease 75(3): 203-7
Study type	RCT
	Appropriate method of randomisation used?
	yes – random numbers table
	Allocation concealment used?
	unclear
	Blinding used?
	unclear
	Groups comparable at baseline?
Study quality	yes
	Groups received the same care apart from the intervention(s) studied?
	yes
	Groups followed up for an equal and appropriate length of time?
	follow-up was equal in both groups although was only for 3 months after treatment initiation (i.e. not for the full treatment period)
	Groups comparable for treatment completion and availability of outcome data?
	yes
	Study used precise definitions and reliable measures of outcome?

	'full/partial recovery' and 'unchanged' status not defined
	Population studied is the same as the population of interest?
	yes
	Intervention used is the same as the intervention of interest?
	antituberculosis chemotherapeutic regimens lacked ethambutol
	Have substitute outcomes been used instead of the patient-important outcomes of interest?
	yes – used composites of outcomes of interest: 'poor' and 'good' outcome were composites of mortality and changes in signs and symptoms
	Analysis followed the intent-to-treat principle?
	some data was only available for patients with either 'severe' or 'mild-to-moderate' disease on admission who survived; since the authors do not provide the number of patients with either 'severe' or 'mild-to-moderate' disease on admission who were randomised to each intervention, this data could not be analysed in accordance with the intent-to-treat principle
	Randomised = 47
	dexamethasone group = 24
Number of restingto	antituberculosis chemotherapy alone group = 23
Number of patients	Outcome data available at 3 months = 41
	dexamethasone group = 20
	antituberculosis chemotherapy alone group = 21
Patient	Inclusion
	Probable tuberculous meningitis
characteristics	Diagnostic criteria
	Diagnosis of probable tuberculous meningitis was made if at least 3 of the following criteria were present:

clinical: fever >38°C, headache, neck stiffness with or without seizures or altered sensorium for at least 2 weeks		
characteristic CSF findings: leukocytes >20 /mm ³ with lymphocytotic predominance, proteins >1 g/l, sugar <2/3 of corresponding blood sugar, cultures negative for pyrogenic organisms and fungi, and negative cytology for malignant cells		
contrast-enhanced CT scan of the head: basal exudates or hydroceph	alus with or without infarcts and tuberculoma	
clinical, radiological or histological evidence of extracranial tuberculosi	S	
Severity of disease		
Analysed on admission using the following scoring system:		
Parameter	Weightage (points)	
Sensorium		
normal	1	
delirium	2	
drowsy	3	
semi-coma	4	
coma	5	
Associated pulmonary tuberculosis	0.5	
Associated extensive tuberculous or non-tuberculous disease	0.5	
Age <10 years or >50 years	0.5	
CSF protein >3 g/l	0.5	
CT scan evidence		
exudates		

grade I 1	
grade II 2	
grade III 3	
hydrocephalus	
mild 1	
moderate 2	
severe 3	
mid-line shift 1	
Leukopenia or leukocytosis 0.5	
Systolic hypotension 1	
'Severe' disease = a score of 8 or more	
'Mild-to-moderate' disease = a score of less than 8	
Exclusion	
Aged <10 years	
Previous antituberculosis chemotherapy for >4 weeks	
Previous glucocorticoid use	
Baseline	
Dexamethasone Antituberculosis group chemotherapy al	
Clinical features	

			1
	meningeal signs, %	92	100
	altered sensorium, %	92	74
	seizures, %	46	30
	papilloedema, %	50	22
	cerebrovascular event, %	29	35
	spinal arachnoiditis, %	17	4
	extrameningeal tuberculosis, %	46	52
	CSF parameters		
	abnormal cell count, %	83	100
	lymphocyte predominance, %	63	61
	raised proteins, %	75	83
	low glucose levels, %	91	88
	CT parameters		
	exudates, %	79	91
	hydrocephalus, %	58	52
	infarct, %	13	22
	tuberculoma, %	21	9
	Antituberculosis chemotherapy plus dexamethasone		
Intervention	Dexamethasone (6 weeks)		
	adults: 16 mg divided into 4 doses in the first week, for	lowed by 8 mg/day for 21 d	lays, after which doses were tapered

	off over the next 14 days			
	children: 0.6 mg/kg of body weight/day for the first 7 days, followed by 0.3 mg/kg of body weight/day for 21 days, after which doses were tapered off over the next 14 days			
	Antituberculosis chemotherapy: isoniazid (300 mg/day in adults, or 10 mg/kg of body weight/day in children), rifampicin (450 mg/day in adults, or 15 mg/kg of body weight/day in children) and pyrazinamide (1500 mg/day in adults, or 30 mg/kg of body weight/day in children); total duration of antituberculosis chemotherapy unknown			
	Pyridoxine supplements were given routinely			
	Antituberculosis chemotherapy alone			
Comparison	Antituberculosis chemotherapy: isoniazid (300 mg/day in adults, or 10 mg/kg of body weight/day in children), rifampicin (450 mg/day in adults, or 15 mg/kg of body weight/day in children) and pyrazinamide (1500 mg/day in adults, or 30 mg/kg of body weight/day in children); total duration of antituberculosis chemotherapy unknown			
	Pyridoxine supplements were given routinely			
Length of follow up	3 months after treatment initiation			
Location	New Delhi, India			
	Mortality			
	Number of deaths			
	dexamethasone group = 9 of 24			
Outcomes	antituberculosis chemotherapy alone group = 9 of 23			
measures and effect	OR ¹ (95% CI) = 0.93 (0.29 to 3.03)			
size	i.e. not statistically significant			
	Response to treatment – full/partial recovery			
	Definition not provided			
	Number of patients to achieve a full or partial recovery			

dexamethasone group = 15 of 24
antituberculosis chemotherapy alone group = 13 of 23
OR ¹ (95% CI) = 1.28 (0.40 to 4.12)
i.e. not statistically significant
Number of patients who were defined as 'severe' on admission and to survive to achieve a full or partial recovery
dexamethasone group = 4 of 4
antituberculosis chemotherapy alone group = 1 of 2
OR ¹ (95% CI) = 9.00 (0.22 to 362.50)
i.e. not statistically significant
Number of patients who were defined as 'mild-to-moderate' on admission and to survive to achieve a full or partial recovery
dexamethasone group = 11 of 11
antituberculosis chemotherapy alone group = 12 of 12
OR ¹ (95% CI) = 0.92 (0.02 to 50.28)
i.e. not statistically significant
Response to treatment – unchanged status
Definition not provided
Number of patients whose status was unchanged
dexamethasone group = 0 of 24
antituberculosis chemotherapy alone group = 1 of 23
OR ¹ (95% CI) = 0.31 (0.01 to 7.91)

i.e. not statistically significant
Number of patients who were defined as 'severe' on admission and to survive whose status was unchanged
dexamethasone group = 0 of 4
antituberculosis chemotherapy alone group = 1 of 2
OR ¹ (95% CI) = 0.11 (0.00 to 4.48)
i.e. not statistically significant
Number of patients who were defined as 'mild-to-moderate' on admission and to survive whose status was unchanged
dexamethasone group = 0 of 11
antituberculosis chemotherapy alone group = 0 of 12
OR ¹ (95% CI) = 1.09 (0.02 to 59.40)
i.e. not statistically significant
Response to treatment – 'poor' outcome
Defined as death or survival with major sequelae (persistent vegetative state, blindness, symptomatic hydrocephalus, moderate-to-severe intellectual impairment, severe functional disability (totally dependent), or uncontrolled seizures)
Number of patients to experience a poor outcome
dexamethasone group = 5 of 24
antituberculosis chemotherapy alone group = 8 of 23
OR ¹ (95% CI) = 0.49 (0.13 to 1.82)
i.e. not statistically significant
Response to treatment – 'good' outcome
Defined as survival with minor (mild intellectual impairment, mild-to-moderate functional disability (able to enact the activities of daily living with minimal or no assistance)) or no sequelae

Number of patients to experience a good outcome
dexamethasone group = 15 of 24
antituberculosis chemotherapy alone group = 13 of 23
OR ¹ (95% CI) = 1.28 (0.40 to 4.12)
i.e. not statistically significant
Changes in signs and symptoms – sensorium
Time (mean, days) to recovery of sensorium amongst patients who survived
dexamethasone group $(n = 15)^2 = 14.6$
antituberculosis chemotherapy alone group $(n = 14)^2 = 11.3$
MD ³ = 3.3
Time (mean, days) to recovery of sensorium amongst patients who were defined as 'severe' on admission and who survived
dexamethasone group $(n = 4) = 19$
antituberculosis chemotherapy alone group (n = 2) = 25
MD ³ = -6
Time (mean, days) to recovery of sensorium amongst patients who were defined as 'mild-to-moderate' on admission and who survived
dexamethasone group (n = 11) = 13
antituberculosis chemotherapy alone group (n = 12) = 9
MD ³ = 4
Changes in signs and symptoms – fever
Time (mean, days) to recovery of fever amongst patients who survived

dexamethasone group (n = 15) ² = 13
antituberculosis chemotherapy alone group $(n = 14)^2 = 10.3$
MD ³ = 2.7
Time (mean, days) to recovery of fever amongst patients who were defined as 'severe' on admission and who survived
dexamethasone group (n = 4) = 13
antituberculosis chemotherapy alone group (n = 2) = 18
MD ³ = -5
Time (mean, days) to recovery of fever amongst patients who were defined as 'mild-to-moderate' on admission and who survived
dexamethasone group (n = 11) = 13
antituberculosis chemotherapy alone group (n = 12) = 9
MD ³ = 4
Changes in signs and symptoms – headache
Time (mean, days) to recovery of headache amongst patients who survived
dexamethasone group (n = 15) ² = 18.5
antituberculosis chemotherapy alone group $(n = 14)^2 = 11.1$
MD ³ = 7.4
Time (mean, days) to recovery of headache amongst patients who were defined as 'severe' on admission and who survived
dexamethasone group (n = 4) = 20
antituberculosis chemotherapy alone group (n = 2) = 12
MD ³ = 8

	Time (mean, days) to recovery of headache amongst patients who were defined as 'mild-to-moderate' on admission and who survived
	dexame has one group $(n = 11) = 18$
	antituberculosis chemotherapy alone group (n = 12) = 11
-	MD ³ = 7
	Changes in signs and symptoms – cognitive status
	Assessed using a mini-mental score (tests orientation, registration, calculation, recall and language functions; scores range from 0 to 30, with 0 being the worst performance and 30 being 'normal')
	Time (mean, days) to improvement in mini-mental score amongst patients who survived
	dexamethasone group $(n = 15)^2 = 8.3$
	antituberculosis chemotherapy alone group $(n = 14)^2 = 4.9$
	$MD^3 = 3.4$
	Time (mean, days) to improvement in mini-mental score amongst patients who were defined as 'severe' on admission and who survived
	dexamethasone group $(n = 4) = 9$
	antituberculosis chemotherapy alone group $(n = 2) = 10$
	MD ³ = -1
	Time (mean, days) to improvement in mini-mental score amongst patients who were defined as 'mild-to-moderate' on admission and who survived
	dexamethasone group (n = 11) = 8
	antituberculosis chemotherapy alone group (n = 12) = 4
	MD ³ = 4
	Changes in signs and symptoms – activity of daily living

	Assessed using the Barthel index (includes bowel and bladder control, grooming, toilet use, feeding, transfer, mobility, dressing, walking upstairs and bathing; a score of 0 indicates a totally dependent patient, whereas a score of 20 means an independent existence)
	Time (mean, days) to improvement in Barthel score amongst patients who survived
	dexamethasone group $(n = 15)^2 = 7.6$
	antituberculosis chemotherapy alone group $(n = 14)^2 = 2.3$
	MD ³ = 5.3
	Time (mean, days) to improvement in Barthel score amongst patients who were defined as 'severe' on admission and who survived
	dexamethasone group $(n = 4) = 12$
	antituberculosis chemotherapy alone group $(n = 2) = 4$
	MD ³ = 8
	Time (mean, days) to improvement in Barthel score amongst patients who were defined as 'mild-to-moderate' on admission and who survived
	dexamethasone group (n = 11) = 6
	antituberculosis chemotherapy alone group (n = 12) = 2
	MD ³ = 4
Source of funding	No details provided
Comments	
¹ Odds ratio and 95% of	confidence interval calculated by reviewer
	evere disease on admission who survived and those with mild-to-moderate disease on admission who survived was d mean difference by reviewer
³ Mean difference calc	ulated by reviewer

³ Mean difference calculated by reviewer

Abbreviations: CI, confidence intervals; CSF, cerebrospinal fluid; CT, computerised tomography; H, isoniazid; OR, odds ratio; R, rifampicin; RCT, randomised controlled trial; S, streptomycin; TB, tuberculosis

1.1.17 Schoeman et al, 1997

Bibliographic reference	Schoeman JF, Van Zyl LE, Laubscher JA et al (1997) Effect of corticosteroids on intracranial pressure, computed tomographic findings, and clinical outcome in young children with tuberculous meningitis. Pediatrics 99(2): 226-31			
Study type	RCT			
	RCT Appropriate method of randomisation used? unclear Allocation concealment used? unclear Blinding used? blinded: clinical psychologist assessing intelligence, clinician testing hearing, ophthalmologist testing vision, and physical therapist testing motor function unclear patients or other health professionals were blinded Groups comparable at baseline? yes, although details provided are limited Groups received the same care apart from the intervention(s) studied? yes Groups followed up for an equal and appropriate length of time?			
	yes Groups comparable for treatment completion and availability of outcome data?			
	yes			

	Study used precise definitions and reliable measures of outcome?
	yes
	Population studied is the same as the population of interest?
	yes
	Intervention used is the same as the intervention of interest?
	yes
	Have substitute outcomes been used instead of the patient-important outcomes of interest?
	yes
	Analysis followed the intent-to-treat principle?
	yes
	Randomised = 141
	prednisolone group = 70
	antituberculosis chemotherapy alone group = 71
	Outcome data available for incidence of mortality and the incidence of tuberculoma = 141
	prednisolone group = 70
Number of patients	antituberculosis chemotherapy alone group = 71
	Outcome data available for IQ = 119
	prednisolone group = 65
	antituberculosis chemotherapy alone group = 54
	Outcome data available for motor function = 126
	prednisolone group = 66

	antituberculosis chemotherapy alone group = 60
	Outcome data available for vision = 119
	prednisolone group = 63
	antituberculosis chemotherapy alone group = 56
	Outcome data available for hearing = 116
	prednisolone group = 60
	antituberculosis chemotherapy alone group = 56
	Inclusion
	Tuberculous meningitis
	Children (age threshold not provided)
	Diagnostic criteria
	Based on history and typical CSF changes, together with 2 or more of the following:
	strongly positive (>15 mm) Mantoux test
Patient characteristics	chest radiograph findings suggesting tuberculosis i.e. a miliary picture or hilar lymph node adenopathy, often accompanied by a segmental lesion
	acute hydrocephalus with basal enhancement on CT scanning
	isolation of <i>M. tuberculosis</i> in gastric aspirate and/or CSF
	Severity of disease
	Classified according to the system of the British Medical Research Council:
	stage 1: mild cases; without altered consciousness or focal neurologic signs
	stage 2: moderately advanced cases; altered consciousness; not comatose; moderate neurologic deficits, such as single cranial nerve palsies, parapesis and hemiparesis

	stage 3: severe cases; comatose patients; multiple cranial nerve palsies; hemiplegia and/or paraplegia				
	Only patients with stage 2 or 3 were included				
	Baseline				
			Prednisolone group	Placebo group	
		Severity of disease			
		stage 2, n	37	36	
		stage 3, n	33	35	
		Baseline pressure (mean±SD), mm Hg	28.5±12.7	26.0±11.8	
		Pulse pressure (mean±SD), mm Hg	6.1±5.5	5.6±5.8	
		Ventricular size (mean±SD), ratio of biventricular diameter to biparietal diameter	0.26±0.08	0.25±0.08	
	Antitubercu	llosis chemotherapy plus prednisolone			
	Prednisolone (1 month)				
	2 to 4 mg/kg of body weight/day - the first 16 patients in the steroid group received prednisolone at 2 mg/kg/day, and the remaining patients received 4 mg/kg/day ²				
Intervention	Antituberculosis chemotherapy: 6HRZE				
	20 mg/kg of body weight/day isoniazid, 20 mg/kg of body weight/day rifampicin, 40 mg/kg of body weight/day pyrazinamide and 20 mg/kg of body weight/day ethambutol daily for 6 months				
All children with communicating hydrocephalus were treated with daily acetazolamide (100 furosemide (1 mg/kg of bodyweight) for 1 month				mide (100 mg/kg of bodywei	ight) and
	All children with non-communicating hydrocephalus were referred for immediate ventriculoperitoneal shunting surge				g surgery

	Antituberculosis chemotherapy alone
Comparison	Antituberculosis chemotherapy: 6HRZE
	20 mg/kg of body weight/day isoniazid, 20 mg/kg of body weight/day rifampicin, 40 mg/kg of body weight/day pyrazinamide and 20 mg/kg of body weight/day ethambutol daily for 6 months
	All children with communicating hydrocephalus were treated with daily acetazolamide (100 mg/kg of bodyweight) and furosemide (1 mg/kg of bodyweight) for 1 month
	All children with non-communicating hydrocephalus were referred for immediate ventriculoperitoneal shunting surgery
Length of follow up	6 months from treatment initiation (i.e. full treatment period)
Location	South Africa
	Mortality
	Number of deaths
	prednisolone group = 4 of 70
	antituberculosis chemotherapy alone group = 13 of 71
	OR ¹ (95% CI) = 0.28 (0.09 to 0.90)
Outcomes	i.e. statistically significant
measures and effect	Number of deaths among those classified as stage 2 on admission
size	prednisolone group = 1 of 37
	antituberculosis chemotherapy alone group = 1 of 36
	OR ¹ (95% CI) = 0.97 (0.06 to 16.16)
	i.e. not statistically significant
	Number of deaths among those classified as stage 3 on admission
	prednisolone group = 3 of 33

	antituberculosis chemotherapy alone group = 12 of 35
	OR ¹ (95% CI) = 0.19 (0.05 to 0.76)
	i.e. statistically significant
	Changes in signs and symptoms - disability
	Number of patients to be disabled (severely or mildly) at 6 months
	prednisolone group = 54 of 70
	antituberculosis chemotherapy alone group = 49 of 71
	OR ¹ (95% CI) = 1.52 (0.71 to 3.21)
	i.e. not statistically significant
	Number of patients to be severely disabled at 6 months
	prednisolone group = 14 of 70
	antituberculosis chemotherapy alone group = 19 of 71
	OR ¹ (95% CI) = 0.68 (0.31 to 1.50)
-	i.e. not statistically significant
	Changes in signs and symptoms - tuberculoma
	Number of patients to develop tuberculomas in the first month of treatment
	prednisolone group = 2 of 70
	antituberculosis chemotherapy alone group = 9 of 71
	OR ¹ (95% CI) = 0.20 (0.04 to 0.97)
r	i.e. statistically significant
	Changes in signs and symptoms - IQ

Number of patients to have an IQ of less than 75 at 6 months
prednisolone group = 31 of 70
antituberculosis chemotherapy alone group = 36 of 71
OR ¹ (95% CI) = 0.77 (0.40 to 1.50)
i.e. not statistically significant
Changes in signs and symptoms – motor function
Number of patients to be experience hemiplegia or quadriplegia at 6 months
prednisolone group = 24 of 70
antituberculosis chemotherapy alone group = 24 of 71
OR ¹ (95% CI) = 1.02 (0.51 to 2.05)
i.e. not statistically significant
Changes in signs and symptoms - vision
Number of patients with visual deterioration (decreased vision or blindness) at 6 months
prednisolone group = 9 of 70
antituberculosis chemotherapy alone group = 7 of 71
OR ¹ (95% CI) = 1.35 (0.47 to 3.85)
i.e. not statistically significant
Number of patients to be blind at 6 months
prednisolone group = 3 of 70
antituberculosis chemotherapy alone group = 3 of 71
OR ¹ (95% CI) = 1.01 (0.20 to 5.21)

	i.e. not statistically significant						
	Changes in signs and symptoms - hearing						
	Number of patients with deterioration in their hearing (decreased hearing, though not deaf) at 6 months						
	prednisolone group = 3 of 70						
	antituberculosis chemotherapy alone group = 6 of 71						
	OR ¹ (95% CI) = 0.49 (0.12 to 2.02)						
	i.e. not statistically significant						
	Number of patients to be deaf at 6 months						
	prednisolone group = 0 of 70						
	antituberculosis chemotherapy alone group = 0 of 71						
	OR ¹ (95% CI) = 1.01 (0.02 to 51.82)						
	i.e. not statistically significant						
Source of funding	South Africa Medical Research Council						
Comments							
¹ Odds ratio and 95%	confidence interval calculated by reviewer						

² The doubling of the dose was enacted when the investigators became aware of a study that showed rifampicin to decrease the bioavailability of prednisolone by 66% and increased the plasma clearance of the drug by 45%

Abbreviations: CI, confidence intervals; CSF, cerebrospinal fluid; CT, computed tomography; H, isoniazid; OR, odds ratio; R, rifampicin; RCT, randomised controlled trial; S, streptomycin; TB, tuberculosis

1.1.18 Thwaites et al, 2004/7 / Török et al, 2011

Study type RCT	
----------------	--

	Appropriate method of randomisation used?
	yes – computer-generated sequence of random numbers was used to allocate treatment in blocks of 30
	Allocation concealment used?
	yes
	Blinding used?
	double-blinded: placebo and dexamethasone were identical in appearance; all participants, enrolling physicians, and investigators remained blinded to the treatment allocation until the last patient completed follow-up
	Groups comparable at baseline?
	yes
	Groups received the same care apart from the intervention(s) studied?
Study quality	yes
	Groups followed up for an equal and appropriate length of time?
	yes
	Groups comparable for treatment completion and availability of outcome data?
	yes
	Study used precise definitions and reliable measures of outcome?
	yes
	Population studied is the same as the population of interest?
	yes
	Intervention used is the same as the intervention of interest?
	yes

	Have substitute outcomes been used instead of the patient-important outcomes of interest?				
	no				
	Analysis followed the intent-to-treat principle?				
	yes				
	Randomised = 545				
	dexamethasone group = 274				
	placebo group = 271				
Number of patients	Lost to follow-up (last observation carried forward) = 62				
	dexamethasone group = 35				
	placebo group = 27				
	Inclusion				
	Clinical evidence of meningitis				
	Over 14 years of age				
	Diagnostic criteria				
	Combination of nuchal rigidity and CSF abnormalities				
Patient characteristics	'Definite' tuberculosis = acid-fast bacilli were seen in the CSF				
	'Probable tuberculosis = patients with one or more of the following:				
	suspected active pulmonary tuberculosis on chest radiography				
	acid-fast bacilli found in any specimen other than the CSF				
	clinical evidence of other extrapulmonary tuberculosis				
	'Possible" tuberculosis = patients with at least four of the following:				


a history of tuberculosis, predominance of lymphocytes in the CSF								
a duration of illness of more than five days								
a ratio of CSF glucose to plasma glucose of less than 0.5								
altered consciousness								
yellow cereb	prospinal fluid							
focal neurol	ogic signs							
Severity of a	disease							
Patients we	re stratified on entry according to the British	Medical Research Counc	il criteria, modified as follo	ws:				
stage 1 = a score on the Glasgow coma scale of 15 (possible range, 3 to 15, with higher scores indicating better status) with no focal neurologic signs								
stage 2 = a score on the Glasgow coma scale of either 11 to 14, or of 15 with focal neurologic signs								
stage 3 = a score on the Glasgow coma score of 10 or less								
Exclusion								
Corticosteroids contraindicated								
>1 dose of any corticosteroid								
>30 days of antituberculosis chemotherapy immediately before study entry								
Baseline								
Dexamethasone Placebo								
(n = 274) (n = 271)								
Age								
	median, years 36.0 35.0							

range, years	15–88	15–84
Sex		
male, n (%)	168 (61.3)	163 (60.1)
Diagnosis		
definite	98 (35.8)	89 (32.8)
probable	130 (47.4)	131 (48.3)
possible	44 (16.1)	47 (17.3)
not tuberculous meningitis	2 (0.7)	4 (1.5)
Weight		
median, kg	45.0	45.0
range, kg	25–75	30–70
Score on the Glasgow coma scale		
median	14	14
range	3–15	3–15
Cranial nerve palsy, n (%)	82 (29.9)	74 (27.3)
Hemiparesis, n (%)	48 (17.5)	37 (13.7)
Paraparesis, n (%)	28 (10.2)	11 (4.1)
Severity of disease		
stage 1, n (%)	90 (32.8)	86 (31.7)
stage 2, n (%)	122 (44.5)	125 (46.1)
stage 3, n (%)	62 (22.6)	60 (22.1)


		HIV status						
		positive, n (%)	44 (16.1)	54 (19.9)				
		negative, n (%)	227 (82.8)	209 (77.1)				
		Lymphocyte count						
		CD4						
		median, /mm3	64	66				
		range, /mm3	14–694	7–359				
		CD8						
		median, /mm3	606	386				
		range, /mm3	134–998	28–1001				
	Antitubercu	losis chemotherapy plus dexamethasone						
	Dexamethasone sodium phosphate (8 weeks)							
	stage 1 disease: received 2 weeks of intravenous therapy (0.3 mg/kg of body weight/day for week 1 and 0.2 mg/kg of body weight/day for week 2) and then 4 weeks of oral therapy (0.1 mg/kg of body weight/day for week 3, then a total 3 mg/day, decreasing by 1 mg each week)							
Intervention	stage 2 or 3 disease: received intravenous treatment for 4 weeks (0.4 mg/kg of body weight/day for week body weight/day for week 2, 0.2 /kg of body weight/day for week 3, and 0.1 /kg of body weight/day for week then oral treatment for 4 weeks, starting at a total of 4 mg/day and decreasing by 1 mg each week							
	Antituberculosis chemotherapy:							
	3HRZS/6HRZ – 5 mg/kg of body weight/day isoniazid, 10 mg/kg of body weight/day rifampicin, 25 mg/kg weight/day pyrazinamide and 20 mg/kg of body weight/day streptomycin (up to a maximum of 1 g/day) da months, followed by isoniazid, rifampicin and pyrazinamide for 6 months							


	HIV-positive patients: 3HRZE/6HRZ – 5 mg/kg of body weight/day isoniazid, 10 mg/kg of body weight/day rifampicin, 25 mg/kg of body weight/day pyrazinamide and 20 mg/kg of body weight/day ethambutol (up to a maximum of 1.2 g/day) daily for 3 months, followed by isoniazid, rifampicin and pyrazinamide for 6 months
	previously treated patients: 3HRZSE/6HRZ – 5 mg/kg of body weight/day isoniazid, 10 mg/kg of body weight/day rifampicin, 25 mg/kg of body weight/day pyrazinamide, 20 mg/kg of body weight/day streptomycin (up to a maximum of 1 g/day) and 20 mg/kg of body weight/day ethambutol (up to a maximum of 1.2 g/day) daily for 3 months, followed by isoniazid, rifampicin and pyrazinamide for 6 months
	None of the patients received antiretroviral drugs
	Antituberculosis chemotherapy plus placebo
	Placebo (8 weeks)
	stage 1 disease: received 2 weeks of intravenous therapy (0.3 mg/kg of body weight/day for week 1 and 0.2 mg/kg of body weight/day for week 2) and then 4 weeks of oral therapy (0.1 mg/kg of body weight/day for week 3, then a total of 3 mg/day, decreasing by 1 mg each week)
	stage 2 or 3 disease: received intravenous treatment for 4 weeks (0.4 mg/kg of body weight/day for week 1, 0.3 /kg of body weight/day for week 2, 0.2 /kg of body weight/day for week 3, and 0.1 /kg of body weight/day for week 4) and then oral treatment for 4 weeks, starting at a total of 4 mg/day and decreasing by 1 mg each week
	Antituberculosis chemotherapy:
Comparison	3HRZS/6HRZ – 5 mg/kg of body weight/day isoniazid, 10 mg/kg of body weight/day rifampicin, 25 mg/kg of body weight/day pyrazinamide and 20 mg/kg of body weight/day streptomycin (up to a maximum of 1 g/day) daily for 3 months, followed by isoniazid, rifampicin and pyrazinamide for 6 months
	HIV-positive patients: 3HRZE/6HRZ – 5 mg/kg of body weight/day isoniazid, 10 mg/kg of body weight/day rifampicin, 25 mg/kg of body weight/day pyrazinamide and 20 mg/kg of body weight/day ethambutol (up to a maximum of 1.2 g/day) daily for 3 months, followed by isoniazid, rifampicin and pyrazinamide for 6 months
	previously treated patients: 3HRZSE/6HRZ – 5 mg/kg of body weight/day isoniazid, 10 mg/kg of body weight/day rifampicin, 25 mg/kg of body weight/day pyrazinamide, 20 mg/kg of body weight/day streptomycin (up to a maximum of 1 g/day) and 20 mg/kg of body weight/day ethambutol (up to a maximum of 1.2 g/day) daily for 3 months, followed by isoniazid, rifampicin and pyrazinamide for 6 months
	None of the patients received antiretroviral drugs


Location	Ho C	Ho Chi Minh City, Vietnam							
Bibliographic reference		Török ME, Bang ND, Chau TTH et al (2011) Dexamethasone and Long-Term Outcome of Tuberculous Meningitis in Vietnamese Adults and Adolescents. PLoS One 6(12): e27821							
Length of follow up	5 yea	5 years after randomisation							
	Morta	ality	1						
		Dexamethas		one	Placebo				
		Years after	(n = 274)	-	(n = 271)	-	Difference in survival		
	treatment initiation	Number at risk	Survival rate (95% CI)	Number at risk	Survival rate (95% CI)	rate (95% CI); p-value			
		0	274	-	271	-	-		
Outcomes measures and effect		1	160	0.65 (0.60 to 0.71)	131	0.57 (0.51 to 0.63)	0.09 (0.00 to 0.17); p = 0.04		
size		2	152	0.63 (0.57 to 0.69)	125	0.55 (0.49 to 0.69)	0.08 (0.00 to 0.16); p = 0.07		
	3	3	147	0.61 (0.55 to 0.67)	124	0.55 (0.49 to 0.61)	0.06 (-0.02 to 0.15); p = 0.15		
		4	130	0.55 (0.50 to 0.62)	117	0.53 (0.47 to 0.59)	0.03 (-0.06 to 0.11); p = 0.56		
		5	82	0.54 (0.48 to 0.60)	64	0.51 (0.45 to 0.57)	0.03 (-0.06 to 0.12); p = 0.51		



i.e	OR ¹ (95% CI) = 0.88 (0.63 to 1.24) i.e. not statistically significant Stage 1 disease:								
	Years after	Dexamethas (n = 90)	one	Placebo (n = 86)		Difference in survival			
	treatment initiation	Number at risk	Survival rate (95% CI)	Number at risk	Survival rate (95% CI)	rate (95% CI); p-value			
	0	90	-	86	-	-			
	1	65	0.82 (0.74 to 0.90)	46	0.66 (0.57 to 0.77)	0.15 (0.02 to 0.29); p = 0.02			
	2	61	0.79 (0.71 to 0.88)	42	0.63 (0.54 to 0.75)	0.16 (0.02 to 0.29); p = 0.02			
	3	59	0.71 (0.68 to 0.86)	41	0.62 (0.52 to 0.74)	0.15 (0.01 to 0.29); p = 0.04			
	4	53	0.69 (0.59 to 0.80)	39	0.60 (0.50 to 0.72)	0.08 (-0.06 to 0.23); p = 0.27			
	5	34	0.69 (0.59 to 0.80)	23	0.55 (0.44 to 0.68)	0.14 (-0.01 to 0.29); p = 0.07			







	Number of patients in an intermediate disability status 5 years after randomisation:
	dexamethasone group = 43 of 274
	placebo group = 36 of 271
	OR ¹ (95% CI) = 1.22 (0.75 to 1.96)
	i.e. not statistically significant
	Number of patients in a severe disability status 5 years after randomisation:
	dexamethasone group = 17 of 274
	placebo group = 18 of 271
	OR ¹ (95% CI) = 0.93 (0.47 to 1.84)
	i.e. not statistically significant
Bibliographic reference	Thwaites GE, Bang ND, Dung NH et al (2004) Dexamethasone for the treatment of tuberculous meningitis in adolescents and adults. New England Journal of Medicine 351: 1741-51
Length of follow up	9 months after treatment initiation
	Changes in signs and symptoms – fever
	Time to fever clearance (median, days from randomisation to observation of a maximal daily temperature of less than 37.5°C for more than five consecutive days)
	dexamethasone group (n = 274) = 9
Outcomes measures and effect	placebo group (n = 271) = 11
size	p = 0.03
	i.e. statistically significant
	Changes in signs and symptoms – coma
	Time to coma clearance (median, days from randomization until observation of a Glasgow coma score of 15 for more

than two consecutive days)
dexamethasone group (n = 274) = 9
placebo group (n = 271) = 11
p = 0.23
i.e. not statistically significant
Changes in signs and symptoms – paresis
Number of patients with hemiparesis at baseline to resolve after 9 months of treatment
dexamethasone group = 36 of 48
placebo group = 30 of 37
OR ¹ (95% CI) = 0.70 (0.24 to 2.00)
p = 0.51
i.e. not statistically significant
Number of patients without hemiparesis at baseline to be experiencing hemiparesis after 9 months of treatment
dexamethasone group = 14 of 226
placebo group = 11 of 234
OR ¹ (95% CI) = 1.34 (0.59 to 3.01)
i.e. not statistically significant
Number of patients to with paraparesis at baseline to resolve after 9 months of treatment
dexamethasone group = 19 of 28
placebo group = 9 of 11
OR ¹ (95% CI) = 0.47 (0.08 to 2.63)

e. not statistically significant
Number of patients without paraparesis at baseline to be experiencing paraparesis after 9 months of treatment
dexamethasone group = 11 of 246
placebo group = 11 of 260
OR ¹ (95% CI) = 1.06 (0.45 to 2.49)
e. not statistically significant
Relapse
Defined by the onset of new focal neurologic signs or a fall in the Glasgow coma score of 2 points or more for two or more days after more than seven days of clinical stability or improvement at any time after randomization
Number of patients to experience relapse
dexamethasone group = 41 of 274
placebo group = 48 of 271
OR ¹ (95% CI) = 0.82 (0.52 to 1.29)
e. not statistically significant
Time to relapse (median, days)
dexamethasone group = 41
placebo group = 38
p = 0.12
e. not statistically significant
Adverse events – 'severe' events
Defined as any event causing or threatening to cause prolonged hospital stay, disability, or death

	Number of patients to experience a severe event
	dexamethasone group = 26 of 274
	placebo group = 45 of 271
	OR ¹ (95% CI) = 0.53 (0.31 to 0.88)
	i.e. statistically significant
Bibliographic reference	Thwaites GE, Macmullen-Price J, Tran TH et al (2007) Serial MRI to determine the effect of dexamethasone on the cerebral pathology of tuberculous meningitis: an observational study. Lancet Neurology 6(3): 230-6
Length of follow up	9 months after treatment initiation
	Changes in signs and symptoms – tuberculoma
	Number of patients to experience a tuberculoma
	dexamethasone group = 9 of 274
	placebo group = 5 of 271
	OR ¹ (95% CI) = 1.81 (0.60 to 5.46)
Outcomes	i.e. not statistically significant
measures and effect size	Changes in signs and symptoms – hydrocephalus
	Number of patients to experience hydrocephalus
	dexamethasone group = 10 of 274
	placebo group = 7 of 271
	OR ¹ (95% CI) = 1.43 (0.54 to 3.81)
	i.e. not statistically significant
Source of funding	Wellcome Trust

Comments

¹ Odds ratio and 95% confidence interval calculated by reviewer

Abbreviations: CI, confidence intervals; CSF, cerebrospinal fluid; E, ethambutol; H, isoniazid; HR, hazard ratio; OR, odds ratio; R, rifampicin; RCT, randomised controlled trial; S, streptomycin; Z, pyrazinamide

BONE & JOINT, INCLUDING SPINAL, TUBERCULOSIS

1.1.19 Cathro, 1958

Bibliographic reference	Cathro AJM (1958) A clinical trial of prednisolone in bone and joint tuberculosis. East African Medical Journal 35(1): 31-5
Study type	RCT
Study type	Appropriate method of randomisation used? unclear Allocation concealment used? unclear Blinding used? unclear Groups comparable at baseline? details provided are limited, but site of disease varies between the 2 groups: prednisolone group = 7 spinal, 2 knee, 1 hip; antituberculosis chemotherapy alone = 4 hip, 2 knee Groups received the same care apart from the intervention(s) studied? yes, although details provided are limited Groups followed up for an equal and appropriate length of time? no – not for the full treatment period Groups comparable for treatment completion and availability of outcome data?
	yes, although follow-up not for the full treatment period and therefore completion of antituberculosis chemotherapy could not be assessed

	Study used	precise definitions and reliable mea	nsures of out	tcome?	
	yes				
	Population	studied is the same as the populatio	on of interest	t?	
	yes, althoug	gh details provided are limited			
	Intervention used is the same as the intervention of interest?				
	antituberculosis chemotherapeutic regimens lacked rifampicin, pyrazinamide and ethambutol				
	Have subst	itute outcomes been used instead of	f the patient	t-important outcomes o	f interest?
	yes - respor	nse to treatment			
	Analysis followed the intent-to-treat principle?				
	yes				
	Randomised = 16				
Number of patients	prednisolone group = 10				
	antituberculosis chemotherapy alone group = 6				
	Inclusion				
	Active tuber	rculosis of bone and joint			
	Baseline				
Patient	Ages range	d from 4 to 47, with an average of 16	6 years		
characteristics			Pr	rednisolone	Antituberculosis chemotherapy alone
		Site of disease			
		spinal, n (%)	7 ((70)	0 (0)

		knee, n (%)	2 (20)		4 (67)	
		hip, n (%)	1 (10)		2 (33)	
	Antitubercul	osis chemotherapy plus prednisc	lone			
	Prednisolon	e (2 months)				
	adults: 20 m	g/day				
Intervention		osis chemotherapy: isoniazid (60 osis chemotherapy unknown	0 mg/day in adults) an	d streptomycir	n (1 g/day in adults); to	otal duration of
	Children rec	eived proportionally smaller dose	es according to age			
	All patients received surgery					
	Antitubercul	osis chemotherapy alone				
Comparison	Antituberculosis chemotherapy: isoniazid (600 mg/day in adults) and streptomycin (1 g/day in adults); total du antituberculosis chemotherapy unknown				otal duration of	
Children received proportionally smaller doses according to age						
	All patients received surgery					
Length of follow up	3 months aff	ter treatment initiation				
Location	Nairobi, Ken	уа				
	Response t	o treatment – need for additior	nal surgical interventi	on		
	Number of p	atients requiring surgery due to i	nsufficient shrinkage o	f the swollen j	oint	
Outcomes measures and effect	prednisolone	e group = 9 of 10				
size	antituberculo	osis chemotherapy alone group =	5 of 6			
	OR ¹ (95% CI) = 1.80 (0.09 to 35.43)					

	i.e. not statistically significant
	Changes in signs and symptoms – weight
	Number of patients that failed to gain weight
	prednisolone group = 1 of 10
	antituberculosis chemotherapy alone group = 1 of 6
	OR ¹ (95% CI) = 0.56 (0.03 to 10.93)
	i.e. not statistically significant
Source of funding	Prednisolone supplied by Pfizer Ltd.
Comments	
¹ Odds ratio and 95% o	confidence interval calculated by reviewer
Abbreviations: CI, conf	idence intervals; H, isoniazid; OR, odds ratio; RCT, randomised controlled trial; S, streptomycin

PERICARDIAL TUBERCULOSIS

1.1.20 Hakim et al, 2000

Bibliographic reference	Hakim JG, Ternouth I, Mushangi E et al (2000) Double blind randomised placebo controlled trial of adjunctive prednisolone in the treatment of effusive tuberculous pericarditis in HIV seropositive patients. Heart 84: 183-8
Study type	RCT
	Appropriate method of randomisation used?
	yes – use of a computer generated randomisation list
	Allocation concealment used?
	unclear
	Blinding used?
	double-blind: clinicians and patients were blinded to the identity of the tablets; a randomisation code list was kept sealed and was released at the end of the study
	Groups comparable at baseline?
Study quality	yes
	Groups received the same care apart from the intervention(s) studied?
	yes
	Groups followed up for an equal and appropriate length of time?
	yes
	Groups comparable for treatment completion and availability of outcome data?
	unclear
	Study used precise definitions and reliable measures of outcome?

	yes
	Population studied is the same as the population of interest?
	yes
	Intervention used is the same as the intervention of interest?
	yes
	Have substitute outcomes been used instead of the patient-important outcomes of interest?
	yes – pill counts are a surrogate for adherence; improvement in cardiothoracic ratio and echocardiographic measurement of pericardial fluid are surrogates for improvement in pericardial effusion
	Analysis followed the intent-to-treat principle?
	unclear
	Randomised = 58
Number of patients	prednisolone group = 29
	antituberculosis chemotherapy alone group = 29
	Inclusion
	Age 18–55 years
	Residence in Harare city to ensure good follow up
Patient	HIV seropositive
characteristics	No diagnosis of tuberculosis within the past two years
	Large pericardial effusion on echocardiography (>1 cm anteriorly and >1 cm posteriorly
	Pericardial aspirate with >50% lymphocytes
	Protein content >30 g/l

Diagnostic criteria		
Patients were admitted into the study on pericardial effusion and a clinical diagno high protein content in the pericardial as	sis of tuberculous pericarditis, supporte	
Diagnostic and/or therapeutic pericardio	centesis was undertaken in all patients	
The typical two dimensional (cross section thickened pericardium with layers of shat appearances were observed		
Clinical examination and appropriate tes	ts excluded alternative causes of perica	arditis
Exclusion		
Antituberculous treatment started more t	than 48 hours before recruitment	
Corticosteroid treatment within previous	one month	
Presence of Kaposi's sarcoma or any ot	her malignancy	
Coexisting life threatening disease		
Bacterial pneumonia		
Pregnancy		
Cavitating pulmonary tuberculosis		
Other causes of pericardial effusion		
Baseline		
	Prednisolone	Antituberculosis chemotherapy alone
	(n = 29)	(n = 29)
Age (mean (range)), years	33 (19–53)	29 (21–41)

Sov. malo:fomalo	22:7	18:11
Sex, male:female	22.1	10.11
Duration of illness		
unknown	1	1
<2 weeks, n	4	3
2–8 weeks, n	20	15
>8 weeks, n	4	10
Symptoms		
cough, n	27	28
sputum production, n	22	22
haemoptysis, n	6	3
dyspnea		
nil, n	3	5
on exertion, n	16	18
at rest, n	10	6
chest pain, n	26	23
Past medical history		
pneumonia, n	2	2
Signs		
fever (>37.7°C), n	16	18
pulse		
≤100 beats/min	0	0


101–120 beats/min	24	19
>120 beats/min	5	10
systolic blood pressure		
<100 mm Hg	1	2
≥100 mm Hg	28	27
pulsus paradoxus	18	16
jugular venous pressure		
≤5 cm, n	4	3
6–10 cm, n	10	14
>10 cm, n	12	8
Respiratory rate (mean (range)), /min	29 (18–46)	30 (18–44)
Weight (mean (range)), kg	57 (42–75)	54 (35–67)
Oedema		
nil/just detectable, n	21	18
affecting legs, n	4	5
affecting sacrum, n	1	2
Ascites		
nil/just detectable, n	26	22
shifting/dullness, n	1	3
tense abdomen, n	0	0


Hepatomegaly		
≤4 cm, n	7	6
5–8 cm, n	16	16
>8 cm, n	4	3
Patients' perception of wellbeing		
completely well, n	0	0
well, but not perfect, n	12	11
unwell, n	17	17
Level of physical activity		
unrestricted, n	11	11
out and about, but restricted, n	11	12
restricted to home or hospital, n	6	5
bedridden, n	1	1
Haemoglobin <12 g/dl, n	20	19
Total white cell count <4.0 cells/µl, n	6	1
Platelet count <100 cells/µl, n	2	1
CD4+ count (median (IQR))	374 (220–418)	254 (132–352)
<200 cells/µl, n	3	5
200–500 cells/µl, n	10	5
>500 cells/µl, n	2	3
Liver function tests (median (IQR))		

	bilirubin	11 (10–180)	11 (10–27)	
	aspartate transaminase	35 (5–520)	32 (6–127)	
	alkaline phosphatase	178 (145–361)	237 (100–610)	
	albumin	16	12	
	Cardiothoracic ratio (chest x-ray)			
	<55%	0	0	
	55–75%	9	6	
	>75%	5	8	
	Low voltage ECG	4	5	
	Pericardial effusion size (mean±SE))		
	anterior, cm	2.5±2.1	2.2±1.3	
	posterior, cm	2.6±1.0	2.8±1.3	
	subcostal,cm	2.7±1.0	2.7±1.0	
	Antituberculosis chemotherapy plus	prednisolone		
	Prednisolone (6 weeks)			
Intervention	starting at a dose of 60 mg (12 tablets	s) and tapering by 10 mg per week ur	ntil completion at the end of the sixth week	
	Antituberculosis chemotherapy: 2HRZE/4HR			
	doses not provided			
Compania on	Antituberculosis chemotherapy plus placebo			
Comparison	Placebo (6 weeks)			

	starting at a dose of 60 mg (12 tablets) and tapering by 10 mg per week until completion at the end of the sixth week		
	Antituberculosis chemotherapy: 2HRZE/4HR		
	doses not provided		
Length of follow up	18 months after treatment initiation		
Location	Harare, Zimbabwe		
Outcomes measures and effect size	Mortality 1.00 0.75 0.75 0.50 0.25 0.00 20 40 60 80 Follow up (weeks) Number of deaths after 18 months prednisolone group = 5 of 29 antituberculosis chemotherapy alone group = 10 of 29 p = 0.004		
	i.e. statistically significant OR ¹ (95% CI) = 0.40 (0.12 to 1.36)		

i.e. not statistically significant
Changes in signs and symptoms – physical activity
Number of patients to experience improvement in physical activity
p = 0.017
i.e. statistically significant
Changes in signs and symptoms – constrictive pericarditis
Number of patients to experience constrictive pericarditis
prednisolone group = 2 of 29
antituberculosis chemotherapy alone group = 2 of 29
OR ¹ (95% CI) = 1.00 (0.13 to 7.62)
i.e. not statistically significant
Changes in signs and symptoms – pericardial effusion
Change in cardiothoracic ratio, as measured serially in the prednisolone and placebo treatment groups (p = 0.80, i.e. not statistically significant) ²





	prednisolone group = 169 of 230	
	antituberculosis chemotherapy alone group = 119 of 182	
	p = 0.008	
	i.e. statistically significant	
	OR ¹ (95% CI) = 1.47 (0.96 to 2.24)	
	i.e. not statistically significant	
Source of funding	CAPS(Pvt) Ltd. provided the prednisolone and placebo tablets and financial support	
Comments		
¹ Odds ratio and 95% confidence interval calculated by reviewer		
² Authors do not specif	² Authors do not specify the statistic used (mean vs median etc)	
Abbreviations: CI, confidence intervals; E, ethambutol; ECG, echocardiogram; H, isoniazid; IQR, interguartile range; OR, odds ratio; R,		

Abbreviations: CI, confidence intervals; E, ethambutol; ECG, echocardiogram; H, isoniazid; IQR, interquartile range; OR, odds ratio; R, rifampicin; RCT, randomised controlled trial; SD, standard deviation; Z, pyrazinamide

1.1.21 Reuter et al, 2006

Bibliographic reference	Reuter H, Burgess LJ, Louw VJ et al (2006) Experience with adjunctive corticosteroids in managing tuberculous pericarditis. Cardiovascular Journal of South Africa 17(5): 233-8
Study type	RCT
Study quality	Appropriate method of randomisation used? yes – predetermined randomisation schedule for 100 patients on a 3:3:4 basis; numbers were drawn from a hat, stored on a list on a computer <i>Allocation concealment used?</i> yes – randomisation schedule provided to the treating physician with the assigned treatment by a non-clinical administrator

Blinding used?
double-blind: randomisation code remained concealed and was not revealed to the investigators or the study subjects until completion of the study; however, physician administering the intrapericardial steroids/placebo was unblinded
Groups comparable at baseline?
yes
Groups received the same care apart from the intervention(s) studied?
yes
Groups followed up for an equal and appropriate length of time?
yes
Groups comparable for treatment completion and availability of outcome data?
yes
Study used precise definitions and reliable measures of outcome?
yes
Population studied is the same as the population of interest?
yes
Intervention used is the same as the intervention of interest?
yes
Have substitute outcomes been used instead of the patient-important outcomes of interest?
no
Analysis followed the intent-to-treat principle?
yes

Number of patients	Randomised = 57 prednisolone group = 16 triamcinolone group = 17				
	placebo group = 24				
	Inclusion				
	Large pericardial effusion on echocardiogra	aphy (epi-pericardial dista	ance > 10 mm)		
	Pericardial aspirate with protein content > 3	30 g/l; (4) pericardial fluid	adenosine deaminase (A	DA) activity > 35 U/I	
	Aged 13 to 75 years				
	Exclusion				
	CD4 counts <200 cells/µl were excluded due to uncertainty as to the effects of corticosteroids on immunocompromised patients with TB with regard to risk for disseminated disease				
Patient	Patients presenting with signs of constrictive pericarditis or requiring pericardial surgery within the first 5 days of admission				
characteristics	Baseline				
	40 of the 57 patients (70.0%) had microbiological and/or histological evidence of TB, the remaining 17 patients (30.0%) were diagnosed by clinical and supportive laboratory data				
		Prednisolone group	Triamcinolone group	Placebo group	
		(n= 16)	(n= 17)	(n= 24)	
	Sex				
	female, n	7	4	12	
	male, n	9	13	12	
	HIV-seropositive	9	6	6	

Age (mean±SD (range)), years	34.4±9.86 (17–58)	38.6±10.16 (22–66)	33.3±15.86 (17–66)
Symptoms			
fever, n (%)	13 (81)	12 (71)	18 (75)
night sweats, n (%)	7 (44)	7 (41)	10 (42)
weight loss, n (%)	13 (81)	13 (76)	19 (79)
anorexia, n (%)	12 (75)	12 (71)	19 (79)
dyspnea, n (%)	15 (94)	16 (94)	22 (92)
chest pain, n (%)	6 (38)	4 (24)	7 (29)
cough, n (%)	14 (88)	15 (88)	20 (83)
Physical signs			
lymphadenopathy, n (%)	5 (31)	4 (24)	7 (29)
soft cardiac sounds, n (%)	13 (81)	14 (82)	20 (83)
hepatomegaly, n (%)	10 (63)	11 (65)	16 (67)
peripheral oedema, n (%)	6 (38)	6 (35)	11 (46)
ascites, n (%)	2 (13)	2 (12)	3 (13)
tachycardia, n (%)	13 (81)	13 (76)	20 (83)
pulsus paradoxus, n (%)	3 (19)	5 (29)	7 (29)
Kassmaul's sign, n (%)	2 (13)	2 (12)	3 (13)
jugular venous pressure >4 cm, n (%)	13 (81)	15 (88)	20 (83)
systolic blood pressure <100 mm Hg, n (%)	1 (6)	1 (6)	1 (4)

	Antituberculosis chemotherapy plus prednisolone
	Prednisolone (injection plus 11 weeks)
	oral prednisone plus intrapericardial placebo (5 ml 0.9% saline solution)
	intrapericardial placebo: 5 ml 0.9% saline solution
Intervention 1	oral prednisone: started at 60 mg/day for 4 weeks, followed by 30 mg/day for 4 weeks, 15 mg/day for 2 weeks and 5 mg/day for 1 week
	Antituberculosis chemotherapy: 2HRZE/4HR
	doses not provided
	Patients were discharged on antituberculous therapy and pyridoxine with adjunctive prednisone
	Antituberculosis chemotherapy plus triamcinalone
	Triamcinolone (injection)
	200 mg (5 ml) intrapericardial triamcinolone hexacetonide
Intervention 2	due to limited resources, an oral placebo was not used in conjunction with the intrapericardial triamcinolone
	Antituberculosis chemotherapy: 2HRZE/4HR
	doses not provided
	Patients were discharged on antituberculous therapy and pyridoxine
	Antituberculosis chemotherapy plus placebo
Comparison	Placebo (injection)
Companson	200 mg (5 ml) intrapericardial placebo
	due to limited resources, an oral placebo was not used in conjunction with the intrapericardial placebo

	Antituberculosis chemotherapy: 2HRZE/4HR
	doses not provided
	Patients were discharged on antituberculous therapy and pyridoxine
Length of follow up	1 year
Location	Western Cape, South Africa
	Mortality
	Number of deaths
	prednisolone group = 0 of 16
	triamcinolone group = 0 of 17
	placebo group = 0 of 24
	Any corticosteroid ¹ vs placebo
	OR ² (95% CI) = 0.73 (0.01 to 38.15)
Outcomes	i.e. not statistically significant
measures and effect size	Prednisolone ³ vs triamcinalone
	OR ² (95% CI) = 2.06 (0.04 to 112.94)
	i.e. not statistically significant
	Prednisolone ³ vs placebo
	OR ² (95% CI) = 2.88 (0.05 to 156.88)
	i.e. not statistically significant
	Response to treatment – need for additional intervention
	Number of patients to require surgery

prednisolone group = 2 of 16
triamcinolone group = 0 of 17
placebo group = 0 of 24
Any corticosteroid ¹ vs placebo
OR ² (95% CI) = 3.66 (0.17 to 79.63)
i.e. not statistically significant
Prednisolone ³ vs triamcinalone
OR ² (95% CI) = 6.18 (0.23 to 168.11)
i.e. not statistically significant
Prednisolone ³ vs placebo
OR ² (95% CI) = 8.65 (0.32 to 233.13)
i.e. not statistically significant
Changes in signs and symptoms – activity levels
Number of patients to experience reduced levels of activity at 1-year of follow-up
prednisolone group = 2 of 16
triamcinolone group = 2 of 17
placebo group = 3 of 24
Any corticosteroid ¹ vs placebo
OR ² (95% CI) = 0.97 (0.20 to 4.78)
i.e. not statistically significant
Prednisolone ³ vs triamcinalone

	OR ² (95% CI) = 1.07 (0.08 to 13.90)
	i.e. not statistically significant
	Prednisolone ³ vs placebo
	OR ² (95% CI) = 1.00 (0.09 to 11.24)
	i.e. not statistically significant
Source of funding	Crossley Fund and the South African Medical Research Council
Comments	

¹ Data for the 2 corticosteroid groups pooled by reviewer

² Odds ratio and 95% confidence interval calculated by reviewer

³ Data for prednisolone arm split in 2 to allow 2 pairwise comparisons of prednisolone *vs* triamcinolone and prednisolone *vs* placebo

Abbreviations: CI, confidence intervals; E, ethambutol; H, isoniazid; OR, odds ratio; R, rifampicin; RCT, randomised controlled trial; SD, standard deviation; Z, pyrazinamide

1.1.22 Strang et al, 1987/2004

Study type	RCT
	Appropriate method of randomisation used? quasi-randomised: randomised in blocks of by entering names consecutively into a register Allocation concealment used?
Study quality	yes
	Blinding used?
	double-blind; all the clinical, radiographic, bacteriological, echocardiogram and histological data reviewed blind by an independent assessor

	Groups comparable at baseline?
	yes
	Groups received the same care apart from the intervention(s) studied?
	yes, although details provided are limited
	Groups followed up for an equal and appropriate length of time?
	yes
	Groups comparable for treatment completion and availability of outcome data?
	yes
	Study used precise definitions and reliable measures of outcome?
	yes
	Population studied is the same as the population of interest?
	yes
	Intervention used is the same as the intervention of interest?
	antituberculosis chemotherapeutic regimens lacked ethambutol and contained streptomycin
	Have substitute outcomes been used instead of the patient-important outcomes of interest?
	yes – favourable response to treatment is a substitute for changes in signs and symptoms; isoniazid metabolites in the urine is a substitute for adherence
	Analysis followed the intent-to-treat principle?
	yes
Number of retirets	Randomised = 143
Number of patients	prednisolone group = 70

	placebo group = 73
	Outcome data available at 24 months = 114
	prednisolone group = 53
	placebo group = 61
	Outcome data available at 10 years = 140
	prednisolone group = 69
	placebo group = 71
	Inclusion
	Active tuberculous constrictive pericarditis
	Normal, or only moderately enlarged, cardiac shadow on x-ray
	5 years and older
	Diagnostic criteria
	Reduced physical activity and breathlessness
Patient	Increased jugular venous pressure
characteristics	Arterial pulsus paradoxus
	Tachycardia
	Hepatomegaly
	Ascites
	Non-specific but widespread T-wave changes and low voltage QRS complexes on the electrocardiogram
	Diagnosis considered definitely or probably correct in 136 of 143 patients
	Exclusion

aseline		
	Prednisolone group	Placebo grou
Sex		
males, n (%)	23 (43)	25 (41)
Age		
<15 years, n (%)	1 (2)	1 (2)
15–34 years, n (%)	3 (6)	7 (11)
35–54 years, n (%)	24 (45)	33 (54)
≥55 years, n (%)	25 (47)	20 (33)
Pulse		
≤100/min, n (%)	18 (34)	16 (26)
101–120/min, n (%)	25 (47)	33 (54)
>120/min, n (%)	10 (19)	12 (20)
Paradoxus >10 mm Hg, n (%)	10 (20)	21 (35)
Jugular venous pressure		
≤5 cm, n (%)	2 (4)	6 (10)
6–10 cm, n (%)	25 (47)	24 (39)
>10 cm, n (%)	26 (49)	31 (51)
Liver		

		4 (0)	2 (2)
	≤4 cm, n (%)	4 (8)	2 (2)
	5–8 cm, n (%)	33 (62)	29 (48)
	>8 cm, n(%)	16 (30)	30 (49)
	Ascites ¹		
	0–1, n (%)	16 (30)	14 (23)
	2, n (%)	27 (51)	40 (66)
	3, n (%)	10 (19)	7 (11)
	Oedema ²		
	0–1, n (%)	33 (62)	25 (41)
	2, n (%)	6 (11)	10 (16)
	3, n (%)	14 (26)	26 (43)
	Activity ³		
	1, n (%)	2 (4)	4 (7)
	2, n (%)	27 (51)	27 (44)
	3, n (%)	15 (28)	13 (21)
	4, n (%)	9 (17)	17 (28)
	Echocardiogram voltage <6 mm in V6 and <4 mm along frontal axis, n (%)	17 (34)	21 (35)
	Cardiothoracic ratio >55%, n (%)	32 (67)	36 (73)
Intervention	Antituberculosis chemotherapy plus prednisolone		

	Prednisolone (11 weeks)					
		3x daily for			du daile fan woale dd	
	Age, years	weeks 1 to 4 (total daily dose, mg)	weeks 5 to 8 (total daily dose, mg)	weeks 9 to 10 (total daily dose, mg)	1x daily for week 11 (total daily dose, mg)	
	5–9	30	15	7.5	2.5	
	10–14	45	22.5	7.5	2.5	
	≥15	60	30	15	5	
Antituberculosis chemotherapy: 3HRZS/HR						
		1x daily				
	Weight, kg	Streptomycin	Isoniazid	Rifampicin	Pyrazinamide	
		(total daily dose, mg)	(total daily dose, mg)	(total daily dose, mg)	(total daily dose, mg)	
	<20	300	150	250	500	
	20–29	500	250	400	1000	
	30–39	700	300	450	1500	
	40-49	900	300	450	1500	
	≥50	1000	300	600	2000	
	Every dose given under direct supervision of the hospital staff					
	Antituberculosis chemotherapy plus placebo					
	Placebo (11 weeks)					
Comparison		3x daily for		1x daily for week 11		
	Age, years	weeks 1 to 4	weeks 5 to 8	weeks 9 to 10	(total daily dose, mg)	

		(total daily dose, mg)	(total daily dose, mg)	(total daily dose, mg)	
	5–9	30	15	7.5	2.5
	10–14	45	22.5	7.5	2.5
	≥15	60	30	15	5
	Antituberculosis chemo	therapy: 3HRZS/HR			
		1x daily			
	Weight, kg	Streptomycin	Isoniazid	Rifampicin	Pyrazinamide
		(total daily dose, mg)	(total daily dose, mg)	(total daily dose, mg)	(total daily dose, mg)
	<20	300	150	250	500
	20–29	500	250	400	1000
	30–39	700	300	450	1500
	40–49	900	300	450	1500
	≥50	1000	300	600	2000
	Every dose given under	direct supervision of th	e hospital staff		
Location	Transkei				
Bibliographic reference	Strang JIG, Nunn AJ, Johnson DA (2004) Management of tuberculous constrictive pericarditis and tuberculous pericardial effusion in Transkei: results at 10 years follow-up. Quarterly Journal of Medicine 97: 525-35				
Length of follow up	10 years				
Outcomes measures and effect size	Mortality Number of deaths durin				
	prednisolone group = 1	6 of 70			

placebo group = 21 of 73
OR ⁴ (95% CI) = 0.73 (0.35 to 1.56)
i.e. not statistically significant
Response to treatment – need for surgical intervention
Number of patients to require surgical intervention (pericardeictomy, as indicated by signs of severe constriction despite at least 3 months of antituberculosis chemotherapy) during 10 years of follow-up
prednisolone group = 18 of 70
placebo group = 22 of 73
OR ⁴ (95% CI) = 0.80 (0.39 to 1.67)
i.e. not statistically significant
Changes in signs and symptoms – physical activity
Number of patients to with unrestricted physical activity after 10 years of follow-up
prednisolone group = 9 of 70
placebo group = 14 of 73
OR ⁴ (95% CI) = 0.62 (0.25 to 1.55)
i.e. not statistically significant
Number of patients to be 'out and about' but with restricted physical activity after 10 years of follow-up
prednisolone group = 37 of 70
placebo group =32 of 73
OR ⁴ (95% CI) = 1.44 (0.74 to 2.78)
i.e. not statistically significant

	Number of patients to confined to home or hospital after 10 years of follow-up
	prednisolone group = 5 of 70
	placebo group = 2 of 73
	OR ^₄ (95% CI) = 2.73 (0.51 to 14.56)
	i.e. not statistically significant
Bibliographic reference	Strang JIG, Kakaza HHS, Gibson DG et al (1987) Controlled trial of prednisolone as adjuvant in treatment of tuberculous constrictive pericarditis in Transkei. Lancet 2(8573): 1418-22
Length of follow up	24 months
	Response to treatment – favourable
	Defined by the following criteria (or if only 1 were still abnormal):
	pulse rate of ≤100/min
	jugular vein pulse of ≤5 cm
	arterial pulsus paradoxus of ≤10 mm Hg
Outcomes	ascites and oedema classified as nil or just detectable
measures and effect	physical activity unrestricted
size	cardiothoracic ration of ≤55%
	echocardiogram voltage of ≥6 mm in V6 or ≥4 mm along the frontal axis
	Number of patients to be considered in a favourable status after 24 months of follow-up
	prednisolone group = 50 of 70
	placebo group = 52 of 73
	OR ⁴ (95% CI) = 1.01 (0.49 to 2.08)

	i.e. not statistically significant			
Source of funding	Grant from the Wellcome Trust; Ciba-Geigy and Gruppo Lepetit provided the rifampicin and the isoniazid; Bracco provided the pyrazinamide; Glaxo provided the prednisolone and the placebo			
Comments				
¹ Degree of ascites sc	ored as follows: 0 = nil; 1 = just detectable; 2 = shifting dullness; 3 = tense, distended abdomen			
² Degree of peripheral	oedema scored as follows: 0 = nil; 1 = just detectable; 2 = affecting legs but not sacrum; 3 = affecting legs and sacrum			
³ Degree of physical activity scored as follows: 0 = nil; 1 = activity unrestricted; 2 = out and about but activity restricted; 3 = confined to home or hospital; 4 = bedridden				
⁴ Odds ratio and 95% confidence interval calculated by reviewer				
Abbreviations: CI, confidence intervals; H, isoniazid; OR, odds ratio; R, rifampicin; RCT, randomised controlled trial; S, streptomycin; TB, tuberculosis				

1.1.23	Strang	et al,	1988/2004
--------	--------	--------	-----------

Study type	RCT
Study type	RC1 Appropriate method of randomisation used? quasi-randomised: randomised in blocks of by entering names consecutively into a register Allocation concealment used? yes Blinding used? double-blind; all the clinical, radiographic, bacteriological, echocardiogram and histological data reviewed blind by an independent assessor Groups comparable at baseline?
	unclear

	Groups received the same care apart from the intervention(s) studied?
	yes, although details provided are limited
	Groups followed up for an equal and appropriate length of time?
	yes
	Groups comparable for treatment completion and availability of outcome data?
	yes
	Study used precise definitions and reliable measures of outcome?
	yes
	Population studied is the same as the population of interest?
	yes
	Intervention used is the same as the intervention of interest?
	antituberculosis chemotherapeutic regimens lacked ethambutol and contained streptomycin
	Have substitute outcomes been used instead of the patient-important outcomes of interest?
	yes – favourable response to treatment is a substitute for changes in signs and symptoms; isoniazid metabolites in the urine is a substitute for adherence
	Analysis followed the intent-to-treat principle?
	no
	Randomised = 240
Number of restingt	prednisolone group = 117
Number of patients	placebo group = 123
	Outcome data available at 24 months = 198

	prednisolone group = 97						
	placebo group = 101						
	Outcome data available	e at 10 years = 228					
	prednisolone group = 1	12					
	placebo group = 116						
	Inclusion						
	Active tuberculous perior correct in 238 of 240 pa		d by pericardiocentesis	(diagnosis considered o	definitely or probably		
Patient characteristics	5 years and older						
	Exclusion						
	Previous antituberculosis chemotherapy, or antituberculosis chemotherapy for 2 weeks or more during the previous year						
	Antituberculosis chemotherapy plus prednisolone						
	Prednisolone (11 weeks)						
		3x daily for					
	Age, years	weeks 1 to 4	weeks 5 to 8	weeks 9 to 10	1x daily for week 11		
		(total daily dose, mg)	(total daily dose, mg)	(total daily dose, mg)	(total daily dose, mg)		
Intervention	5–9	30	15	7.5	2.5		
	10–14	45	22.5	7.5	2.5		
	≥15	60	30	15	5		
	Antituberculosis chemotherapy: 3HRZS/HR						
	Weight, kg	1x daily					

		Streptomycin	Isoniazid	Rifampicin	Pyrazinamide		
		(total daily dose, mg)	(total daily dose, mg)	(total daily dose, mg)	(total daily dose, mg)		
	<20	300	150	250	500		
	20–29	500	250	400	1000		
	30–39	700	300	450	1500		
	40–49	900	300	450	1500		
	≥50	1000	300	600	2000		
	Patients that gave t	nder direct supervision of th their consent were also rand emotherapy plus placebo)		lete open surgical drain	age or		
		3x daily for					
	Age, years	weeks 1 to 4 (total daily dose, mg)	weeks 5 to 8 (total daily dose, mg)	weeks 9 to 10 (total daily dose, mg)	1x daily for week 11 (total daily dose, mg)		
Comparison	5–9	30	15	7.5	2.5		
	10–14	45	22.5	7.5	2.5		
	≥15	60	30	15	5		
	Antituberculosis ch	Antituberculosis chemotherapy: 3HRZS/HR					
		1x daily					
	Weight, kg	Streptomycin	Isoniazid	Rifampicin	Pyrazinamide		

		(total daily dose, mg)	(total daily dose, mg)	(total daily dose, mg)	(total daily dose, mg)	
	<20	300	150	250	500	
	20–29	500	250	400	1000	
	30–39	700	300	450	1500	
	40-49	900	300	450	1500	
	≥50	1000	300	600	2000	
	Every dose given under	direct supervision of th	e hospital staff	1		
	Patients that gave their pericardiocentesis	consent were also rand	lomised to receive comp	lete open surgical draina	age or	
Location	Transkei					
Bibliographic reference	Strang JIG, Nunn AJ, Johnson DA (2004) Management of tuberculous constrictive pericarditis and tuberculous pericardial effusion in Transkei: results at 10 years follow-up. Quarterly Journal of Medicine 97: 525-35					
Length of follow up	10 years					
	Mortality					
	Number of deaths during 10 years of follow-up					
	prednisolone group = 20	prednisolone group = 26 of 117				
Outcomes	placebo group = 33 of 123					
measures and effect size	OR ⁴ (95% CI) = 0.78 (0.43 to 1.41)					
	i.e. not statistically significant					
	Survival analysis					

Patient group	Variable*		Adjusted HR	95%CI
Constriction (n = 143)	Treatment	Prednisolone Placebo	0.61 1.00	0.32-1.19
	Age Gender	1-year increase Male Female	1.03 2.80 1.00	1.00–1.06 1.39–5.63
Effusion $(n = 175^{**})$	Treatment	Prednisolone Placebo	0.68 1.00	0.38-1.24
	Age Gender	1-year increase Male Female	1.06 2.72 1.00	1.04–1.09 1.48–5.02
All (n=318)	Pericarditis Treatment	Constriction Effusion Prednisolone	1.00 1.02 0.64	0.66–1.57 0.41–0.99
	Age Gender	Placebo 1-year increase Male Female	1.00 1.05 2.70 1.00	1.03–1.07 1.71–4.28
* Includes significant pre their age was unavailabl		ne patient allocated to placeb	oo was not included in this	analysis because
Response to treat	tment – need for s	urgical intervention		
Number of patients to require surgical intervention during 10 years of follow-up				
prednisolone group	o = 11 of 117			
placebo group = 7	of 123			
OR4 (95% CI) = 1.7	72 (0.64 to 4.60)			
i.e. not statistically	significant			
Changes in signs	and symptoms –	physical activity		
Number of patients	to with unrestricted	d physical activity afte	r 10 years of follow	-up
prednisolone group	o = 21 of 117			

	placebo group = 30 of 123
	OR ⁴ (95% CI) = 0.68 (0.36 to 1.27)
	i.e. not statistically significant
	Number of patients to be 'out and about' but with restricted physical activity after 10 years of follow-up
	prednisolone group = 57 of 117
	placebo group = 46 of 123
	OR ⁴ (95% CI) = 1.59 (0.95 to 2.66)
	i.e. not statistically significant
	Number of patients to confined to home or hospital after 10 years of follow-up
	prednisolone group = 8 of 117
	placebo group = 7 of 123
	OR ⁴ (95% CI) = 1.22 (0.43 to 3.47)
	i.e. not statistically significant
Bibliographic reference	Strang JIG, Kakaza HHS, Gibson DG et al (1987) Controlled trial of prednisolone as adjuvant in treatment of tuberculous constrictive pericarditis in Transkei. Lancet 2(8573): 1418-22
Length of follow up	24 months
	Response to treatment – favourable
	Defined by the following criteria (or if only 1 were still abnormal):
Outcomes measures and effect	pulse rate of ≤100/min
size	jugular vein pulse of ≤5 cm
	arterial pulsus paradoxus of ≤10 mm Hg

	ascites and oedema classified as nil or just detectable		
	physical activity unrestricted		
	cardiothoracic ration of ≤55%		
	echocardiogram voltage of ≥6 mm in V6 or ≥4 mm along the frontal axis		
	Number of patients to be considered in a favourable status after 24 months of follow-up		
	prednisolone group = 91 of 117		
	placebo group = 88 of 123		
	OR ⁴ (95% CI) = 1.39 (0.77 to 2.50)		
	i.e. not statistically significant		
Source of funding	Grant from the Wellcome Trust; Ciba-Geigy and Gruppo Lepetit provided the rifampicin and the isoniazid; Bracco provided the prednisolone and the placebo		
Comments			
¹ Degree of ascites scored as follows: 0 = nil; 1 = just detectable; 2 = shifting dullness; 3 = tense, distended abdomen			

² Degree of peripheral oedema scored as follows: 0 = nil; 1 = just detectable; 2 = affecting legs but not sacrum; 3 = affecting legs and sacrum

³ Degree of physical activity scored as follows: 0 = nil; 1 = activity unrestricted; 2 = out and about but activity restricted; 3 = confined to home or hospital; 4 = bedridden

⁴ Odds ratio and 95% confidence interval calculated by reviewer

Abbreviations: CI, confidence intervals; H, isoniazid; OR, odds ratio; R, rifampicin; RCT, randomised controlled trial; S, streptomycin; TB, tuberculosis

IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME

1.1.24 Meintjes et al, 2010

Bibliographic reference	Meintjes G, Wilkinson RJ, Morroni C (2010) Randomised placebo-controlled trial of prednisolone for paradoxical tuberculosis-associated immune reconstitution inflammatory syndrome. AIDS 24: 2381-90				
Study type	RCT				
Study type	RCT Appropriate method of randomisation used? yes – a randomization sequence assigning participants in a 1:1 ratio was generated using Excel by the study statistician and given to an independent pharmacist Allocation concealment used? unclear Blinding used? double-blind Groups comparable at baseline? there was a longer period (p = 0.02) between taking antituberculosis chemotherapy and initiating ART amongst patients in the prednisolone arm (66 days) than the placebo arm (43.5 days) Groups received the same care apart from the intervention(s) studied? yes Groups followed up for an equal and appropriate length of time? study period only 12 weeks Groups comparable for treatment completion and availability of outcome data?				
	yes				

	Study used precise definitions and reliable measures of outcome?
	yes
	Population studied is the same as the population of interest?
	yes
	Intervention used is the same as the intervention of interest?
	yes, although patients received streptomycin instead of ethambutol, and some patients did not receive rifampicin
	Have substitute outcomes been used instead of the patient-important outcomes of interest?
	no
	Analysis followed the intent-to-treat principle?
	yes
	Randomised = 110
Number of patients	prednisolone group = 55
	antituberculosis chemotherapy alone group = 55
	Inclusion
Patient characteristics	New or recurrent tuberculosis symptoms and ≥1 of the following TB-IRIS manifestations were enrolled:
	infiltrate on chest radiograph
	enlarging lymph node/s
	serous effusion
	cold abscess
	Exclusion
	Age < 18 years

Known rifampicin-resistant tuberculosis		
Previous glucocorticoid therapy during this tubero	ulosis episode	
Prior ART exposure, pregnancy		
Uncontrolled diabetes mellitus		
Kaposi's sarcoma		
Immediately life-threatening TB-IRIS, defined as: respiratory failure with arterial pO2 < 8 kPa, altered leve consciousness, new focal neurological sign/s, or compression of a vital structure		02 < 8 kPa, altered level o
Baseline		
	Prednisolone	Placebo
	(n = 55)	(n = 55)
Age (mean (range)), years	31.5 (19.1–46.0)	31.6 (19.0–56.9)
Sex, male:female	17:38	23:32
Previous tuberculosis, n	15	10
CD4+ count prior to ART (mean (range)), cells/μl	56 (30–103)	48 (20–92)
WHO stage 4 at ART initiation	29	33
Duration antitubercular therapy to ART (mean (range)), days	66 (35–84)	43.5 (23.8-76)
Duration ART to TB-IRIS (mean (range)), days	14 (7–21)	10 (7–19)
Duration TB-IRIS to enrolment (mean (range)), days	12.5 (7–21)	14 (8–23.5)
TB-IRIS manifestations		

	new/recurrent lymphadenopathy, n	19	28
	new/recurrent cold abscess, n	1	1
	new/recurrent pulmonary infiltrate, n	19	16
	new/recurrent serious effusion, n	9	9
	CD4+ count (mean (range)), cells/µl	138 (78–243)	109 (55–190)
	Random glucose (mean (range)), mmol/l	5.1 (4.8–6.0)	5.3 (4.8–5.7)
	Haemoglobin (mean (range)), g/dl	9.1 (8.1–10.3)	9.2 (7.8–10.1)
	Albumin (mean (range)), g/l	23 (20–26)	23 (19.5–26.5)
	C-reactive protein (mean (range)), mg/l	104 (50–150)	106 (79–172)
	Random cortisol (mean (range)), nmol/l	471 (350–614)	559.5 (405.8–774.0)
	Hepatitis B surface antigen positive, n	3/42	3/52
	Weight (mean (range)), kg	51.6 (48.1–56.5)	52.2 (46.6–58.8)
	Hospitalised at enrolment	14	19
	Antibiotics prior to enrolment	25	19
	Karnofsky performance score (mean (range))	70 (30–80)	70 (30–80)
	MOS-HIV health survey		
	physical health summary score	36.3 (33.4–43.1)	37.9 (32.8–44.9)
	mental health summary score	49.7 (44.5–56.0)	49.8 (39.1–56.9)
	Antituberculosis chemotherapy plus prednisolone		
Intervention	Prednisolone (4 weeks)		

	1.5mg/kg/day for 2 weeks followed by 0.75mg/kg/day for 2 weeks
	If significant clinical deterioration occurred after 2 weeks of follow up, the study protocol allowed participants to be switched to open label prednisone
	Antituberculosis chemotherapy:
	treatment-naïve: 2HRZE/4HR
	re-treatment: 2HRZSE/1HRZE/5HRE
	doses not described
	Antituberculosis chemotherapy plus placebo
	Placebo (4 weeks)
	1.5mg/kg/day for 2 weeks followed by 0.75mg/kg/day for 2 weeks
Comparison	If significant clinical deterioration occurred after 2 weeks of follow up, the study protocol allowed participants to be switched to open label prednisone
	Antituberculosis chemotherapy:
	treatment-naïve: 2HRZE/4HR
	re-treatment: 2HRZSE/1HRZE/5HRE
	doses not described
Location	Western Cape Province, South Africa
Length of follow up	12 weeks
	Mortality
Outcomes measures and effect size	Number of deaths
	prednisolone group = 3 of 55
	antituberculosis chemotherapy alone = 2 of 55

OR ¹ (95% CI) = 1.53 (0.25 to 9.53)
i.e. not statistically significant
Change in signs and symptoms – improvement/deterioration
Symptom response was graded in 1 of 3 categories: deteriorated, no change, or improved/resolved; all patients who developed new TB-IRIS symptoms were graded as 'deteriorated'
Number of patients in whom symptoms improved or were resolved after 4 weeks
prednisolone group = 44 of 55
antituberculosis chemotherapy alone = 31 of 55
OR ¹ (95% CI) = 1.81 (0.72 to 4.50)
i.e. not statistically significant
Number of patients in whom symptoms deteriorated after 4 weeks
prednisolone group = 7 of 55
antituberculosis chemotherapy alone = 9 of 55
OR ¹ (95% CI) = 0.75 (0.26 to 2.17)
 i.e. not statistically significant
Change in signs and symptoms – chest radiograph
Utilized a 3-point scale (deteriorated, no change, or improved/resolved
Number of patients in whom chest radiographs were improved or resolved after 4 weeks
prednisolone group = 40 of 55
antituberculosis chemotherapy alone = 25 of 55
OR ¹ (95% CI) = 3.20 (1.44 to 7.09)

	i.e. statistically significant
	Number of patients in whom chest radiographs were deteriorated after 4 weeks
	prednisolone group = 4 of 55
	antituberculosis chemotherapy alone = 18 of 55
	OR ¹ (95% CI) = 0.16 (0.05 to 0.52)
	i.e. statistically significant
	Adverse events
	Number of patients in to experience adverse drug reactions
	prednisolone group = 8 of 55
	antituberculosis chemotherapy alone = 3 of 55
	OR ¹ (95% CI) = 2.95 (0.74 to 11.78)
	i.e. not statistically significant
	Number of patients in to experience infections
	prednisolone group = 27 of 55
	antituberculosis chemotherapy alone = 17 of 55
	OR ¹ (95% CI) = 2.16 (0.99 to 4.70)
	i.e. not statistically significant
Source of funding	Financial support from Medical Research Council of South Africa, Wellcome Trust, EDCTP, Fogarty International Center, United States Agency for International Development and PEPFAR
	Gulf Drug Company (Durban, South Africa) donated the prednisone and placebo tablets
Comments	

¹ Odds ratio and 95% confidence interval calculated by reviewer

Abbreviations: ART, antiretroviral therapy; CI, confidence intervals; E, ethambutol; H, isoniazid; IRIS, immune reconstitution inflammatory syndrome; OR, odds ratio; R, rifampicin; RCT, randomised controlled trial; S, streptomycin; TB, tuberculosis